Essays on Personnel and Health Economics

by

Pieter De Vlieger

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Economics) in The University of Michigan 2020

Doctoral Committee:

Professor John Bound, Co-Chair Assistant Professor Sarah Miller, Co-Chair Professor Ying Fan Professor Kevin Stange Pieter De Vlieger

pdvl@umich.edu

ORCID ID 0000-0002-3149-5849

 \bigodot Pieter De Vlieger 2020

All Rights Reserved

For Tadeja

ACKNOWLEDGEMENTS

While this dissertation carries my name, it is the product of several people and institutions who provided support and guidance along the way.

I would like to thank my committee members John Bound, Sarah Miller, Ying Fan, and Kevin Stange for their patience and commitment, and knowing when a push or support was warranted. Their thoughtful comments and feedback have been instrumental in shaping this dissertation.

Additionally, this dissertation in its current form would not have existed without the support and data access provided by the Inter-Mutual Agency (IMA) and the National Institute for Health and Disability Insurance (NIHDI/RIZIV) in Belgium. Koen Cornelis, Birgit Gielen, and Johan Vanoverloop at IMA and Marc De Falleur and Joos Tielemans at RIZIV in particular were instrumental in setting up this collaboration. Financial support of The Ryoichi Sasakawa Young Leaders Fellowship Fund (SYLFF), the Rackham graduate school at the University of Michigan, and the MITRE center at the Department of Economics at the University of Michigan is greatly appreciated. Andras Avonts, André Decoster, Erik Schokkaert, and Karla Vander Weyden provided crucial input in ensuring the administrative details were processed in a timely fashion. Erik Schokkaert and Johan Vanoverloop provided important institutional support and insights.

Similarly, I am grateful to the IAB in Germany for making available the Cross-Sectional model of the Linked Employer-Employee Data (LIAB) (Version 3, Years 1993-2010) for the research presented in the second chapter of this dissertation. Data access was provided via on-site use at the Research Data Centre (FDZ) of the German Federal Employment Agency (BA) at the Institute for Employment Research (IAB) and subsequently remote data access. Finally, I am grateful to Hinrich Eylers and Ashok Yadav at the University of Phoenix for many discussions and for providing access to the data used for the analyses and research in the third chapter of this dissertation.

I would also like to thank the many people at the University of Michigan and beyond who provided thoughtful insights and comments. Especially Charlie Brown and Zach Brown have played an important role in the final form of this dissertation. Thomas Buchmueller, Kimberly Conlon, James Cooke, Sebastian Fleitas, Jeremy Fox, Tadeja Gračner, Andreas Hagemann, Kyle Handley, Sara Heller, Daniela Hochfellner, Iris Kesternich, Gaurav Khanna, Meera Mahadevan, Edward Norton, Erwin Ooghe, Aniko Öry, Yesim Orhun, Stephanie Owen, Dhiren Patki, Johannes Schmieder, Erik Schokkaert, Andrew Simon, Jeff Smith, Johannes Spinnewijn, Mel Stephens, Katalin Springel, Brenden Timpe, Matthias Umkehrer, and Frank Verboven provided insightful comments and suggestions. Finally, useful comments by seminar participants at several seminars at the University of Michigan, Katholieke Universiteit Leuven, IZA, the GSOEP User Workshop, and the IHEA conference have improved the different chapters in this dissertation. Brian Jacob and Kevin Stange, who were co-authors on one of the chapters in this dissertation, were great collaborators.

I also want to thank family members and friends for their support. My parents have always been supportive of my various pursuits, and their curiosity and healthy skepticism have transpired into this dissertation. The support of Dries, Veerle, Jan, Jonas, Pieter, Greet, Bart, Victor, Celine, Ellis, Amber, and Lucas also needs acknowledging. The wise words of Does and Joos deserve special mention.

Finally, I would like to especially thank Tadeja Gračner for her support and being there every single step of the way z Goričkega v pir dvainštirideset.

TABLE OF CONTENTS

DEDICATION		ii
ACKNOWLEDGEMENTS	•••	iii
LIST OF FIGURES	V	iii
LIST OF TABLES		х
LIST OF APPENDICES		кіі
ABSTRACT	x	iii

CHAPTER

I. Quantifying Sources of Persistent Prescription Behavior: Evidence			
fro	om İ	Belgium	1
	1.1	Introduction	1
	1.2	The Minimum Prescription Rate (MPR)	10
		1.2.1 Setting	10
		1.2.2 The Market for Physicians and Prescription Drugs	11
		1.2.3 The Minimum Prescription Rate (MPR)	14
	1.3	IMA Farmanet: Transaction-Level Prescription Data	15
		1.3.1 Defining Starters and Patient Profiles	18
		1.3.2 Sample Selection and Descriptive Statistics	19
		1.3.3 Descriptive Evidence on the MPR	20
	1.4	Reduced Form Evidence on the introduction of MPR	21
		1.4.1 Do Physicians Switch to Generics?	22
		1.4.2 Do Physicians Move Away from On-Patent Drugs?	25
		1.4.3 Is Switching Longstanding Patients Costly for Health Out-	
		comes ?	27
		1.4.4 2SLS Results \ldots \ldots \ldots \ldots \ldots \ldots \ldots	28
		1.4.5 Which Longstanding Patients are Costly to Switch?	31
		1.4.6 Discussion of Reduced Form Results	33
	1.5	A Structural Model of Prescription Behavior under the MPR Mandate	34

		1.5.1 Set-up \ldots	35
		1.5.2 The physician's prescription decision	35
		1.5.3 The MPR Mandate	41
		1.5.4 Identification and Estimation	44
	1.6	Decomposition and Policy Counterfactuals	49
	-	1.6.1 Decomposition	49
		1.6.2 Counterfactuals	50
	1.7	Conclusion	53
11.	Fairne	ess Considerations in Wage Setting: Evidence from Domestic	
	Outso	ourcing Events in Germany	75
	0.1	T / T /·	
	2.1		75
	2.2	Background	78
	2.3	Theoretical Framework	79
		2.3.1 Labor Supply	80
		2.3.2 Firm Problem	81
		2.3.3 Wage Setting	83
		2.3.4 Assumptions on Fairness and Demand	84
		2.3.5 Comparative Statics	84
	2.4	Data and Institutional Setting	86
		2.4.1 Data \ldots	86
		2.4.2 Institutional Setting	88
	2.5	Domestic Outsourcing	89
		2.5.1 Measuring Domestic Outsourcing	89
		2.5.2 Summary Statistics	91
	2.6	Empirical Strategy and Results	92
		2.6.1 Establishment-Level Outcomes and Structure	92
		2.6.2 Worker-Level Results	93
		2.6.3 Importance of Change in Structure	96
	2.7	Robustness Checks	97
	2.8	Conclusion	98
III.	Meas	uring Instructor Effectiveness in Higher Education	109
	3.1	Introduction	109
	3.2	Prior Evidence and Institutional Context	112
		3.2.1 Prior Evidence	112
		3.2.2 Context: College Algebra at The University of Phoenix	115
	3.3	Data	119
	5.0	3.3.1 Data Sources	119
		3.3.2 Sample Selection	122
		3.3.3 Descriptive Statistics	124
	34	Empirical Approach	125
	5.1	3.4.1 Course and Instructor Assignment	120
			±40

	3.4.2 Outcomes	128
	3.4.3 Cross-Campus Comparisons	130
	3.4.4 Implementation	130
3.5	Results on Instructor Effectiveness	133
	3.5.1 Main Results for Course Grades and Final Exam Scores	133
	3.5.2 Robustness of Grade and Test Score Outcomes	137
	3.5.3 Student Evaluations and Other Outcomes	138
3.6	Does Effectiveness Correlate with Experience and Pay?	140
3.7	Conclusion and Discussion	142
APPENDICI	ES	158
BIBLIOGRA	PHY	215

LIST OF FIGURES

Figure

1.1	Example of Prescription Note in Belgium	63
1.2	Differences between Brand Name and Generic Drugs	64
1.3	Distribution of Physician Generic Prescription Rates in 2004 and 2006	65
1.4	Descriptive Graphs: Prescription and Switching Rate of Generics	66
1.5	Impact of the mandate on Starters and Longstanding Patients	67
1.6	Prescription rate of On-Patent Drugs	68
1.7	Estimated Physician Inertia Before and After Mandate	69
1.8	Heterogeneous Effects in Switching of Longstanding Patients	70
1.9	Structurally Estimated Physician Bias Before and After Mandate	71
1.10	Adoption Rate of Generics (over 5 years)	72
1.11	Framework for Policy Simulations	73
1.12	Policy Simulations	74
2.1	Incidence of Outsourcing	103
2.2	Effect of outsourcing on establishment employment	104
2.3	Effect of outsourcing on establishment Skill Ratio.	105
2.4	Effect of outsourcing on wages of workers that stay	106
2.5	Nonparametric specification	107
2.6	Effect of outsourcing on establishment investments	108
3.1	Relationship between Instructor Effectiveness (Grades) and Teaching Expe-	
	rience	156
3.2	Relationship between Instructor Effectiveness (Test Scores) and Teaching	
	Experience	157
A.1	Stylized Facts: Overall Prescription Rate 2000-2010	160
A.2	Descriptive Graphs: Prescription and Switching Rate of Generics	161
A.3	Stylized Facts: Changes in Prices	165
A.4	Determination of Status Prescription Drug	167
A.5	Processing and collection flow of the data	169
A.6	Market for Product Groups in Belgium	174
A.7	Dominance of Administration Method at Active Ingredient Level	175
A.8	Dominance of Administration Method at Active Ingredient Level	175
A.9	Definition of Starters and Longstanding Patients	176

A.10	Fraction of Product Group Prescription as a function of Baseline Prescrip-	
	tion (in deciles) \ldots	180
A.11	Within-Physician Correlations of Generic Prescription Rates across Product	
	Groups	181
A.12	Kernel Density of Generic Prescription Rate (Physician by Product Group	
	Level)	183
A.13	Descriptive Graphs: Prescription and Switching Rate of Generics	185
A.14	Physician Switching	187
A.15	Robustness Checks for Quality of Drugs Dispensed	190
B.1	Firing Rate by Occupation	206

LIST OF TABLES

<u>Table</u>

1.1	Classification of ATCs into Product Groups
1.2	Physician Descriptives
1.3	Summary Statistics for Patients and Precriptions
1.4	Split Sample Reduced Form Coefficients
1.5	Dose-Response Models
1.6	The effect of switching a patient on medication adherence
1.7	Pooled Chronic Drugs Reduced Form Results
1.8	Structural Parameter Estimates
2.1	Summary Statistics for Establishments
2.2	Summary Statistics for Workers Remaining in the Establishment 101
2.3	Event Study coefficients Interacted with Change in Share Low over High Skill102
3.1	Descriptive Statistics for Sections and Instructors (Full Sample) 145
3.2	Descriptive Statistics for Students (Full Sample)
3.3	Randomization Check
3.4	Main Course Grade and Test Score Outcomes
3.5	Robustness to Having Same Instructor for MTH208 and MTH209, FTF
	Sections
3.6	Robustness of Test Score Results to First-Stage Model (with Selection Shocks)150
3.7	Robustness to Imputation Method
3.8	Relationship between Course Grade or Test Effect and Teaching Evaluation 152
3.9	Instructor Effects for Alternative Outcomes
3.10	Correlates of Instructor Effectiveness
3.11	Correlates of Instructor Salary
A.1	Balance of Patients
A.2	Robustness Checks Level of Fixed Effects
A.3	Robustness Checks Level of Fixed Effects
A.4	Robustness Checks Quality Dispensed Drugs
A.5	The effect of switching a patient on medication adherence
A.6	Predicting Generic Switching Using Feature Selection Methods 197
B.1	Occupation Codes for different Business Service Occupations
B.2	Industry Codes for different Business Service Industries
ВЗ	Descriptives of Employment 205

C.1	Descriptive Statistics for Sections and Instructors (Test Sample)	209
C.2	Descriptive Statistics for Students (Test Score Sample)	210
C.3	How much switching is there between online and FTF campuses?	211
C.4	Correlation across Outcomes (Restricted to Test Sample)	212

LIST OF APPENDICES

Appendix

А.	Appendix to Quantifying Sources of Persistent Prescription Behavior: Evi- dence from Belgium	159
В.	Appendix to Fairness Considerations in Wage Setting: Evidence from Domestic Outsourcing Events in Germany	198
С.	Appendix to Measuring Instructor Effectiveness in Higher Education	208

ABSTRACT

This dissertation examines the importance of incentive schemes or personnel policies in three distinct labor markets.

The first essay answers the following question: How important are patient and physicianspecific factors in explaining persistent prescription behavior? A wide range of research has suggested that prescription behavior is highly persistent and an important barrier to realizing cost savings, but the sources of this persistence are not well understood. I quantify the importance of physician and patient factors in physician prescription behavior by exploiting a policy mandate in Belgium requiring physicians to prescribe a minimum percentage of cheap drugs, using detailed administrative data on 24 million prescription drugs dispensed to 152,000 patients. First, I show that physicians increase the prescription rate of generics for first-time users of an active ingredient by 10 percentage points. They do so without compromising on quality of dispensed drugs. Second, I find that first-time patients are more likely to receive a generic than long-time patient are likely to be switched from a branded to a generic drug, suggesting physicians consider the latter costly to switch. I find that switching a patient indeed comes at a cost, measured in decreased medication adherence. Building on this reduced form evidence, I develop and estimate a structural model. I use the model estimates to simulate the entry of generics and find physician and patient factors are about equally important in explaining the slow adoption of generics. Requiring pharmacists to only dispense generics decreases welfare, unless patient considerations are decreased by at least 60%.

In a second essay, I estimate the effect of domestic outsourcing events on wages of workers remaining in outsourcing establishments. I use employer-employee linked data from Germany that includes detailed administrative information on earnings, industry and occupation of employment. I exploit outsourcing event as my main source of identification and find substantial effects on the wages of workers that stay: holding worker ability constant, high skilled workers receive, on average, an immediate wage increase of about five log points, while low skilled worker face a wage cut of about one log points. On average, wage increases enjoyed by high skilled workers are positively correlated with changes in the skill ratio within the establishment. I propose a new theoretical model of wage setting in which fairness considerations generate spillover effects that are consistent with these two empirical findings. Taken together, these results indicate fairness considerations may play a role in wage setting.

In a third essay, co-authored with Kevin Stange and Brian Jacob, we investigate the role of instructors in promoting student success. We explore this issue in the context of the University of Phoenix, a large for-profit university that offers both online and in-person courses in a wide array of fields and degree programs. We focus on instructors in the college algebra course that is required for all BA degree program students. We find substantial variation in student performance across instructors both in the current class and subsequent classes. Variation is larger for in-person classes, but is still substantial for online courses. Effectiveness grows modestly with course-specific teaching experience, but is unrelated to pay. Our results suggest that personnel policies for recruiting, developing, motivating, and retaining effective postsecondary instructors may be a key, yet underdeveloped, tool for improving institutional productivity.

CHAPTER I

Quantifying Sources of Persistent Prescription Behavior: Evidence from Belgium

1.1 Introduction

Physicians frequently prescribe costly treatments even when cheaper alternatives become available or are recommended by clinical practice guidelines (Chandra, Cutler and Song, 2011). Policymakers who have tried to address this behavior to reduce health care costs have achieved limited success: studies consistently show that physician behavior is highly persistent and difficult to change.¹ One example is the use of generic prescription drugs that offer the same therapeutic value as their branded equivalents, but at a lower cost.² "Generic substitution," moving patients from branded to equally effective generic prescription drugs, could substantially reduce prescription drug costs – the fastest-growing segment of health care spending worth \$325 billion annually in the US and \$1.2 trillion worldwide (CMS, 2015; IQVIA, 2019). Specifically, estimates suggest that generic substitution could save the US 11% and EU more than 20% on overall prescription drug spending (Haas et al., 2005; Carone, Schwierz and Xavier, 2012; Choudhry, Denberg and Qaseem, 2016). A large body

¹Persistence refers to a tendency in prescribing behavior not explained by patient illness characteristics, demographics, or indicators of preferences (Phelps, 2000). Grimshaw et al. (2012), Ivers et al. (2012) and Wilensky (2016) review policies.

 $^{^{2}}$ The active ingredient is the chemical in the compound producing the biological or chemical effect. After patent expiration, generic manufactures can enter the market and manufacture the same (and equally effective) active ingredient.

of research argues, however, that persistent prescribing behavior is an important barrier to realizing these cost savings. Yet, the sources of this persistence are not well understood (Hellerstein, 1998; Kesselheim, Avorn and Sarpatwari, 2016).

In this paper, I study the importance of physician and patient factors in the persistence of physician prescribing decisions. On the one hand, physicians may prescribe the more expensive drug because of their habits (Hellerstein, 1998), preferences (Shrank et al., 2011), or financial incentives from physician dispensing or detailing (Iizuka, 2012; Grennan et al., 2018). This is often referred to as partial altruism, as physicians only partially act in the patient's best interest (Ellis and McGuire, 1986). On the other hand, physicians may take patients' needs or preferences into account, and as such, resist switching between equally effective drugs for patient-specific reasons. Patients exhibit brand loyalty (Sinkinson and Starc, 2018) or rely on pill appearance in their medication regimen (Sarpatwari et al., 2019). Changing a patient's prescription may lead to confusion and worse medication adherence (Kesselheim et al., 2014), possibly resulting in higher hospitalization rates and healthcare costs (Sokol et al., 2005; Bosworth et al., 2011). In such cases, persistence in prescription behavior may not be wasteful. Quantifying the relative importance of both provider and patient factors in physician treatment decisions, along with understanding their welfare effects, is critical for designing policy efforts aimed at containing healthcare costs while maintaining the quality of care. Nevertheless, empirical evidence on this question is limited.

I quantify the relative importance of physician and patient factors in prescribing decisions of primary care physicians (PCPs) in Belgium by exploiting a national policy mandating a change in prescribing habits. The mandate required PCPs to prescribe a minimum percentage of cheap or generic drugs. It was announced in June 2005 and went into effect starting 2006. The minimum prescription rate was set to 27% for PCPs, up from an average prescription rate of 18% in 2004. Physicians had to meet this quote over the course of a full year, and the mandate was binding for almost all PCPs.³

 $^{^{3}}$ Non-compliance resulted in physicians having to justify their decisions before the Order of Physicians. See section 1.2.3.

The analysis in this paper is organized in two parts. As a first step, I present reduced form evidence of physician and patient factors in PCPs' prescribing decisions. I document physicians' tendency to prescribe brand name drugs without quality or therapeutic justifications to do so. I refer to this tendency as *physician bias*, but do not take a stand on whether this bias is driven by habits, inattention, preferences or industry interactions. Additionally, I show that changing a patient's prescription drug decreases their medication adherence, and that physicians take this behavior into account. Patients who are prescribed a drug for the first time ("starters") are therefore more likely to receive a generic than patients who were using a brand name before ("longstanding patients"). I refer to this as *patient considerations*. As a second step, I develop and estimate a structural model to quantify the relative importance of both factors and to analyze counterfactual policies.

The Belgian healthcare market serves as a useful setting for several reasons. First, universal insurance alleviates concerns that physicians face uncertainty over differences in formularies or insurance plans, and rules out the possibility that patients might choose different plans (or none at all) in response to the policy mandate. This also simplifies modeling assumptions. Second, direct-to-consumer-advertising (DTCA) is not allowed. As a result, patients rarely request generics when they are prescribed a drug for the first time, and few patients can differentiate between branded and generic versions of the same prescription drug (Fraeyman et al., 2015).⁴ Changes in the demand for generics among starters therefore capture physician bias. Third, physicians prescribe on product name and pharmaceutical substitution is not allowed (i.e. pharmacists dispense as written).⁵ Detailed transaction data from pharmacies, stored in a central database to operationalize reimbursements in the healthcare system, therefore reflect physician prescribing behavior.

I draw rich and novel administrative data on 26 million dispensed prescription drugs between 2004 and 2009 for 152,000 randomly selected patients from this central database

 $^{^{4}}$ Physicians and healthcare officials confirmed patients rarely request branded drugs during an initial visit.

 $^{{}^{5}}$ See Section 1.2.2 for details on the absence of pharmaceutical substitution in Belgium at the time of the policy mandate.

to compute these patients' prescription profiles. For a random subset of 300 distinct PCPs, the dataset also records all 6 million prescriptions dispensed to their patients, which I use to track their average prescription rate of generics over time across different patients and prescription drugs. I merge this data with detailed drug characteristics, such as daily doses, potency, and extended release version, based on the product's unique barcode that is scanned upon dispensing in the pharmacy. Finally, I link census demographic records using unique patient and physician identifiers to precisely characterize the demographic profile of patients and physicians.

Physicians exhibit bias, as they respond to the mandate by increasing the prescription rate of generics without compromising on the quality of dispensed drugs. To isolate this bias, I focus solely on prescriptions for starters. Starters are unlikely to request a branded prescription drug, so limiting the analysis to these patients allows me to address concerns of unobservable demand factors or costs related to switching between drugs. The mandate increased the average prescription rate of generics for starters by about 10 percentage points, up from a pre-mandate average of 35%. PCPs far from the threshold ("low prescribers") responded more. PCPs did not decrease the use of (possibly superior) on-patent prescription drugs to comply with the mandate, with no discernible differences across high and low prescribers.⁶ Assuming generic and branded versions of the same active ingredients are equally effective, this is evidence of physician bias.⁷ I further strengthen this claim by showing no changes in other quality characteristics of dispensed drugs, such as administration method (e.g. pill or injection) or extended release formulation.

I show evidence of patient considerations by contrasting how PCPs respond to the mandate for starters and longstanding patients. I find that PCPs increase the switching rate for longstanding patients by about 1 to 2 percentage points, which is substantially lower than the 10 percentage point increase for starters described above. These differences imply

⁶On-patent drugs face no generic competition and are typically newer, so may be superior to older drugs with competition.

⁷See Kesselheim et al. (2008) and (Choudhry, Denberg and Qaseem, 2016) for meta-analyses on the equal clinical effectiveness of generics.

that it is less costly for a patient who needs a new prescription to receive a generic than for a longstanding patient to switch, and that PCPs take these costs into account. This lines up with previous work that finds physicians differentiate between starters and longstanding patients (Dickstein, 2011*b*; Sinkinson and Starc, 2018; Shapiro, 2018*a*; Feng, 2019).

Leveraging the quasi-experimental design of the mandate, I develop an instrumental variables framework and show that switching a patient from a brand-name to generic version of the same prescription drug indeed comes at a cost, measured with decreased medication adherence. I instrument the endogenous decision to switch a longstanding patient with exogenous variation in the timing of the mandate and whether the patient visits a low prescriber. I find that a switch causally reduces medication adherence by about 30%, and that a naive OLS estimate would understate the effect by a factor of two. A patient in my sample refills their prescription, on average, every two months, so a change in prescription drugs increases the time between refills by about three to four weeks. This decrease in medication adherence is short-lived and does not generate persistent reductions in adherence, suggesting an initiation cost to switching prescription drugs for longstanding patients. These costs are likely driven by patient behavior, such as confusion or mistrust, and can therefore be interpreted as an increase in "behavioral hazard" as defined by Baicker, Mullainathan and Schwartzstein (2015).

I complement this IV approach with a complier analysis where I investigate which patient observables predict an increase in switching probability in response to the policy mandate. I use linear probability models and non-parametric machine learning methods. Patients using an active ingredient for only 6 months are equally likely to be switched as those using it for at least 1.5 years, i.e. evidence of lock-in effects. Furthermore, PCPs are unlikely to switch older patients who take multiple prescription drugs. These results support the hypothesis that patient behavior likely drives patient switching costs.

To quantify the relative importance of physician bias and patient considerations, and understand the impact of counterfactual policies, I develop a structural choice model of physician prescribing behavior. I first model the demand for generic drugs, and then model how the policy mandate affects physician behavior. In my demand model, PCPs are decisionmakers maximizing transaction utility by choosing either a brand name or a generic drug.⁸ They take into account the patient's copay but also derive (private) utility from prescribing the brand-name drug, giving rise to physician bias. For longstanding patients, the PCP observes the cost of changing a patient's prescription drug. For chronic starters, I assume an exclusion restriction imposing this switching cost is zero, motivated by the absence of patient considerations for these patients and the inability of pharmaceutical companies to steer demand through changes in DTCA.⁹ It is typically difficult to separately identify switching costs from persistent preferences (such as physician bias); it is unclear whether the lack of switching is due to high switching costs or strong persistent preferences.¹⁰ I identify both sources of persistence separately by exploiting the exclusion restriction on starters, along with the introduction of the policy mandate. I use a difference-in-difference type argument to identify switching costs: the difference between the change in the generic share for longstanding patients and starters identifies the switching cost. Additionally, the postpolicy share of generic drugs among starters identifies post-policy physician biases. Similarly, pre-policy shares identify the pre-policy fixed effects.

I use the model to simulate the adoption of generics over a five-year period under three different scenarios. In one scenario, only the copay differential and physician bias affect PCPs' prescription decisions; in a second scenario, only the copay differential and patient considerations do. Finally, I simulate the adoption of generics in a scenario where the copay differential, physician bias and patient considerations all drive prescription decisions. Generics only achieve a market share of about 60% and 70% in scenarios one and two respectively. The market share in the final scenario plateaus at about 50%. The outcomes for scenario one and two are very similar, so physician bias and patient considerations seem

⁸This binary simplification is reasonable, as generic markets for a drug are typically dominated by one or two manufacturers.

⁹See, for instance, Sinkinson and Starc (2018) who show DTCA may impact demand for starters.

¹⁰See (Heckman, 1981) and (Torgovitsky, 2019) for more detailed discussions of these challenges.

to be almost equally important in the slow dissemination of generics in the prescription drug market. The steady inflow of chronic starters, however, does decrease the importance of patient considerations in the longer run.

Finally, I use the model estimates to simulate the introduction of a Mandatory Generic Substitution (MGS) policy, in which pharmacies are required to dispense the generic drug whenever possible – effectively overruling physician decisions. I assume that patient welfare can be characterized by the copay sensitivity and switching costs in the transaction utility.¹¹ I find that an MGS policy is predicted to decrease total insurance expenditures by 20%, but that it also leads to a welfare loss in patient considerations. The weight the social planner puts on patient considerations therefore guide whether an MGS policy increases overall welfare. I use the Minimum Prescription Rate policy mandate to calculate that the Belgian health care system is willing to accept a ≤ 1.5 increase in prescription drug costs for a ≤ 1 decrease in patient considerations (or less). This welfare weight suggests that the MGS for the Belgian health care system is welfare-decreasing. However, complementary policies that reduce patient switching costs by at least 60% could make the introduction of an MGS policy welfare-increasing.

These model simulations therefore suggest two take-aways for policy design. First, it highlights important trade-offs in the continuity of care. Policymakers increasingly consider policies that override physician decisions and pharmacies around the world regularly change generic suppliers depending on the cost. My results suggest these policies might result in costs for patients – especially since welfare losses are incurred on longstanding patients, who typically represent the majority of patients. Second, combining such policies with attempts to mitigate these negative effects (e.g. by making it easier to switch between prescription drugs) could increase overall welfare, and is therefore a promising area for future research. These concerns are particularly salient as chronic care accounts for about 75% of the overall health care budget (CMS, 2018).

¹¹In other words, patient welfare is the utility derived from the transaction taking out the physician bias.

The magnitude of this tradeoff in other healthcare markets, however, depends on how the results in this study extrapolate to these markets. The unique setting in Belgium allows for a transparent interpretation of how physician and patient factors interact, and what their relative importance is. By minimizing and eliminating several important confounding factors, I provide some of the first evidence that physicians take patient behavior and medication adherence into account in their decisions, and show this factor is quantitatively important (relative to physician biases). Nevertheless, healthcare markets where these confounding factors are present will therefore face different tradeoffs, and the direction of these effects is not always clear ex ante.¹² Understanding these interactions is a promising area for future research.

This paper adds to a rich literature on factors influencing physician prescribing behavior. I suggest medication adherence and patient behavior as novel factors driving persistence of prescription decisions that are not necessarily wasteful (Sokol et al., 2005; Chandra, Handel and Schwartzstein, 2018). To the best of my knowledge, this is the first study to do so. In contrast, researchers have studied other influencing factors such as physicians learning about the (static) match quality between a patient and an active ingredient (Crawford and Shum, 2005; Dickstein, 2011*a*), or the extent to which physicians act on (possibly perverse) financial incentives – typically referred to as agency (Iizuka, 2012; Rischatsch, Trottmann and Zweifel, 2013; Grennan et al., 2018). Other papers have considered the role of physician habits (Hellerstein, 1998; Janakiraman et al., 2008; Emanuel et al., 2016), or direct-to-consumer advertising of prescription drugs to patients (Sinkinson and Starc, 2018; Shapiro, 2018*b*). Furthermore, in contrast to other studies of medication adherence, the sample of patients in this study is also remarkably representative.¹³

This paper also speaks to a broader literature on persistent physician behavior and treatment choices (Phelps, 2000; Chandra, Cutler and Song, 2011). The clean identification of

 $^{^{12}}$ DTCA, for instance, may affect demand for, especially for starters (Sinkinson and Starc, 2018), and the perceived effectiveness of generics – and therefore medication adherence after a switch.

¹³Other studies typically rely on smaller samples from specific pharmacies, providers, or regions in the US or other countries (Glombiewski et al., 2012; Lam and Fresco, 2015).

patient switching costs in the presence of persistent physician bias addresses challenges surveved by Farrell and Klemperer (2007).¹⁴ Researchers' inability to observe initial choices in micro-level panel datasets confounds their ability to separately identify switching costs from persistent preferences. I exploit rich micro-level panel data covering six years of prescriptions over different prescription drugs, to observe active choices for starters before and after the policy mandate, and contrast them to choices for longstanding patients. This allows me to disentangle switching costs from persistent preferences, and quantify their relative importance. Other studies rely on controlling for patient characteristics and stated preferences (Baicker et al., 2004; O'Hare et al., 2010), or exploiting moving Medicare beneficiaries (Finkelstein, Gentzkow and Williams, 2016). To a lesser extent, my paper also provides a view of health care services as credence goods - complex products or services sold on markets with information asymmetries between informed experts and uninformed buyers. I show that one may overstate the extent to which expert advice is biased if patient face switching costs (Darby and Karni, 1973). One may also interpret this as extending the literature on consumers facing switching costs (Klemperer, 1995) to allow for these consumers to visit biased experts.

This paper proceeds as follows. Section 1.2 presents the policy studied in this paper and highlights several key features of the Belgian healthcare market. Section 1.3 presents the data sources that are used, while section 1.4 presents the reduced form results. Section 1.5 presents the structural model. Section 1.6 presents the decompositions and policy counterfactuals, while section 1.7 concludes.

¹⁴Thus, this paper also relates to the literature separating persistent preferences from switching costs surveyed in this paper.

1.2 The Minimum Prescription Rate (MPR)

1.2.1 Setting

Belgium counts about 11 million inhabitants and 11,000 certified and active primary care physicians, making its health care market comparable to Michigan, Pennsylvania, or Ohio.¹⁵ The healthcare system in Belgium is organized through a tightly regulated health insurance market providing universal health insurance.¹⁶ Universal health coverage is achieved by requiring every eligible person to acquire Mandatory Health Insurance (MHI) by enrolling at one of several competing health insurance providers (called "sickness funds") that are set up as not-for-profit organizations.¹⁷

The National Institute for Health and Disability Insurance (NIHDI) specifies the services that are covered in the standard MHI plan, and negotiates prices for these services. Prices are set nationally, with certain well-defined demographic groups receiving "increased reimbursements," which I will denote as IR patients in this paper.¹⁸ As a result, the plan is homogenous across sickness funds, and competition is therefore mostly on service.¹⁹ Sickness funds are reimbursed for their costs using risk-adjustment formulas similar in spirit to

 $^{^{15}}$ Belgian population statistics for 2011 and retrieved from ec.europa.eu/eurostat/data/database on 11/2/2017. Healthcare statistics reported for 2005 and obtained from Roberfroid et al. (2008). Population and physician workforce statistics for Michigan, Pennsylvania, and Ohio retrieved from Center for Workforce Studies (2013).

¹⁶The Belgian model is sometimes classified as a "social insurance" or "Bismarck" system, with similar systems being used in Germany, the Netherlands, France, Japan and Switzerland (Reid, 2010).

¹⁷One is eligible if over 25 years of age, or if 25 years of age or younger but employed or receiving unemployment insurance. People younger than 25 are insured through their parents. Source: https://www.vlaanderen.be/nl/gezin-welzijn-en-gezondheid/gezondheidszorg/ziekteverzekering, accessed 01/27/2018. In 2016, there were 53 mutual funds that were grouped into five national associations, who have deep political and ideological roots. The five national associations are the Christian Mutalities, the Socialist Mutualities, the Liberal Mutualities, the Independent Sickness Funds, and the Neutral Sickness Funds. Entry (or exit) into the MHI market is not allowed.

¹⁸These demographic groups are orphans, persons with disabilities, widows, pensioners, or people on unemployment insurance. Prices for prescription drugs could in principle change every month, and can be consulted online.

¹⁹Mutual funds can differentiate by including services that are not part of the standard MHI plan. This supplementary insurance has become more popular in recent decades, and this market is fully competitive – mutual funds and private insurers compete in a fully competitive market. As Schokkaert, Guillaume and Van de Voorde (2017) point out, supplementary insurance schemes are typically used for ambulatory services, not prescription drugs, and this therefore does not affect the design of this study.

Medicare reimbursements to offset the cost for non-selective contracting (Schokkaert, Guillaume and Van de Voorde, 2017).²⁰ The system is financed through employer and employee contributions (Grosse-Tebbe and Figueras, 2005).²¹

Taken together, the Belgian healthcare market provides a setting where patients do not face insurance plan choices for prescription drugs and there is no outside option (as noninsurance is not allowed). There are no economic incentives to prefer one sickness fund over another, so switching between these funds is rare – about 1% of enrollees switch in any given year (Schokkaert, Guillaume and Van de Voorde, 2017). Furthermore, physicians face no uncertainty regarding the plan a certain patient is on or which prices they face, as patients with higher reimbursement rates are typically easily identified by physicians (Farfan-Portet et al., 2012).

1.2.2 The Market for Physicians and Prescription Drugs

Physicians. Enrollees are free to choose their primary care physician.²² Even though the state enforces strict regulation on the insurance market and that products in the standard MHI plan, there is a long tradition of physician autonomy in how they choose to treat their patients. Physicians receive a flat fee for a visit, and if, during the course of this visit, they decide to prescribe a certain drug (or set of drugs), this prescription is provided free of charge.²³ There are no direct financial incentives embedded in the health care system for physicians to prescribe a generic (or a brand name) drug.

Prescription Filling. Figure 1.1 provides an example of a prescription. The bar code

 $^{^{20}}$ For a variety of reasons, including political ones, there are no direct steps to move towards selective contracting in the near future (Schokkaert, Guillaume and Van de Voorde, 2017).

 $^{^{21}\}mathrm{See}$ Appendix A.1 for a short discussion and additional references.

 $^{^{22}}$ In other words, there are no networks that differ across sickness funds as in the US. The profession of physician is regulated through a licensing-type system for "Free Professions," where there is a strong focus on autonomous decision-making with little direct state involvement (see Appendix A.1.3). Unlicensed physicians are not be reimbursed by the NIHDI.

²³In most cases, patients pay the full amount and then use a pay slip to receive the reimbursement directly from his or her mutual fund. Patients receiving higher reimbursements (if they are part of the well-defined at-risk groups discussed above) only pay the required copay and the physician directly bills their sickness fund.

on top uniquely identifies the physician who prescribes the exact product to be dispensed in the text box indicated by the number 5 on figure 1.1b. A physician will write down the branded or generic name (with manufacturer), potency, size and number of packages.²⁴ The patient then takes this prescription to the pharmacy, where the pharmacist dispenses the product exactly as prescribed by the physician.²⁵. An electronic health insurance card that is inserted into a chip reader identifies the patient and associated insurance plan. Patients generally pay the full price, and the recover the reimbursement by handing the prescription over to their mutual fund, along with a sticker that identifies the patient.²⁶ Prescription drugs are dispensed in the original packaging produced by the manufacturer, that can differ across manufacturers (see Figure 1.2 for an example).

Prescription Drug Markets and Pricing. Within a market for an active ingredient, almost all transactions (99%) make use of one single active ingredient, and the two largest manufacturers capture about 85-90% of the market. Appendix A.2.3 describes this in larger detail.

The Belgian healthcare system uses a reference pricing system (RPS) for prescription drugs, introduced in 2001 (Farfan-Portet et al., 2012; Cornelis, 2013).²⁷ An RPS consists of a set of *drug clusters* and the *reference prices* that applies to these clusters. The clusters are groups of prescription drugs that the policymaker considers to be equivalent, while the reference price is the maximum price manufacturers can charge within a cluster. Belgium has a "generic RPS" where all drugs with the exact same active ingredient form one cluster (Vrijens et al., 2010; Farfan-Portet et al., 2012).

The reference price is based on a well-defined estimate of the production cost of the

 $^{^{24}\}mathrm{A}$ program to prescribe active ingredients rather than product name was available during this period, but not used.

²⁵Suggesting (or dispensing) an alternative but equivalent prescription drug was, in fact, illegal (Farfan-Portet et al., 2012). In practice, pharmacists may send patients to another pharmacy, or dispense a generic of a different make (e.g. Sandoz rather than Mylan) if the prescribed generic brand is not in stock.

 $^{^{26}}$ Exceptions are made for (typically expensive) drugs and patients on an *IR* plan, where only the copay is charged.

 $^{^{27}}$ RPSs are used in other countries, as discussed in Dylst, Vulto and Simoens (2012), Simoens (2012) and Farfan-Portet et al. (2012).

branded drug. If a branded prescription drug charges the reference price, it is considered cheap. The NIHDI then also only covers the reimbursement based on this reference price (i.e. they cover $(1 - c) \times P$ where c is the copay rate and P is the reference price). If the branded drug charges more than the reference price, it is considered expensive and the patient pays the remaining amount. While there some changes in the RPS in Belgium, the copay differential between branded and generic prescription drugs remained largely constant and the mandate did not affect tis gap, as is further detailed in Appendix A.1.5.

Prescription Drug Advertising and Detailing. Direct-to-consumer advertising (DTCA) for prescription drugs is not allowed in Belgium (Rekenhof, 2013).²⁸ As a result, patients typically cannot tell brand name and generic drugs apart and are unlikely to request the branded version when they are prescribed a prescription drug for the very first time (Fraeyman et al., 2015). Detailing, the process through which pharmaceutical companies inform physicians about their products, is strictly regulated. Pharmaceutical companies can disseminate scientific information through publications and visits of representatives, but regulations require the content be sufficiently scientific. Similarly, conferences to which physicians can be invited need to have sufficient scientific merit, and costs need to "reasonable."²⁹

Take-away. Given the institutional features described above, the Belgian healthcare market provides a setting where dispensed drugs closely reflect physician decisions. Furthermore, the generic market for a given active ingredient is typically dominated by one or two manufacturers, indicating the choice between generics is not a first-order concern. Patients are unlikely to request the brand name drug during an initial diagnosis and there are no (direct) financial incentives for physicians to prescribe a generic or a brand-name drug. Detailing is allowed, but regulations limit the extent to which pharmaceutical companies can respond to a policy requiring physicians to change their prescription practices.

²⁸There are provisions for exceptions regarding campaigns of public interest (such as vaccination program). Advertising (non-prescription) over-the-counter drugs is legal.

²⁹ "Reasonable" as specified in the Royal Decree of 7 April 1995. In practice, such events are typically a presentation including scientific results, followed by a dinner or event.

1.2.3 The Minimum Prescription Rate (MPR)

Historically, the take-up of generics drugs in Belgium has been low, and expenditures on prescription drugs rose at faster rates than healthcare expenditures during the 1990s and early 2000s (Cornelis, 2013).³⁰ Cheap drugs – brand name drugs that match the price of generics – were also very uncommon. In fact, the market share of generics and cheap drugs, measured in Defined Daily Dosage (DDD), was only about 12 and 15 percent respectively in 2004.³¹

In response, the government and NIHDI announced the introduction of a Minimum Prescription Rate (MPR) in 2005: physicians were required to prescribe a minimum percentage of generic or cheap drugs, but were free in how to comply with this percentage. Physician organizations resisted, as there was a strong tradition of independence in their decisionmaking.³² At the same time, NIHDI was aware that abrupt changes to prescription behavior could be detrimental to patient health and industry relations.³³ After several weeks of discussion, this percentage was set at 27 percent for primary care physicians, and announced at the end of June 2005, and went into effect starting in January 2006.³⁴

Knowing the exact prescription rate throughout the year, however, is challenging for physicians. They were not informed about their prescription rate in 2004 or 2005 before

³⁰Drivers of cross-country differences in the adoption generic drugs are complex. See Costa-Font, McGuire and Varol (2014) and Wouters, Kanavos and McKee (2017) for a discussion. Important determinants include, but are not limited to, price regulation, the organization of the health care sector (e.g. the use of generic substitution at the pharmacy) and the cost differential between generics and brand-name drugs. However, Wouters, Kanavos and McKee (2017) point out that there are substantial methodological challenges in reliably calculating these differences across countries.

 $^{^{31}}$ DDD is a well-defined quantity measure used by the World Health Organization to capture a typical daily dose. While this quantity-measure is well-defined, physicians are not fully familiar are aware of its magnitude. See https://www.whocc.no/ddd/ for further information. Website accessed 01/31/2018.

 $^{^{32}}$ This tradition was, in part, reason for the relative freedom the mandate afforded physicians in how to comply.

³³Possible adverse effects on patients were a concern when discussing the threshold in the MPR: policymakers I talked to specifically mentioned this as a reason to not set the threshold too high and why thresholds were set by specialty.

³⁴In practice, NIHDI had calculated the average share of cheap drugs by specialty in 2004 (in DDD), multiplied this number by 1.25, and set this number to be the MPR for the relevant specialty. Physicians prescribing less than 200 packs of prescription drugs on an annual basis are precluded from the minimum threshold. This exemption largely targeted older physicians that had effectively retired, but still prescribed some prescription drugs for home and family use.

the mandate went into effect. There was no way for them to track it in real-time, and the volume measure (DDD) was not typically used by physicians. The NIHDI, however, did recognize the need to inform physicians and sent out reports with the 2005 prescription rate in 2006. If a physician did not meet the MPR threshold, he or she was required to prepare documentation and defend their prescription behavior in person to the Order of Physicians, located in Brussels.³⁵ Ultimately, the majority of physicians complied with the mandate, and no physicians were ever called upon to defend her prescription behavior.³⁶

This policy mandate therefore provides a unique opportunity to understand how physicians make prescription decisions, how costly it is to adjust their prescription practices, and whether these costs differ across different types of patients. Furthermore, this mandate also provides a unique opportunity to try and evaluate whether switching longstanding patients can actually results in worse health outcomes or not.

1.3 IMA Farmanet: Transaction-Level Prescription Data

I use two novel datasets drawn from Farmanet, a database maintained by the NIHDI that links physicians and patients to prescription drugs dispensed in public pharmacies in Belgium, and merge them to a rich set of physician and patient-level demographics and vital statistics.³⁷ At the transaction level, pharmacists scan the prescription bar code (containing a unique physician identifier as shown in figure 1.1), and the product bar from the packaging. Patients insert their health insurance card (containing a unique patient identifier) that automatically calculates the copay based on the patients' insurance plan. The patient and

³⁵The Order of Physicians in Belgium can be compared to the American Medical Association, in that it decides, among other things, the number of medical profession jobs that open up each year and continuing education for physicians. Physicians that are charged with misconduct or professional violations go through a similar first step, therefore, these costs can be considered significant in terms of effort, stigma and reputation. In contrast to misconduct charges, however, it was not made clear what additional steps would be taken after an unsatisfactory defense.

³⁶They were, in part, helped by a substantial shift of brand name multisource drugs that matched the reference price and became cheap. However, these changes were difficult to anticipate.

³⁷Figure A.5 provides a graphical overview, but see RIZIV/INAMI (2009) for a detailed discussion on data collection and processing. Hospital pharmacies are excluded from this data source, as are drugs not eligible for reimbursement.

physician identifier are based on their National Registry Identification Number and therefore consistently track the same individual over time, and the data undergo extensive quality review at different points in time.

NIHDI. The first dataset is provided by NIHDI and draws a 10% random sample of physicians and provides their full transaction history from January 2004 through December 2009. Physician-level information includes anonymized identifiers, sex, age, year of degree, and province of residence. NIHDI has collected these data on all prescription drug transactions in pharmacies since January 2004. At the patient level, there is information on the insurance plan, age, and sex of the patient, but no patient identifiers. Barcode identifiers at the product level allow me to match hand-collected product-level information, including dosage and strength of the drug, DDD of the transaction, brand and manufacturer name, along with the exact active chemical element as denoted by the ATC (Anatomical Therapeutic Chemical) Classification System.³⁸ This dataset is primarily used for descriptive statistics and to compute prices and determine when generic prescription drugs were introduced.

IMA. The second dataset is provided by the InterMutualistic Agency (IMA), a joint research venture created by several mutual funds, that augments the Farmanet data described above with patient identifiers that I use to merge on patient-specific zip code, demographics, healthcare information and vital statistics.³⁹ I randomly sample 300 physicians, select all patients they see between January 2004 and December 2009 that are over 35 years old in 2006, and obtain the full transaction history of these patients.⁴⁰

This sampling frame provides three distinct advantages. First, patient-specific anonymized identifiers consistently track patients over time and across prescriptions, which is crucial to

³⁸The ATC system classifies active ingredients of prescription drugs, and consists of five levels. At the most detailed level, drugs have the exact same active chemical ingredient. The fourth level suggests therapeutic equivalence.

³⁹All mutual funds participate in this effort.

⁴⁰Therefore, the dataset contains both prescriptions written by physicians that are part of the 3% random sample, and physicians that are not part of this random sample but were seen by the patients in question. This sampling frame was, in part, motivated by proportionality requirements put forward by the privacy review that set forward a maximum number of patients that could be part of the study. The physicians in the IMA dataset cannot be linked to the physicians in the NIHDI dataset.

identify patients that are prescribed a prescription drug for the first time and get a full picture of patients' prescription profile (e.g. the number of different prescription drugs a patient is taking). Second, it allows me to describe detailed prescription profiles of patients incorporating information from all prescriptions and visits, even when physicians are not part of the original 3% random sample. Third, I can measure the impact on, among others, healthcare expenditures or number of days the person was incapacitated for work, and can take into account a rich set of demographics (such as whether the person is part of a one-person household or receives welfare) or regional information using the NIS code (which is roughly comparable to a US zip code).

Limitations. Both datasets, however, exhibit some limitations that are worth noting. First, the data cover prescriptions that are filled and dispensed at pharmacies, not all that are written. Therefore, the transaction data only provide a proxy of the actual prescription behavior. Second, hospital pharmacies and drugs that are not covered by health insurance are not included in the dataset. Third, while most patients are prescribed their first chronic prescription drugs at older ages, the sampling frame does not include patients that are prescribed chronic drugs at early ages (i.e. under 35 years old).⁴¹

Additional data. Finally, I hand-collect several additional datasets with detailed product information at the product barcode level. A first dataset collects product details such as ATC code, manufacturer, number of daily doses per pack, number of pills, strength of the pill, and mode of administration. A second dataset was hand-collected and provides the exact date of introduction of all prescription drugs in Belgium. This information is available for prescription drugs with differences in dosage, method of administration, active chemical and manufacturer. A third, and final dataset, differentiates between two types of generics: "copies" and generics. The latter refers to standard generic prescription drugs, that differ in inactive ingredients and are therefore tested rigorously before making it onto the market. The former are exact copies of the brand name drugs, based on the specific manufacturing

⁴¹Given the age restriction, this study will not focus on anticonceptive prescription drugs.

process of the brand name manufacturer. As a result, they require less extensive testing and documentation.

1.3.1 Defining Starters and Patient Profiles

I compute several measures that capture the disease and risk profile of the patient receiving a prescription. First, I define starters as patients that have been using an active ingredient for 3 months or less, as patients typically refill their prescription drugs every 2 months (see below).⁴² Second, I compute a polypharmacy measure that counts the number of prescription drugs the patient regularly takes.⁴³

Third, I describe how well a patient follows the prescriptions of a physician by computing an adherence measure. Specifically, I compute the ratio of the number of daily doses prescribed in a transaction by the number of days between the current and the next prescription fill, which is formally written out in equation 1.1, where j indexes the patient, p indexes the active ingredient, and t indexes the prescription date.⁴⁴

$$Adherence_{jpt} = \frac{DDD_{jpt}}{Date_{jpt+1} - Date_{jpt}}$$
(1.1)

An adherence measure below one suggests the patient does not follow the prescriptions as ordered, where a measure of one reflects perfect adherence.⁴⁵

⁴²Figure A.9 in appendix A.2.4 discusses censoring issues when using this definition in the data: it is impossible to distinguish between starters and longstanding patients in the first three months of the dataset. Therefore, I only employ this definition for starters after April 2004, and denote all transactions in the first three months of 2004 as written for longstanding patients.

⁴³The specific measure is the number of different ATCs the patient takes in 2004. I restrict to active ingredients of which the patient picks up a minimum of 100 daily doses in 2004, and visits a pharmacy for this specific prescription drug at least on three different dates in that year – this to exclude small one-time medications that are not taken regularly. This polypharmacy measure is computed using prescriptions across all physicians (not only the core sample).

⁴⁴I compute this difference in days at the patient by active ingredient level.

 $^{^{45}}$ I correct for some outliers, and only compute this measure if there are at least (most) 7 (500) days between filling. Adherence measures for patients who were prescribed large daily dosage amounts (over 200 daily doses) were also set to missing.

1.3.2 Sample Selection and Descriptive Statistics

Sample Selection. The IMA dataset consists of 6,440,115 dispensed transactions that are written by the core sample of 300 physicians for 152,589 patients that are at least 35 years old in 2006. The full dataset, containing other physicians these patients see, consists of 25,449,736 dispensed transactions and covers 44,872 physicians. Further details on sample selection and statistics on merging are discussed in Appendix A.2.1. The NIHDI dataset contains 42,398,960 transactions. The primary use of this dataset is to compute the full price that is paid for a prescription drug to a pharmaceutical company, along with the copay and the reimbursement. Details on sample selection are reported in Appendix A.2.2.

Descriptive Statistics. This section describes key features of patients and physicians in the analysis sample. Table 1.2 compares the overall physician population in Belgium (column one and two) to the physicians in the NIHDI dataset (column three and four) and the IMA dataset (column five and six). Overall, physicians in the IMA and NIHDI datasets are comparable and representative of the wider physician population.⁴⁶ On average, physicians in the baseline year (2004) are about 45 years old with about 20 years of experience. About three out of four physicians in the sample is male. The baseline prescription rate of generics is 12.2 percent, while it is 17.2 percent for cheap drugs.

Table 1.3 describes the IMA prescription dataset in 2004. The left panel covers all dispensed prescription drugs, while the right panel focuses on active ingredients for which a generic equivalent was available. Physicians prescribe an on-patent prescription drug (that has no generic equivalent) about half of the time. Prescription drugs intended to treat chronic conditions make up the bulk of transactions (about 75 to 80% for both off-patent and on-patent prescriptions).⁴⁷ A typical patient receiving a prescription drug is about 65 years of age and slightly more likely to be female. About one transaction in four is intended

 $^{^{46}\}mathrm{The}$ total number of daily doses in the IMA sample is lower, as patients under 35 years old are not included.

 $^{^{47}}$ I determine whether an active ingredient is a chronic drug using the classification suggested by Huber et al. (2013).

for a patient on an increased reimbursement schedule, one transaction in seven is intended for a starter. A prescription typically covers about 45 DDDs or approximately a 1.5 month supply. Patients refill their prescriptions just over every month and a half. Adherence therefore centers around 1, and a patient takes, on average, about 3.5 active ingredients on a regular basis.⁴⁸

Baseline Prescription Behavior of Physicians. Physicians exhibit variation in the prescription rate of generics, as highlighted in Figure 1.3. As is often documented in the literature, differences in patient characteristics or disease profiles do not explain this variation. Appendix A.3.1 documents these findings in more detail. Appendix A.3.1 also documents that a physician prescribing high levels of generics for one prescription drug does not necessarily prescribe high rates of generics for another prescription drug. In fact, the within-physician correlation of the prescription rate *across* prescription drugs is typically in the 0.2-0.4 range.

1.3.3 Descriptive Evidence on the MPR

Figure 1.3 shows the (smoothed) distribution of prescription rates of generics in 2004 (before the announcement of the mandate) and in 2006 (after the introduction of the policy mandate). It shows a clear shift towards a higher prescription rate of generics. Appendix A.3.2 discusses the distribution of generic prescription rates in more detail, and shows that physicians primarily increased the use of generic prescription drugs where they were prescribing low shares in 2004. Furthermore, Appendix A.3.1 also shows that the prescription rate of generics was relatively stable between 2000 and 2004, with a sudden increase in 2005-2006.

In Figure 1.4, I investigate this further by zooming in on the fraction of generic drugs prescribed to starters and the switching rate of brand name drugs to generic drugs for long-

⁴⁸There are three reasons for the missing values in adherence measures. First, these are not computed for prescription drugs intended for non-chronic conditions. Second, the first time a chronic patient shows up in the data, no adherence measure can be computed, as the previous date cannot be observed in the data. Relatedly, the measure exhibits many outliers in the first three months, that are therefore excluded. Finally, there are additional restrictions described above.

standing patients.⁴⁹ The upper panel shows the overall effect for starters (Figure 1.4a) and longstanding patients (Figure 1.4b). In both graphs, the prescription rates are stable before the announcement of the mandate and exhibit an increase after the mandate is announced. The prescription rate for starters remains high after the mandate goes into effect, while the rate of switching longstanding patients from brand name to generic goes up in response to the mandate, and returns to its initial levels after about a year. Additionally, the switching rate from generic to brand name drugs is stable for chronic longstanding patients, suggesting that physicians did not decide to switch patients back from generic to brand name drugs after the mandate was announced.

The lower panel of Figure 1.4 breaks these graphs down by physicians far from and close to the threshold (I refer to these as "low" and "high" prescribers respectively). Specifically, a low prescriber's prescription rate of generics in 2004 was in the bottom quartile of the distribution of generic prescription rates in 2004, while high prescribers had one in the top quartile.⁵⁰ The graphs display stable prescription and switching rates before the mandate is announced, supporting the common trends among high and low prescribers. Furthermore, they also display a narrowing of the gap between high and low prescribers.

1.4 Reduced Form Evidence on the introduction of MPR

The descriptive evidence above suggests that the mandate was effective in changing the prescription behavior of physicians, but it is silent on whether this changed the quality of drugs that were prescribed and why physicians might treat starters and chronic longstanding patients differently. This section exploits the quasi-experimental variation of the mandate and provides reduced form evidence on four key research questions that, taken together, help to understand how important physician bias and patient considerations are.

⁴⁹I again focus on the choice within active ingredients for which a generic is available before the mandate is announced.

 $^{^{50}\}mathrm{The}$ physicians in the middle are therefore dropped.
1.4.1 Do Physicians Switch to Generics?

I estimate the treatment effect of the law on the fraction of generics prescribed for nonchronic prescription drugs, chronic starters and chronic longstanding patients by running the following regression.⁵¹

$$g_{ijpt} = \sum_{\tau=-T}^{T} \beta_{\tau} \mathbb{I}\{q(t) - q(t^*) = \tau\} + \delta_{ip} + \phi \boldsymbol{X}_{ijpt} + \epsilon_{ijpt}$$
(1.2)

The outcome variable g_{ijpt} is an indicator that takes on value one if a generic is prescribed by physician i for chemical p in period t for patient j, and value zero if not. I run these regressions separately for non-chronic drugs, chronic starters, and chronic longstanding patients. The indicators $\mathbb{I}\{q(t) - q(t^*) = \tau\}$ are quarter-level fixed effects that capture the average prescription rate of generics just before and after the announcement of the mandate in quarter $q(t^*)$ (the third quarter of 2005). The coefficients on indicators β_{τ} capture the dynamic time path of the fraction of generics prescribed conditional on a set of controls X_{ijpt} and physician by chemical fixed effects δ_{ip} . Allowing for physicians to exhibit different biases across different prescription drugs makes sense, given the descriptive evidence of baseline prescription behavior presented in section 1.3.3. As a full set quarter fixed effects are perfectly collinear, I leave out indicator of the announcement month $q(t^*)$ to normalize the coefficients to the announcement of the mandate. The identifying assumption for this model to capture the causal effect of the mandate and ϵ_{ipt} to be an idiosyncratic error term, is that there are no contemporaneous changes in prescribing behavior at the time of the policy that are not caused by the policy. Standard errors are clustered at the physician level to allow for arbitrary correlation across observations at the physician level.

I include the price differential between generic and multisource drugs and an indicator variable for the gender of the patients. The price differential is the copay for a daily dose, and is calculated at the active ingredient by month level.⁵² Additionally, I include an indicator

⁵¹The results for non-chronic drugs are included in appendix A.3.

 $^{^{52}}$ Prices are typically set at the monthly level. I calculate the average price (defined as copay per daily

that takes on value one if the person is on an increased reimbursement plan and an interaction between this indicator and the price differential to test for differences in price sensitivity across these two different patient groups. I run these regressions separately for chronic starters and longstanding patients.

The β_{τ} coefficients from regression 1.2 along with their cluster-robust 95% confidence intervals are shown in Figure 1.5. They suggest that the prescription rate of generics increased by about 10 percentage points for chronic starters, but only by about 1 to 2 percentage points for chronic longstanding patients. For chronic starters, the effect persists well beyond the introduction of the mandate. The prescription rate of generics among longstanding chronic patients, however, only increases by about one percentage point, an effect that only lasts for about a year. The prescription rates are relatively stable before the announcement of the mandate. There is some anticipation in the quarter before the exact mandate was announced, likely the result from public discussions in the two months leading up to the mandate.⁵³ I also obtained additional aggregate pre-data from NIHDI that shows the prescribing behavior was relatively stable before the policy mandate (see Appendix A.1.2).

These regression results suggest that the mandate resulted in physicians adjusting their behavior towards prescribing a higher share of generics. The substantial difference in switching rates between the two types of patients, however, highlights that physicians consider longstanding patients costlier to switch than chronic starters. This is consistent with other recent studies investigating prescription behavior of physicians that find treatment decisions for starters are more prone to respond to physician incentives (Sinkinson and Starc, 2018; Feng, 2019).

Dose-Response Model. In order to exploit the variation in baseline prescription rates, I use the distance to the mandated threshold to estimate dose-response models.⁵⁴ I split

dose) by calculating the average across all products at the active ingredient level, following Iizuka (2012).

⁵³As noted before, it was clear about two or three months before the actual mandate was announced that a minimum percentage would be mandated, even though the exact percentages were still being discussed between key stakeholders such as the NIHDI and the Order of Physicians.

⁵⁴Difference-in-Difference models are not appropriate in this setting, as most physicians had prescription rates well below the threshold, leaving few control units. Furthermore, those physicians above the threshold

physicians into "high" and "low" prescribers based on their baseline prescription rate of cheap drugs, and use the median as a cutoff (i.e. physician above the median are "high" prescribers and vice versa). As before, physicians are indexed by i, patients by j, active ingredients by p and time by t. Standard errors are clustered at the physician level.

$$g_{ijpt} = \beta_1 Post_t + \beta_2 Post_t \times High_i + \delta_{ip} + \delta_{m(t)} + \phi \mathbf{X}_{ijpt} + \epsilon_{ijpt}$$
(1.3)

The results for these Dose-Response model are reported in table 1.5 and highlight that physicians further from the threshold indeed respond by prescribing higher shares of generics for patients, both for chronic starters and longstanding patients. Furthermore, most switching among longstanding patients happens among physicians that are further from the threshold, which will be a useful result that will be exploited below.

Robustness Checks. One possible concern is that patients respond to the mandate by changing their physicians when these physicians start prescribing higher levels of generics. I show in Appendix A.2 that such physician shopping is not a concern when examining the data.

The empirical strategy in this section assumes physicians exhibit biases at the chemical level, and considers patients as chronic starters when they switch the active ingredient they use. In Appendix A.2, I show that the results are robust to including physician by therapeutic fixed effects (rather than physician by chemical ones).⁵⁵ Changes to the definition of starters also do not substantively change the results. For instance, changing the 90-day window to 60 or 120 days does not change results, nor does defining chronic starters at the therapeutic level rather than at the active ingredient level. I also exploit the physician response to non-chronic prescription drugs as a robustness check, as prescription decisions for non-chronic drugs are essentially very similar to those for starters. In appendix A.2, I confirm that the mandate response is indeed very similar across both prescription types. I also show that allowing for

faced some uncertainty over their prescription rates for the reasons mentioned in section 1.2.3.

⁵⁵This is not surprising, as the vast majority of important prescription drug groups (e.g. statins or ACE inhibitors) over the sample period are dominated by one single off-patent active ingredient.

flexible patient demographic controls does not alter the magnitude of the findings in this section.

1.4.2 Do Physicians Move Away from On-Patent Drugs?

While the results above provide clear evidence that physicians switched to generic drugs for chronic starters, this result alone does not provide conclusive evidence that physicians exhibit bias. If the mandate induced physicians to switch from on-patent drugs to generic off-patent drugs, patients are now less likely to receive newer treatments that are possibly superior. If on-patent drugs are more effective or result in fewer side effects, the mandate has then lowered patient welfare. In order to test whether the mandate caused physicians to switch from on-patent drugs to generics, I use an empirical specification similar in spirit to Equation 1.2. It tests whether physicians, when deciding on a therapeutic class of drugs c (e.g. beta blockers or diuretics) were more likely to choose those active ingredients that were on-patent or not.

$$OnPatent_{ijct} = \sum_{\tau = -\Delta}^{\Delta} \beta_{\tau} \mathbb{I}\{q(t) - q(t^*) = \tau\} + \delta_{ic} + \phi \mathbf{X}_{ijct} + \epsilon_{ijct}$$
(1.4)

The variable $OnPatent_{ijct}$ is an indicator that takes on value one if physician *i* prescribes a on-patent drug for patient *j* at time *t*, and zero if not. The subscript *c* indexes the therapeutic class, therefore the variation exploited is the choice for an on-patent or offpatent active ingredient within a therapeutic class. The coefficients β_{τ} in this regression capture the dynamic time path of the fraction of multisource drugs prescribed conditional on a set of controls X_{ijpt} and physician by therapeutic class fixed effects δ_{ic} . The vector of controls includes the price differential between on-patent and off-patent active ingredients and indicator for female patients. As before, standard errors are clustered at the physician level.

The β_{τ} coefficients along with their cluster-robust 95% confidence intervals are shown

in Figure 1.6a. First, I restrict the analysis to salient and important therapeutic classes that are not part of the "Other" product category in table 1.1. The event study coefficients suggest that the mandate had little effect on the prescription rate of on-patent prescription drugs. If anything, it trended up slightly over the analysis period.

Second, I include therapeutic classes that fall under the "Other" product category, and find suggestive evidence that some new (patented) prescription drugs entered the market in 2006 in lesser-used therapeutic classes, as I now document a small and sudden increase. One might therefore worry that low prescribers – that were further from the threshold – did not adopt these on-patent prescription drugs at the same rate as high prescribers. Therefore, I run equation 1.4 separately for high and low prescribers. Figure 1.6b suggests that are no discernible differences in how high and low prescribers adopt on-patent drugs: they both exhibit a similar, increasing proclivity over time to prescribe on-patent drugs.

Robustness Checks. I provide additional evidence that physicians did not compromise on the quality of dispensed drugs using a range of other product characteristics (discussed in Appendix A.4). Physicians did not decrease their use of extended release versions, change the administration method (which may interfere with how people absorb the active ingredient), or adjust the potency of the prescription. Additionally, there is a subset of drugs that have a Narrow Therapeutic Index, which means small changes in dosage or absorption can have large effects on effectiveness or side effects. I again find no evidence that physicians responded to the mandate on this margin. In other words, the quality of dispensed prescription drugs was not affected by the introduction of the policy mandate. Allergies to inactive ingredients (also known as excipients) can also not explain these results, as allergies to them are rare and idiosyncratic.⁵⁶

Taken together, these results suggest that the low initial prescription rates of generics in

 $^{^{56}}$ See Kelso (2014) and Page and Etherton-Beer (2017) for reviews. Recent research does suggest more attention should be given to allergies and excipients as they are often not reported on prescription drug ingredient lists. (Reker et al., 2019b). Additionally, given the low initial prescription rate of generics, the mandate might have resulted in better patient matches to excipients, as patients now get a wider mix of possible prescription drugs.

2004 are driven by physician biases or habits. Physicians opted to not prescribe a generic when choosing an off-patent drug, but rather prescribed the more expensive off-patent brand name drug. They also did not compromise on a range of other product characteristics.

1.4.3 Is Switching Longstanding Patients Costly for Health Outcomes?

The results in section 1.4.1 illustrated that physicians consider it less costly to prescribe a generic for a chronic starter, than to prescribe a generic for a longstanding patient who has been using a brand name drug. This section leverages the quasi-experimental design of the mandate to investigate whether switching a patient's prescription drug comes at a health cost. In order to asses the cost of switching a prescription drug, one could run the following regression, where I use some outcome variable for patient j taking prescription drug p at time t.

$$Outcome_{jpt} = \alpha + \beta Switch_{jpt} + \varepsilon_{jpt} \tag{1.5}$$

However, results from estimating equation 1.5 using an OLS estimator will likely bias the estimate of β , as the identifying assumption $\mathbb{E}[\varepsilon_{jpt}Switch_{jpt}] = 0$ is likely not met. Patients that can cope with a switch more easily and are not as easily confused, exhibit a residual error ε_{jpt} that is above (below) zero, and are more likely to be switched. If these determinants are unobservable to the econometrician, this induces endogeneity and omitted variable bias that understates the effect of switching on health outcomes.

The health outcome of interest in my specification is medication adherence, as measured in equation 1.1, which measures how well a patient follows the treatment plan prescribed by the physician. Changes in this measure are associated with substantial changes in the risk of hospitalization and increased health care costs (Sokol et al., 2005). This outcome is also a first order concern of physicians in the use of prescription drugs and correlational evidence suggests that it is negatively impacted by switching (Kesselheim et al., 2014).

In order to estimate the causal effect of switching a patient's prescription drugs on health

outcomes, I exploit the quasi-experimental variation induced by the mandate in an Instrumental Variables (IV) framework. In particular, I split the sample in physicians that are close and far away from the threshold. As shown in the reduced form section, physicians far from the threshold are more likely to switch longstanding patients from a brand-name drug to a generic drug in response to the mandate. I then instrument the probability of being switched using differences in the type of physician a patient sees (close or far away from the threshold). As a result, the full estimating equation therefore can be written as

$$Adherence_{jpt} = \alpha + \beta Switch_{jpt} + \delta_{pt} + \gamma x_{jt} + \varepsilon_{jpt}$$
(1.6)

where the outcome of interest is medication adherence at time t for patient j taking prescription drug p. Active ingredient by month fixed effects control for level differences across active ingredients, and differences in the availability or use of boxes of different size over time.⁵⁷ A vector of patient-level observable characteristics x_{jt} is also controlled for.

IV Assumptions. The three key assumptions I maintain for the IV estimation, are the exclusion restriction, the relevance condition, and the monotonicity assumption. The latter two are motivated by the reduced form evidence. The exclusion restriction imposes that switching only affects medication adherence through the switch, and not through the type of physician patients see, i.e. physicians closer to the threshold are not "better" at switching their patients without affecting their medication adherence. This assumption is maintained for the analysis, and investigated in the interpretation of the results.

1.4.4 2SLS Results

I estimate the Instrumenal Variable regressions using a 2 Stage Least Squares (2SLS) and report the results in Table 1.6. The upper panel shows the results from the full sample

⁵⁷The use of these fixed effects exploits cross-sectional variation in physicians that are close to or far from the threshold. Not controlling for idiosyncratic changes at the monthly level would easily overstate the effect of medication adherence, as the probability of switching (which is in the denominator of the Wald estimator) is relatively small (physicians typically switch longstanding patients at differential rates of about 1 to 2 percentage points).

where I split up patients by whether their physician is in the top or bottom median of prescribing generics in 2004. The lower panel shows the results from a sample where I split up patients by whether their physician is in the top or bottom quarter of prescribing generics in 2004 (and drop the middle). Employing the full analysis sample has the added value of using more data and obtaining more precise estimates, whereas the restricted sample has the added value of a starker contrast between high and low prescribers.

The first two columns of the upper panel report the coefficients on the switching indicator from estimating equation 1.6 using an OLS estimator. The first column controls for patient and product characteristics, while the second column controls for patient characteristics and active ingredient by month fixed effects. The estimates are fairly similar across both specifications. Focusing on the OLS coefficient in column 2, the coefficient estimate suggests that a patient who normally refills their prescription every two months, will take about 2.5 months to refill their prescription after being switched.

Columns 3 and 4 provide IV estimates of equation 1.6 using 2SLS, and where I use two strategies that exploit the quasi-experimental variation of the mandate to instrument for whether a patient is switched or not. Column 3 interacts an indicator taking on value one if the patient sees a physician far from or close to the threshold and indicator for quarters after the mandate is announced. Column 4 interacts the physician type with a post indicator. Both columns include an interaction between an indicator taking on value one when the mandate is announced and zero if not, and an indicator indicating whether a patient was prescribed a generic during the previous visit. The first stage F-tests are well above the suggested critical values (Staiger and Stock, 1997). In order to ensure weak instruments are detected, I follow Kleibergen and Paap (2006) and allow for arbitrary correlations at the patient level and obtain a robust F test statistic.

The estimated coefficients using an IV strategy (Column 3 and 4) highlight that the causal effect of switching is about -0.3, suggesting the causal effect of switching a patient's prescription drugs on their medication adherence is substantially more negative than the OLS

estimate that is biased upwards. This suggests that physicians target patients that are likely to benefit (or, at least, suffer less negative consequences) from switching prescription drugs. The coefficient magnitude suggests that a patient typically refilling every two months, would take about three months to refill their prescription after being switched from one prescription drug to another.

The estimated effects reported in column 3 and 4 are contemporaneous. Therefore, I explore whether these effects persist by looking at the effect of switching on future medication adherence. Overall, the estimates suggest that the negative effect of switching a patients' prescription drugs is short-lived and does not persist in the future. Figure 1.7 provides a graphical overview. The evidence therefore suggests that there is an initiation cost to moving a patient to a new prescription drug.

These IV results warrant four short remarks. First, comparing OLS and IV estimates suggest that physicians take the drop in medication adherence into account and seek out patients that stand to benefit from a switch. Interpreting results through a Local Average Treatment Effect framework suggests these results likely understate the Average Treatment Effect.⁵⁸ Second, the similarity of IV estimates across panels A and B supports the exclusion restriction: high prescribers do not exhibit a comparative advantage in switching patients' prescription drugs. As physicians play a limited role in how patients use their prescription drugs at home, this is reasonable. This result is also useful in interpreting welfare effects when considering counterfactual policies, as welfare effects do not depend on the type of physician patients see.

Third, several factors impact medication adherence. Their lower cost makes it easier for patients to follow their treatment plan, but switching may also result in mistrust and confusion. I therefore estimate the net effect of switching on medication adherence. The negative effect suggest that mistrust and confusion dominate, and is in line with other research. Financial costs, while important, are not unlikely to be mentioned as an crucial

⁵⁸Both the contemporaneous and the persistence effects may be understated, as the policy mandate may result in physicians paying more attention to adherence and a better follow-up with their patients.

reason for medication non-adherence in the EU.⁵⁹ Finally, the results are consistent with a change in actual adherence, with patients decreasing the number of pills they refill (and take). Persistent side effects or quality differences fail to explain the short-lived effects. I also address the concern that patients may have stockpiled pills in the past, and now use their stock before refilling their new generic prescriptions. I show that the drop in medication adherence does not depend on whether the patient was exhibited high or low medication adherence before the mandate, with the details reported in Appendix A.3.6.

1.4.5 Which Longstanding Patients are Costly to Switch?

The results in section 1.4.3 show that switching a patient's prescription drug decreases medication adherence, and suggest that physicians take this behavior into account. In this section, I investigate heterogeneity in which patients physicians decide to switch. In other words, who are the compliers in this setting?

I start with a simple parametric regression that pools starters and longstanding patients. In particular, I use the following regression framework

$$g_{ijpt} = \alpha_1 S_{jpt} + \alpha_2 L_{jpt} + \beta_1 S_{jpt} \times Post_t + \beta_2 Post_t + \delta_{ip} + \phi \mathbf{X}_{ijpt} + \epsilon_{ijpt}$$
(1.7)

where, as before, *i* indexes the physician. Recall that g_{ijpt} indicates whether patient *j* receives a generic for product *p*. Variable S_{jpt} is an indicator taking on value one if patient *j* is a chronic starter for active ingredient *j* at time *t*, whereas L_{jpt} indicates longstanding patients. Indicator $Post_t$ switches on once the mandate is announced.⁶⁰ Thus, this regression framework pools the split-sample regressions from Equation 1.2 and imposes a parametric assumption on the treatment effect for starters and longstanding patients. Parameters α_1

 $^{^{59}}$ Morgan and Lee (2017) provide cross-country survey evidence. In the EU, only 1.6 and 4% of patients report financial costs as reason for low medication adherence. While the copay gap between branded and generic drugs in the US is typically larger than in the EU, only 16.3% of US patients mention financial costs as a primary reason for non-adherence.

⁶⁰In order to match the reduced form evidence from section 1.4.1 I set $Post_t$ to be one throughout for starters, and $Post_t$ to switch on between months 18 and 36 for chronic longstanding (β_2). For notational simplicity, however, I use $Post_t$ for both.

and α_2 capture the average prescription rate of generics for starters and chronic longstanding patients before the mandate is announced respectively, while parameters β_1 and β_2 capture the increased prescription rate for generics after the mandate is announced for chronic starters and longstanding patients respectively. Interacting the $Post_{ts} \times L_{jpt}$ indicator with various patient-level demographics then provides evidence on which patients are more likely to be switched *after* the mandate is announced. The parametric assumption, that assumes a level shift for both starters and longstanding patients is supported by the reduced form evidence in section 1.4.1. Standard errors are clustered at the patient level.

I primarily focus on three patient characteristics: the amount of time a longstanding patient has been using a drug ("user experience"), the number of prescription drugs a patient is using ("polypharmacy"), and age. The first characteristic primarily tests whether patients exhibit endogenous brand loyalty, as patients using a drug for a longer time might be unwilling to switch.⁶¹ The second and third characteristic are expected to be predictive of switching in response to the mandate if physicians worry about a decrease in medication adherence.

The results of these regressions are reported in Table 1.7 and Figure 1.8. The results suggest that compliers are mostly younger patients using few prescription drugs, as older patients using multiple prescription drugs are less likely to be switched in response to the mandate. I find evidence of immediate lock-in effects, but do not find evidence that user experience predicts an increase in switching in response to the mandate among longstanding patients. A more detailed discussion is also available in appendix A.3.7.

One concern with these results is that the parametric restrictions are driving the results. I address this concern by relying on non-linear machine learning methods to see whether these predictors also hold up when we allow for more flexible parametric restrictions. In particular, I use regression tree and random forest models.⁶² Whereas the actual decision

⁶¹Bronnenberg, Dubé and Gentzkow (2012) discuss endogenous brand loyalty. Exogenous brand loyalty is unlikely to play a major role in Belgium as DCTA for prescription drugs is not allowed and brand awareness is low.

 $^{^{62}}$ LASSO regressions would be another feature selection model that could be used. However, LASSO

rules are difficult to back out from these models, both feature selection methods provide estimates of how important the different variables are in predicting the outcome of interest. The specific results are discussed in Appendix A.3.8, but confirm the results of the parametric regressions.

Taken together, the results from the parametric regressions and feature selection methods suggest that age and polypharmacy are important determinants of whether a physician switches a patient's prescription drugs or not. As a patient takes more prescription drugs, it may be more difficult to keep track of which pill to take (e.g. because of changes in the look of the pill). Older patients may be more easily confused when their prescription drugs are switched and the appearance of their prescription drugs change. Duration of use (which may indicate brand loyalty) seems to be less important. A parsimonious model may therefore primarily focus on polypharmacy and age as important sources of heterogeneity in patient considerations.

1.4.6 Discussion of Reduced Form Results

This section presented four key facts that suggest physician bias and patient considerations are both important. On the one hand, physicians increase their generic prescription rate for chronic starters without moving away from on-patent drugs or compromising the quality of for these patients. Thus, physicians exhibit a bias towards prescribing brand name drugs without therapeutic justification and physician bias plays a role.

On the other hand, the substantial difference in switching between chronic starters and longstanding patients suggests physicians consider the latter costlier to switch. The change in switching rates (in response to the mandate) is relatively lower for older patients using multiple prescription drugs, which is suggestive evidence that the reluctance to switch long-

regressions typically still impose fairly strong linear assumptions and are useful in scenarios where a large number of features (or regressors) is available. In my specific scenario, I am particularly interested in nonlinearities in the decision-making process of physicians. Furthermore, regression trees and random forests do not require me to bin the age and polypharmacy variables. As a result, the number of features (regressors) are therefore manageable, making regression trees and random forests an excellent model to use in my specific context.

standing patients is – at least in part – driven by risks of confusing patients and negative interactions with other prescription drugs, rather than by brand loyalty. I complement this suggestive evidence with causal estimates of the effect of switching on medication adherence, where I document that switching a longstanding patient indeed seems to have (short-lived) effects on medication adherence.

In order to quantify the importance of these two different sources of persistence, put a monetary value on these switching costs, or analyze the welfare effects of introducing different policies aimed at promoting the use of generics, it is necessary to set up a structural model of prescription behavior that allow me to recover the key primitives of the model. I turn to this in the next section.

1.5 A Structural Model of Prescription Behavior under the MPR Mandate

This section develops a structural model of static prescription decisions by physicians facing the MPR incentive scheme. I motivate the key modeling assumptions by relying on the reduced form results and the institutional features of the Belgian healthcare market. The goal of the model is to twofold: on the one hand, quantify the importance of patient considerations, and, on the other hand, strip out these patient considerations to recover the levels of bias before the introduction of the mandate. In a first step, I consider a discrete choice model of a physician's prescription behavior, building on the work of Hellerstein (1998). In a second step, I model the introduction of the MPR, show how it creates a tradeoff for physicians between the cost of adjusting their own bias and the cost of switching a patient, and highlight how the model allows me to map differences in prescription rates into patient considerations. This can then be used to recover levels of physician bias before and after the introduction of the mandate.

1.5.1 Set-up

The healthcare market consists of a set of physicians \mathcal{I} , indexed by *i*, who prescribe different prescription drugs indexed by *p*. During period *t*, each physician sees a set of patients \mathcal{J}_{ipt} indexed by *j*. As is standard, I assume the physician is the decision maker. This physician diagnoses what active ingredient a patient needs, and, if this active ingredient is off-patent, then decides between a multisource or generic drug. I do not model the choice for active ingredient, as the reduced form results highlighted that physicians did not adjust their prescription rate of on-patent drugs: therefore, physicians faced costs to switch from brand name drugs to generics *within* chemical, not *across* chemicals.⁶³ For simplicity, I consider the simple binary decision between a brand-name and generic drug, and do not model product choice within generics.⁶⁴ If physician *i* chooses a generic drug for patient *j* at time *t* for a product group *p*, then the indicator g_{ipt} takes on value 1, and 0 if not.

1.5.2 The physician's prescription decision

1.5.2.1 Utility for Starters

As a starting point, I focus on the utility of a chronic starter, i.e. a patient who is prescribed a prescription drug for the first time. Following other work in this literature, I allow a physician to derive utility from prescribing a certain prescription drug (and term this physician bias), and allow her to take into account patient utility (Hellerstein, 1998; Dickstein, 2011*a*; Iizuka, 2012). At time *t*, physician *i* decides to prescribe a product *p* for patient *j*, deciding between a branded and generic drug. As a result, I assume physician

 $^{^{63}}$ Nevertheless, the chemical choice is an important margin that has been studied in numerous papers: Crawford and Shum (2005) and Dickstein (2011*a*) provide models for how physicians would diagnose and learn about patient-drug match *across* chemicals.

⁶⁴Typically, multiple generic alternatives are available for an active ingredient, especially for the more standard prescription drugs (such as beta blockers, ACE inhibitors, etc.). However, markets are mostly dominated by one or two manufacturers.

utility takes on the following form for brand-name (k = B) or generic drugs (k = G).

$$U(k) = \underbrace{-\alpha_j}_{\text{Copay}} \times \underbrace{c_{pt}^k}_{\text{Copay}} + \underbrace{\xi_{ip0}^k}_{\text{Physician}} + \underbrace{\varepsilon_{ijpt}^k}_{i.i.d.} \quad \text{where } k \in \{B, G\}$$
(1.8)
Sensitivity Bias shock

I model patient utility as a linear function of the copay c_{pt}^k with the coefficient α_j capturing the price sensitivity of the physician. Motivated by the reduced form evidence, I allow the price sensitivity to depend on patient characteristics.⁶⁵

The term ξ_{ip0}^k captures the utility physician *i* derives from one particular prescription drug type (brand-name or generic) and is modeled in a reduced form way as is standard in the literature (Hellerstein, 1998). If $\xi_{ip0}^B > \xi_{ip0}^G$, physicians prefer to prescribe a brand-name rather than a generic drug, resulting in a higher likelihood that the physician will prescribe a brand-name drug even though a cheaper but equally effective product is available. This creates agency issues analyzed by Hellerstein (1998) and Iizuka (2012). In line with the reduced form section, I refer to $\xi_{ip0} \equiv \xi_{ip0}^B - \xi_{ip0}^G > 0$ as physician bias.⁶⁶

I allow for idiosyncratic shocks ε_{ijpt}^k , such as person-specific idiosyncratic allergies to a specific excipient or temporary shortages at the local pharmacy, to drive differential choices holding copay and physician bias fixed.⁶⁷ These idiosyncratic shocks follow the standard type I Extreme-Value distribution.

⁶⁵One can interpret α_j as $\omega \times \alpha_j^*$ where α_j^* represents the patient's "true" price sensitivity and ω represents the weight a physician puts on the patient's utility. If $\omega = 0$, the physician does not take into account the patient's utility and is not altruistic, if $\gamma \to \infty$, the physician only cares about the patient's utility and is fully altruistic. Hellerstein (1998) and Dickstein (2011*a*) model it this way, but highlight identification challenges. As a result, I simply interpret α_j as the price sensitivity of a physician to the price a patient pays.

⁶⁶This utility differential could be the result of habits, detailing (or marketing to physician by representatives) by pharmaceutical companies, preferences, or other underlying mechanisms that are not specifically modeled here.

 $^{^{67}}$ While excipients are typically inactive ingredients for the majority of patients, certain people may have allergic reactions to excipients such as peanut oil (Reker et al., 2019*b*).

1.5.2.2 Introducing Switching Costs

The reduced form evidence clearly demonstrated that PCPs take into account whether the patient was previously prescribed a brand-name or prescription drug when making a decision for a longstanding patient. I model these *patient considerations* as an instantaneous switching cost the physician incurs upon moving a patient from a brand name to a generic drug $C_{jpt}^{B\to G}$ or upon moving a patient from a generic to a brand name drug $C_{jpt}^{G\to B}$.⁶⁸ Such switching costs can be the result of pushback from patients or the risk of decreasing medication adherence when switching longstanding patients. As patient *j*'s status between chronic starter and longstanding can change over time, these switching costs are index by *j* and *t*. While I allow for this switching cost to depend on the type of drug a patient is switched to, the goal of this study will be to estimate $C_{ipt}^{B\to G}$.⁶⁹

I incorporate these patient considerations by describing the value function for physician i making a prescription drug choice for patient j who needs a prescription drug in product group p at time t, where the physician takes the previous choice $k' \in \{B, G\}$ for this patient as a predetermined state variable. Physicians now do not only consider the instantaneous utility U(G) and U(B), which depend on the vector of copay levels and physician bias, but also the cost of switching a patient. I model switching costs to be additively linear. These switching costs do not depend on i, maintaining the exclusion restriction assumed in section 1.4.3. This gives rise to the following expression for the value function $V(k'; c_{pt}, \xi_{ip0})$ where the vectors \mathbf{c}_{pt} and $\boldsymbol{\xi}_{ip0}$ contain the copay levels and physician bias for both brand name and

⁶⁸I model this cost as immediate, with no future costs paid. One could think of this as a Net Present Value (NPV) of the flow of costs to be paid in the future. Again, an altruism parameter ω indicating the weight a physician assigns to patient welfare could be included. The same rationale I presented for the price sensitivity parameter holds here.

⁶⁹The switching cost $C_{jpt}^{G \to B}$ cannot easily be uncovered using the mandate. However, testing the equality of these costs is the topic of future work.

generic drugs.

$$V(k'; \boldsymbol{c}_{pt}, \boldsymbol{\xi}_{ip0}) = \max\left\{ \underbrace{-\alpha_{j}c_{pt}^{B} + \xi_{ip0}^{B} + \varepsilon_{ijpt}^{B}}_{U(B)} - \underbrace{C_{jpt}^{G \to B} \times \mathbb{I}\{k' = G\}}_{\text{Switching Cost}}, \underbrace{-\alpha_{j}c_{pt}^{G} + \xi_{ip0}^{G} + \varepsilon_{ijpt}^{G}}_{U(G)} - \underbrace{C_{jpt}^{B \to G} \times \mathbb{I}\{k' = B\}}_{\text{Switching Cost}}\right\}$$

$$(1.9)$$

It is now possible to write the probability physician *i* prescribes a generic for patient *j* and prescription drug *p* at time *t* (i.e. $g_{ijpt} = 1$) as

$$P(g_{ijpt} = 1; g_{ijpt-1}, \boldsymbol{c}_{pt}, \boldsymbol{\xi}_{ip0}) = P (\text{Utility Brand Name} < \text{Utility Generic})$$
(1.10)
$$= P \left(-\alpha_j c_{pt}^B + \xi_{ip0}^B + \varepsilon_{ijpt}^B - C_{jpt}^{G \to B} \times g_{ijpt-1} \\ < -\alpha_j c_{pt}^G + \xi_{ip0}^G + \varepsilon_{ijpt}^G - C_{jpt}^{B \to G} \times (1 - g_{ijpt-1}) \right)$$

$$= P \left(-\alpha_j \underbrace{(c_{pt}^B - c_{pt}^G)}_{\equiv \Delta c_{pt}} + \underbrace{(\xi_{ip0}^B - \xi_{ip0}^G)}_{\equiv \xi_{ip0}} - \underbrace{(C_{jpt}^{G \to B} + C_{jpt}^{B \to G})}_{\equiv \gamma} g_{ijpt-1} + C_{jpt}^{B \to G} + \varepsilon_{ijpt}^G \right)$$

$$= P \left(\underbrace{-\alpha_j \Delta c_{pt} + \gamma g_{ijpt-t}}_{\text{Observable}} + \underbrace{\xi_{ip0} + C_{jpt}^{B \to G}}_{\text{Unobservable}} < \underbrace{\varepsilon_{ijpt}^G - \varepsilon_{ijpt}^B}_{\sim \text{Logit}} \right)$$

where g_{ijpt-1} is an indicator equal to one if a generic was chosen during the previous visit (and zero if not), $\Delta c_{pt} \equiv c_{pt}^B - c_{pt}^G$ and $\varepsilon_{ijpt} \equiv \varepsilon_{ijpt}^B - \varepsilon_{ijpt}^G$. I assume, for simplicity, that the sum of the switching costs $\gamma \equiv (C_{jpt}^{B \to G} + C_{jpt}^{G \to B})$ is a constant, although I will discuss and relax this assumption during the estimation of the model. The final line in equation 1.10 highlights that, if patient considerations are important, it is difficult to separately identify the importance of physician bias (ξ_{ip0}) from patient considerations ($C_{jpt}^{B \to G}$): both terms are unobservable to the econometrician, not idiosyncratic, and persistent over time.

1.5.2.3 Aggregation

Using the distributional assumption on ε_{ijpt}^k , the fraction of generics that physician *i* prescribes for prescription drug *p* during period *t*, which I denote by s_{ipt}^G can now be characterized by aggregating the probabilities at the appropriate level.

$$s_{ipt}^{G}(\boldsymbol{c}_{pt}, \boldsymbol{g}_{ipt-1}, \xi_{ip0}) = \frac{1}{|\mathcal{J}_{ipt}|} \sum_{j=1}^{|\mathcal{J}_{ipt}|} \frac{1}{1 + \exp\left(-\alpha_j \Delta c_{pt} + \gamma g_{ijpt-t} + \xi_{ip0} + C_{jpt}^{B \to G}\right)}$$
(1.11)

where g_{ipt-1} is a vector containing the lagged choice for all $|\mathcal{J}_{ipt}|$ patients that physician *i* sees at time *t* for prescription drug *p*. Finally, these market shares also depend on physician bias (ξ_{ip0}) and the vector of copay levels (c_{pt}) .

1.5.2.4 Patient Considerations for Chronic Starters

I assume switching costs arise for longstanding patients, or, in other words, that patient considerations do not factor into decisions for chronic starters, i.e. $C_{jpt}^{G \to B} = C_{jpt}^{B \to G} = 0$ for these patients. Three features of the Belgian healthcare market motivate why ex-ante patient preferences are unlikely to play an important role in this specific setting. First, the advertising ban for prescription drugs is strictly enforced. As a result, patients are unlikely to know the name brand-name drug over the name of the generic drugs (Fraeyman et al., 2015).⁷⁰ Second, physicians typically make their prescription decision for the initial choice at the time of diagnosis, making it difficult for the patient to assess whether the prescription.⁷¹ Third, even if some patients specifically request a brand-name drug at the time of prescription, the model would capture physicians' prescription decision as long as

⁷⁰Furthermore, other European countries have similar bans on advertising for prescription drugs (only New-Zealand and the United States allow direct-to-consumer advertising of prescription drugs). Healthcare professionals and researchers in Belgium indeed confirmed patients are not necessarily familiar with the names of brand name prescription drugs before receiving their first prescriptions.

⁷¹If the patient decides to do so afterwards and request a switch to the brand-name drug, the physician would need to provide a new prescription which comes at a cost (a new physician visit). Again, this is rare in practice.

tastes (or distastes) for generics are distributed *i.i.d.* across physicians. This assumption is reasonable in this setting, as the advertising ban rules out regional or temporal variation in advertising that may drive such preferences (Sinkinson and Starc, 2018).⁷²

Furthermore, I assume away (unobserved) quality differences between a brand name drug and its generic equivalent. The active ingredient of a multisource and generic drug are identical in terms of product quality, and several studies have documented no substantial differences between the quality of generics and brand name drugs when used in controlled environments (Kesselheim et al., 2008; Gagne et al., 2014). While it is possible that patients are allergic to excipients (the inactive ingredients), such allergies are typically rare and highly idiosyncratic between patients and can therefore not account for large average quality differences (Kelso, 2014; Page and Etherton-Beer, 2018).⁷³ Therefore, the difference between ξ_{ip0}^B and ξ_{ip0}^G represent a physician's bias towards brand-name drugs.⁷⁴

1.5.2.5 Additional Modeling Assumptions

The model is parsimonious, yet leaves sufficient flexibility to capture physician bias and patient considerations. Furthermore, much of the simplifying assumptions are motivated by the institutional setting and empirical facts. Yet, some additional modeling decisions deserve discussion.

Physician Myopia. Physicians are modeled as myopic in prices and only consider current prices, similar to Handel (2013) and Polyakova (2016). Put differently, prices are

⁷²It, for instance, allows patients to talk to each other about which drugs are brand-name and which are generics so chronic starters are aware of which type they are receiving at the time of the initial diagnosis, but does not allow for this to vary systematically across physicians with different prescription rates of generics. If such tastes are not distributed with a zero mean, this mean cannot be identified from the average level of physician bias, and the assumption that patient considerations are zero for the initial choice amount to a normalization.

 $^{^{73}}$ Excipients are, among others, the binding agents and coating. Sometimes certain oils (such as peanut oils) or chemicals can cause allergies. Nevertheless, researchers nevertheless have recently started acknowledging a better understanding of these inactive ingredients would be useful (Reker et al., 2019*a*).

⁷⁴Some recent concerns regarding the quality of generics being produced in China or India have been raised in recent years. However, in the setting I study, production of prescription drugs was by and large located in Belgium. Additionally, brand name drugs also increasingly outsource their production to India and China, so it's unclear whether offshoring really affects the quality of generics as such, or affects the quality of prescription drugs overall.

assumed to follow an AR(1) process. Illanes (2016) studies inertia with forward-looking patients in pension plan decisions in Chile, and finds that not including them may lead to biased estimates. In this setting, the modeling assumption requires that beliefs about future changes in the price *differential* between generics and brand name multisource drugs are not systematically related differences in baseline physician bias – different beliefs about price levels are therefore not necessarily problematic. Given a transparent pricing system that is common knowledge, this assumption therefore seems reasonable.

Prescription Drug History. Similarly, I assume that conditioning on a patient's previous prescription decision is sufficient to capture the choice between a generic and a multisource drug. Past trajectories with longer histories are often found to be quantitatively important in papers that consider prescription decisions across different chemicals and active ingredients, where the quality of treatment choices is not necessarily held constant (Crawford and Shum, 2005; Dickstein, 2011*a*). However, bioequivalence between multisource and generic drugs makes conditioning on a single previous choice a parsimonious and tractable assumption.

1.5.3 The MPR Mandate

The section above sets up a parsimonious discrete choice model describing how physicians choose between brand name and generic drugs when treating a patient and highlighted the challenges in separately identifying physician bias from patient considerations. This section models the introduction of the MPR mandate and shows how it introduces a clear tradeoff for physicians between these two sources of persistence, and how the differences in switching response across patients can be mapped into patient considerations.

1.5.3.1 The Minimum Prescription Rate

The fraction of brand-name drugs physician i will prescribe at time t can be written as

$$S_{it}^G(\boldsymbol{c}_t, \boldsymbol{g}_{it-1}, \boldsymbol{\xi}_{i0}) = \frac{1}{P} \sum_{p=1}^P s_{ipt}^G(\boldsymbol{c}_{pt}, \boldsymbol{g}_{ipt}, \boldsymbol{z}_{ipt}, \boldsymbol{\xi}_{ip0})$$
(1.12)

$$= \frac{1}{P} \sum_{p=1}^{P} \frac{1}{|\mathcal{J}_{ipt}|} \sum_{j=1}^{|\mathcal{J}_{ipt}|} \frac{1}{1 + \exp\left(-\alpha_j \Delta c_{pt} + \gamma g_{ijpt-t} + \xi_{ip0} + C_{jpt}^{B \to G}\right)} \quad (1.13)$$

where p indexes the different drugs and c_t, g_{it-1} and ξ_{i0} are the vectors containing the variables c_{pt}, g_{ipt-1} and ξ_{ip0} across all prescription drugs.⁷⁵ A physician can adjust her bias ξ_{ip0} by some amount a_{ip} , incurring some adjustment cost $c(a_{ip})$.⁷⁶ Denoting \mathbf{a}_i as the vector containing all P adjustments a_{ip} for physician i, the problem a physician faces can be written as

$$\min_{\mathbf{a}_{i}} \sum_{p=1}^{P} c(a_{ip})$$
such that $S_{i,2006}^{G}(\boldsymbol{c}_{t}, \boldsymbol{g}_{it-1}, \boldsymbol{\xi}_{i0} - \boldsymbol{a}_{i}) \ge q + \nu$

$$(1.14)$$

Such that $\mathcal{Z}_{i,2006}(\mathcal{Z}_i,\mathcal{G}_{i-1},\mathcal{Q}_{i0}) = \mathcal{Q}_i + \mathcal{Q}_i$

The parameter q is the mandated minimum prescription rate (in this case 23%). As detailed before, it is difficult for physicians to exactly hit this target. The mandate was specified in DDD – a unit that is not exactly known by physicians – and PCPs can not monitor their prescription rate throughout the year. Additionally, there was uncertainty about which drugs were cheap and which drugs would change status from expensive to cheap. As a result, physicians did not "bunch" on the mandate: the random variable ν captures this uncertainty as a mean-zero forecasting error independently distributed.

⁷⁵For simplicity, I abstract away from weighting the decisions by DDD.

 $^{^{76}}$ I assume the cost of effort is independent across product group, ie. there are no spillovers across prescription drugs. If bias is driven by not knowing the name of the generic chemicals, the physician still needs to look up the name for all separate generics. If a physician believes generics are less effective and wants to look up which ones are effective, this process again will require work for every separate prescription drug.

1.5.3.2 Solution to adjusting physician bias

Before the mandate goes into effect, q = 0 and the constraint does not bind (as the fraction of generics prescribed cannot be strictly negative). After the mandate goes into effect, however, q = 0.23 > 0: the restriction binds and (most) PCPs need to exert effort in order to meet the threshold. A PCP will then adjust her bias by solving a first order condition for each product group

$$c'(a_{ip}^*) = \frac{\lambda}{P} \frac{1}{|\mathcal{J}_{ipt}|} \sum_{j \in \mathcal{J}_{ipt}} f(-\alpha_j \Delta c_{pt} + \gamma g_{ijpt-1} + \xi_{ip0} - a_{ip}^* + \psi z_{jpt})$$
(1.15)

where f(.) is the logit pdf and λ is the shadow value of the constraint for the physician. This shadow value will be higher for physicians that are far away from the threshold, and smaller for physicians that are close to meeting the requirement. The effort exerted by physicians is correlated, but only through the distance from the threshold.

1.5.3.3 The Post-Mandate probability of Prescribing a Generic

It is now possible to combine the demand model and the adjustment induced by the mandate to describe the probability a generic is prescribed after the mandate is announced.

$$P(g_{ijpt} = 1; g_{ijpt-1}, \boldsymbol{c}_{pt}, \xi_{ip0} - a_{ip}^*) = P\left(-\alpha_j \Delta c_{pt} + \gamma g_{ijpt-t} + \xi_{ip0} - a_{ip}^* + C_{jpt}^{B \to G} < \varepsilon_{ijpt}^G - \varepsilon_{ijpt}^B\right)$$

The unique adjustment of PCPs therefore eliminates the concern to directly model the adjustment using parametric assumptions on how physicians adjust their prescribing behavior post-mandate. In contrast, physician bias can be backed out before and after the mandate, and the difference between these two will then identify a_{ip}^* . Additionally, this is also crucial in estimating patient considerations *after* the mandate is announced. I turn to the identification and estimation strategy in more detail in the following section.

1.5.4 Identification and Estimation

1.5.4.1 Parameterization

Building on the reduced form evidence presented in section 1.4.5, I model the switching cost as a linear cost of patient characteristics $C_{jpt}^{B\to G} = \psi z_{jpt} \times Post_t$. I include the interaction with a post-indicator, as these patient considerations can only be properly identified *after* the announcement of the mandate.

In its simplest form, I assume a fixed cost for longstanding patients, i.e. z_{jpt} is a single variable LS_{jpt} indicating whether a patient is longstanding (1) or not (0). However, I allow for heterogeneity in switching costs by introducing age and polypharmacy bins.

Building on the reduced form evidence presented in section 1.4.1, I model the price sensitivity α_j of patient j as a function of whether the patient is longstanding $(LS_{jpt} = 1)$, and whether the patient receives an increased reimbursement $(IR_{jt} = 1)$. In particular,

$$\alpha_j = \alpha_1 + \alpha_2 L S_{jpt} + \alpha_3 I R_{jt} + \alpha_4 I R_{jt} \times L S_{jpt} = \alpha X_{jpt}^C$$
(1.16)

The coefficient α_1 here captures the price sensitivity of chronic starters, while $\alpha_1 + \alpha_2$ captures the price sensitivity of longstanding patients. Coefficients α_3 and α_4 capture the additional price sensitivity for patients on an increased reimbursement plan.

I include a set of control variables. Motivated by the theoretical section, I include an indicator whether the patient was prescribed a generic during the previous visit (g_{ijpt-1}) . However, I also include the vector of patient characteristics z_{jpt} as these could introduce omitted variable bias if not included in the structural regression. Finally, I also include an indicator for whether the patient is on an increased reimbursement plan. As a result, the set of control variables takes the form

$$\beta x_{ijpt} = \gamma g_{ijpt-1} + \beta_1 I R_{jt} + \beta_2 z_{jpt} \tag{1.17}$$

1.5.4.2 Identification and Normalization

Motivated by the reduced form results, my model incorporates unobserved heterogeneity of physicians (physician bias) and patient-level switching costs (patient considerations). A large literature dating back to Heckman (1981) has discussed the challenges of disentangling unobserved heterogeneity from switching costs.⁷⁷. Farrell and Klemperer (2007) discuss different specific empirical examples and highlight the challenge in finding micro-data where initial choices can be compared to choices affected by switching costs.

In this specific setting, I therefore exploit the prescription behavior of physicians across two sets of patients: chronic longstanding patients who are on branded drugs and chronic starters. The former are affected by switching costs, the latter are not. Analyzing the prescription behavior among chronic starters therefore identifies physician bias, while differences in response across patients identify patient considerations.

Patient Considerations. Patient switching costs are identified by comparing the difference in response across chronic starters and longstanding patients using prescription drugs. For simplicity, I abstract away from copay here to convey the key identification ideas.

$$\underbrace{P(\xi_{ip0} - a_{ip}^*|Starter) - P(\xi_{ip0}|Starter)}_{\text{Change in prescription rate}} - \underbrace{P(\xi_{ip0} - a_{ip}^*|g_{ijpt-1} = 0) - P(\xi_{ip0}|g_{ijpt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^*|g_{ijpt-1} = 0) - P(\xi_{ip0}|g_{ijpt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^*|g_{ijpt-1} = 0) - P(\xi_{ip0}|g_{ijpt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^*|g_{ijpt-1} = 0) - P(\xi_{ip0}|g_{ijpt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^*|g_{ijpt-1} = 0) - P(\xi_{ip0}|g_{ijpt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^*|g_{ijpt-1} = 0) - P(\xi_{ip0}|g_{ijpt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^*|g_{ijpt-1} = 0) - P(\xi_{ip0}|g_{ijpt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^*|g_{ijpt-1} = 0) - P(\xi_{ip0}|g_{ijpt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^*|g_{ijpt-1} = 0) - P(\xi_{ip0}|g_{ijpt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - g_{ipt-1} = 0) - P(\xi_{ip0}|g_{ijpt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - g_{ipt-1} = 0) - P(\xi_{ip0}|g_{ijpt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - g_{ipt-1} = 0) - P(\xi_{ip0}|g_{ijpt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - g_{ipt-1} = 0) - P(\xi_{ip0}|g_{ipt-1} = 0)}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - g_{ipt-1} = 0) - P(\xi_{ip0}|g_{ipt-1} = 0)}_{\text{Change in prescription rate}}$$

Maintaining the assumption that the bias a physician exhibits is the same across all patients, the difference in the change of generics across chronic starters and chronic longstanding patients is attributed to patient switching costs. It is possible to consider heterogeneity in switching costs by considering how the change on the right hand side depends on patient

 $^{^{77}}$ See Torgovitsky (2019) for a recent discussion and advances in the non-parametric identification of state dependence in the presence of unobserved heterogeneity

characteristics z_{jpt} as follows.

$$\underbrace{P(\xi_{ip0} - a_{ip}^* | Starters) - P(\xi_{ip0} | Starter)}_{\text{Change in prescription rate}} - \underbrace{P(\xi_{ip0} - a_{ip}^* | g_{ijpt-1} = 0, z_{jpt}) - P(\xi_{ip0} | g_{ijpt-1} = 0, z_{jpt})}_{\text{Change in prescription rate}} - \underbrace{P(\xi_{ip0} - a_{ip}^* | g_{ijpt-1} = 0, z_{jpt}) - P(\xi_{ip0} | g_{ijpt-1} = 0, z_{jpt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^* | g_{ijpt-1} = 0, z_{jpt}) - P(\xi_{ip0} | g_{ijpt-1} = 0, z_{jpt})}_{\text{Change in prescription rate}} - \underbrace{P(\xi_{ip0} - a_{ip}^* | g_{ijpt-1} = 0, z_{jpt}) - P(\xi_{ip0} | g_{ijpt-1} = 0, z_{jpt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^* | g_{ijpt-1} = 0, z_{jpt}) - P(\xi_{ip0} | g_{ijpt-1} = 0, z_{jpt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^* | g_{ijpt-1} = 0, z_{jpt}) - P(\xi_{ip0} | g_{ijpt-1} = 0, z_{jpt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^* | g_{ijpt-1} = 0, z_{jpt}) - P(\xi_{ip0} | g_{ijpt-1} = 0, z_{jpt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^* | g_{ijpt-1} = 0, z_{jpt}) - P(\xi_{ip0} | g_{ijpt-1} = 0, z_{jpt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - a_{ip}^* | g_{ipt-1} = 0, z_{ipt}) - P(\xi_{ip0} | g_{ipt-1} = 0, z_{ipt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - g_{ipt}) - P(\xi_{ip0} | g_{ipt-1} = 0, z_{ipt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - g_{ipt}) - P(\xi_{ip0} | g_{ipt-1} = 0, z_{ipt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - g_{ipt}) - P(\xi_{ip0} | g_{ipt-1} = 0, z_{ipt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - g_{ipt}) - P(\xi_{ip0} | g_{ipt-1} = 0, z_{ipt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - g_{ipt}) - P(\xi_{ip0} | g_{ipt-1} = 0, z_{ipt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - g_{ipt}) - P(\xi_{ip0} | g_{ipt-1} = 0, z_{ipt})}_{\text{Change in prescription rate}}$$

$$\underbrace{P(\xi_{ip0} - g_{ipt}) - P(\xi_{ip0} | g_{ipt-1} = 0, z_{ipt})}_{\text{Change in prescription rate}}$$

Physician Bias. Physician bias – and the policy-induced change in effort – is identified by comparing the prescription rate of physicians before and after the mandate for chronic starters. As especially chronic starters are not impacted by switching costs, the bias terms are primarily identified off of initial choices made for patients. Copay levels are uniform across patients (conditional on whether they are receiving an increased reimbursement or not) and temporal variation at the prescription drug level identifies the copay sensitivity. Any residual proclivity of a physician to prescribe a generic or brand name drug then is set to match the actual prescription rate of generics before and after the mandate.⁷⁸

The levels of ξ_{ip0}^B and ξ_{ip0}^G are not identified. I therefore normalize ξ_{ip0}^G , the utility the physician derives from prescribing a generic to a generic starter (for a certain prescription drug), to be zero. The difference ξ_{ip0} is then identified as discussed above during the premandate period, while $\xi_{ip0} - a_{ip}^*$ is then identified during the post-mandate period.

1.5.4.3 Estimation

Collecting the theoretical results and the parameterization, I now turn to estimating the parameters $\theta = \{\alpha, \beta, \psi\}$ and physician biases $\{\xi_{ip0}, \xi_{ip0} - a_{ip}^*\}$ for all i, p. I model the biases

⁷⁸It is important to note, however, that I do not make use of the contraction mapping proposed in Berry, Levinsohn and Pakes (1995) during the estimation.

(before and after the mandate) as Fixed Effects. The estimating equation reduces to

$$P(g_{ijpt} = 1; g_{ijpt-1}, \boldsymbol{c}_{pt}, \boldsymbol{\xi}_{ip0}, X_{jpt}^{C}, z_{jpt}, x_{ijpt}) = \begin{pmatrix} & \\ -\underbrace{\alpha \times X_{jpt}^{C}}_{\alpha_{j}} \times \Delta c_{pt} + \underbrace{\xi_{ip0}}_{\text{Pre-Mandate}} - \underbrace{a_{ip}^{*} \times Post_{t}}_{\text{Post-Mandate}} + \underbrace{\psi z_{jpt} \times Post_{t}}_{\text{Patient}} + \underbrace{\beta x_{ijpt}}_{\text{Control}} < \varepsilon_{ijpt}^{G} - \varepsilon_{ijpt}^{B} \end{pmatrix}$$

In order to ensure there are sufficient observations to adequately estimate these fixed effects, I focus on active ingredients where the number of patients is sufficiently large. In essence, I focus on prescriptions for active ingredients that are in the main product group categories posted in table 1.1 (i.e. I exclude "Z: Other") and where the physicians prescribed a strictly positive share of generics both before and after the introduction of the mandate.⁷⁹

I use two different ways to estimate this model. In the first method, I estimate a conditional logistic regression using Maximum Likelihood to recover the parameters $\theta = \{\alpha, \beta, \psi\}$ and then use the contraction mapping proposed by Berry, Levinsohn and Pakes (1995) to recover the bias before and after the announcement of the mandate. The bias terms I estimate are then essentially deviations from zero that match the predicted market shares to the actual market shares, conditional on the parameters estimated in a first step using Maximum Likelihood. In particular, given the vector of MLE estimates $\hat{\theta}$, the contraction mapping solves the following moment condition.

$$S_{ijpt}^G(\boldsymbol{c}_{pt}, \boldsymbol{g}_{ipt-1}, \hat{\theta}; \xi_{ip0} - a_{ip}^* \times Post_t) = s_{ipt}^G$$
(1.20)

In this moment condition, the right hand side s_{ipt}^G is the empirical market share observed in the data, before and after the announcement of the mandate. The left hand side is the essentially the equation in 1.11, where the observable characteristics and the MLE parameters

⁷⁹This induces some selection in the analysis sample. This is currently being worked out in greater detail in a follow-up study that focuses on the adjustment cost of physicians.

 $\hat{\theta}$ are used. This leaves the physician unobservables free to match the model-implied market shares to match the empirical market shares.⁸⁰

In a second approach, I directly estimate all parameters (including the Fixed Effects) using Maximum Likelihood to complement and verify the estimates of the first estimation method. This is computationally more intensive than conditional logistic regression. Nevertheless, the parameter estimates are highly similar across the different estimation methods. The results presented in the next section (and used in the decomposition and counterfactual analyses) draw from the second method. Additional details on the estimation and the two different methods are discussed in the Appendix.

1.5.4.4 Results

The results of the structural estimation are posted in table 1.8. The estimated coefficients line up with the reduced form evidence, lending credibility to the structural model. The price elasticities suggest that physicians are price sensitive, especially for chronic starters. Similar to the reduced form results, I find some evidence that they are more price sensitive for patients on an increased reimbursement plan – especially for starters. The results also suggest (as extensively documented in the reduced form evidence) that the previous choice is highly predictive of the current choice of prescription drug.

When looking at the patient consideration parameters, Column 1 shows that longstanding patients are more likely to be kept on a brand name drug after the mandate is announced. Column 2 shows that patients with higher levels of polypharmacy are somewhat less likely to be switched, even though the numbers are a bit smaller than in the linear probability model results in section 1.4.5. Column 3 highlights that older patients are less likely to be switched, somewhat more starkly than in the reduced form section. Including both measures of polypharmacy and age, these results and interpretations persist.

Furthermore, it is possible to back out the physician biases before and after the mandate.

 $^{^{80}\}mathrm{I}$ use a tolerance of 10e-9 to match these market shares.

These results are shown graphically in figure 1.9. As expected, we find a decrease in physician bias. Furthermore, the average decrease in bias is somewhat bigger than the parameter estimate for patient considerations, in line with the empirical finding that longstanding patients are likely to be switched, but in quite small numbers.

Using these structural parameters, I now turn to quantify the importance of physicians and patients using a decomposition exercise, and analyze the hypothetical introduction of a Mandatory Generic Substitution policy.

1.6 Decomposition and Policy Counterfactuals

1.6.1 Decomposition

Short-term. A simple decomposition of the treatment effect in the short term suggests that patient considerations dominate the importance of physician bias: the overall treatment effect is only about a third of the treatment effect on chronic starters. I use that about 1 in 7 prescriptions is written for starters and the approximate treatment effects recovered in section 1.4 to show

$$\Delta S^{G} = \underbrace{F^{S}}_{\text{Fraction}} \underbrace{\Delta P^{S}}_{\text{TE}} + \underbrace{F^{L}}_{\text{Fraction}} \underbrace{\Delta P^{L}}_{\text{TE}}$$

$$= \Delta P^{S} - F^{L} \left(\Delta P^{S} - \Delta P^{L} \right)$$

$$\approx 10\% - 0.86 \times (10\% - 2\%)$$

$$= 3.12\%$$
(1.21)

Long-term. Nevertheless, as the composition of patients changes over time, and a steady flow of starters arrives, the short term effect likely overstates the importance of patient considerations and is unlikely equal to the long-term effect. In order to get a better sense of these long-term effects, I perform the following decomposition exercise. I set prices at the active ingredient level and physician bias to its 2004 levels (i.e. I set them to be ξ_{ip0}). I simulate the generic prescription rate assuming all drugs in the sample were on-patent until 2004, and go off-patent in January 2005. I assume all patients return every quarter to pick up a new prescription and have the model run for 5 years (or 20 quarters). It is worth noting that this is the market share for prescription drugs where a generic alternative is available: on-patent drugs are not included in this analysis. The predicted market shares can be analyzed in four scenarios.

- 1. Only copay differentials in transaction utility
- 2. Copay differentials and physician bias in transaction utility
- 3. Copay differentials and patient considerations in transaction utility

4. Copay differentials, patient considerations, and physician bias in transaction utility The resulting take-up rates of generics are posted as market shares over time in Figure 1.10. Scenario 1 suggests a fast penetration rate of generics if only copay differentials matter, with the market share stabilizing at about 90 percent after about 2 years (or 8 quarters). Scenario 2 plateaus at about 60 percent, while scenario 3 leads to an adoption rate of about 70% after 5 years (but does not plateau to the same extent). It takes about 2 to 3 years for physician bias to actually become more important than patient considerations in the slow adoption rate of generics over time. If both physician bias and patient considerations matter, the market share stabilizes at about 50 percent. Therefore, taking a longer term view on the decomposition suggests that physician bias and patient considerations are about equally important.

1.6.2 Counterfactuals

Given the reduced form results and the decomposition exercises posted above, it is reasonable to analyze different policies that aim to reduce physician bias or reduce the importance of patient considerations. One particular type of policy that has gained popularity is to override physician authority by allowing or requiring pharmacies to dispense the cheaper generic when a physician has failed to prescribe this cheaper option even when available. Several variations on this policy are possible, but I will simulate the introduction of a stringent Mandatory Generic Substitution (MGS) policy that forcefully requires the pharmacy to overrule the physician decision and dispense the generic option with no possible exception.

Set-up and assumptions. As in the decomposition exercise, I set prices (copay differentials and reimbursement amounts) and physician bias equal to their 2004 levels. Therefore, these welfare analyses should be thought of as partial equilibrium exercises, as pharmaceutical companies are likely to adjust their pricing strategies in response to such a policy.⁸¹ I focus on the short-term introduction of a policy and select all longstanding patients that pick up a prescription in 2004. Over the course of four quarters of 2005, I select the patients that are chronic starters in that quarter. I assume, as before, that the patient comes back every three months to pick up another prescription.⁸² Therefore, initial choices for longstanding patients in January 2004 and the actual incoming starters over the year 2005 along with physician bias levels are based on actual data and structural estimates, as shown in figure 1.11.

I make two important assumptions on the patient considerations estimated in the structural estimation. On the one hand, I assume that patient considerations are actual welfare costs that a social planner would worry about (such as decreased medication adherence resulting in lower productivity and higher healthcare expenditures) and that none of these patient considerations are "wasteful" (resistance from patients that exhibit brand loyalty towards the box they receive or a general unwillingness to be switched). While I can't rule out such "wasteful" considerations are at play, the IV estimates from section 1.4.3 suggest that indeed these patient considerations indeed include important actual welfare considerations. On the other hand, I assume that physicians perceive these costs correctly such that I can

 $^{^{81}}$ These strategies could include both on-patent brand name drugs and those with generic competition. I leave this is a useful avenue for future research to consider.

⁸²As in the decomposition, I therefore ignore the contemporaneous budgetary effect of switching on medication adherence. This will overstate the budget savings, as longstanding patients that are switched will pick up fewer prescription drugs in the months after being switched.

use the structural estimates are correct estimates of these welfare costs.

I assume the following social welfare objective where τ is the (relative) weight the social planner places on patient considerations over reimbursements. I use the compensating variation as the welfare measuring capturing patient considerations. I assume that the social planner does not care about physician bias and considers it wasteful; it is therefore not included as a part of patient welfare.⁸³

$$WF = \underbrace{(1-\tau)}_{\text{Budget Weight}} \underbrace{\sum_{j=1}^{J} \left[P(g_{ijpt} = 1) \times RI_{pt}^{G} + P(g_{ijpt} = 0) \times RI_{pt}^{B} \right]}_{\text{Government Expenditure}} + \underbrace{\tau}_{\text{Government Expenditure}} \underbrace{\sum_{j=1}^{J} -\frac{1}{\alpha_{j}} \ln \left(1 + \exp\left(-\alpha_{j}\Delta c_{pt} + \psi z_{jpt} + \beta x_{ijpt}\right)\right)}_{\text{Compensating Variation Patient } j}$$
(1.22)

I run a model with 2004 prices and bias levels to calculate the baseline reimbursement rates and patient welfare levels. I now turn to two alternative scenarios that I then compare to this baseline scenario to see what the impact of such policies would be.

1.6.2.1 Mandatory Generic Substitution

I simulate the introduction of a mandatory generic substitution (MGS) policy, in which pharmacies are (legally) required to dispense the generic drug when a brand name with the same active ingredient is prescribed. Essentially, all starters that come in over the year 2005 are provided with a generic as initial choice, and the only welfare cost is incurred by those longstanding patients that were previously using brand name drugs. Under these assumptions, the healthcare system would stand to save 205 million \in on their prescription expenditures, or about a 9% overall decrease in prescription drug spending. Figure 1.12a provides a graphical overview of the welfare effect of such a policy. The x axis analyzes

⁸³In other words, the social planner maintains the assumption I use in this paper, namely that a branded and generic version of the same active ingredient are therapeutically and clinically equivalent. These biases do not represent private information of the physician on the quality of one version over another.

the change in overall welfare for different welfare weights. The graph shows that, for a healthcare system putting little weight on patient welfare, the policy would be welfare-increasing. However, if the healthcare system values puts a weight of more than 0.7 on patient welfare (comparable to valuing $1 \in$ in patient welfare at about $3 \in$ in reimbursements), the policy is welfare-decreasing. In order to get some estimate of the welfare weight in Belgium, I run a simulation of the MPR and find that the Belgian healthcare system employs a weight on patient welfare of about 0.7.⁸⁴

1.6.2.2 Focusing on physicians and Patients

As the Belgian healthcare system seems to put a large weight on patient welfare, it is useful to consider under what circumstances the introduction of an MGS could be welfareincreasing. I analyze different scenarios in which I decrease the importance of patient considerations, and I find that combining an MGS with a decrease in patient considerations of at least 60% would result in a welfare-increasing policy under a patient welfare weight of 0.7.

1.7 Conclusion

In this paper, I investigate physician and patient-specific factors in the demand for prescription drugs that give rise to persistence. I do so by studying the impact of a national mandate that required PCPs to adjust their prescribing behavior. In particular, I first focus on the proclivity of physicians to prescribe a brand name drug when equally effective alternatives are available, and whether they adjust this behavior in response to the mandate. I refer to as physician bias. Second, I also investigate whether physicians switch different patient types at different rates. I find that physicians switch chronic starters at much higher rates than chronic longstanding patients, which indicates that physicians consider prescribing a

⁸⁴One should not necessarily take this weight as the "true" welfare weight, as this is an analysis taking the current copay structures as given. A more rigorous estimation of welfare weights should take into account both margins that are set by the social planner. However, this estimate does provide some guidance as to where the weight is likely situated

generic to be less costly for a patient receiving a prescription drug for the first time, than for a chronic longstanding patient to switch, and that they take these costs into consideration. I refer to this as patient considerations. As these changes hold the active ingredient constant, these costs may be behavioral in nature. I investigate this hypothesis in two steps. I find physicians are particularly unlikely to switch older longstanding patients that take multiple prescription drugs. Leveraging the quasi-experimental design of the policy, I find that switching a patient's prescription drug from a branded to a generic version of the same active ingredient indeed comes at a health cost, measured by medication adherence.

Motivated by these reduced form results, I set out to quantify the relative importance of physician bias and patient considerations. I simulate the patent expiration of brand name drugs and the adoption of generics over a five year period under different scenarios, and find that physician bias and patient considerations are about equally important. I then use the model to simulate the introduction of a Mandatory Generic Substitution policy, in which pharmacies only dispense the generic version of an active ingredient. I assume all physician bias is wasteful (and therefore do not include in my welfare measure) and assume that the perceived cost of switching a patient is fully driven by the risk of decreasing medication adherence (and therefore fully include it in my welfare measure). I find that such policy may decrease overall welfare. Taking active steps to mitigate patient considerations would, however, increase overall welfare.

These results suggest that policymakers should carefully consider the effect of policies that target physician behavior and reallocate patients between treatments if the way they use care is subject to behavioral hazard. A better understanding of how patients use care, and how this can be improved, is therefore an interesting area for future research.

anca C moncod	MAIN CHEN WITH GEN	AICAL ERIC	2004 Market Suare	ATCs wirdt WHO Discriminal in Brazizine
I MUDUCI GROUF	TRAIOPET	TNT	DHARE	AT CO WITH WIND DESCRIFTION IN DRACKETS
1. DIABETES DRUGS	<u>Brand</u> Diamicron	A10BB09	0.0539	Anv ATC code that starts with A10 (Drugs used in diabetes).
2. DIURETICS	Fludex Lasix	C03BA11 C03CA01	0.0552	Any ATC code that starts with C03 (Diuretics).
3. Beta Blockers	Emconcor	C07AB07	0.0852	Any ATC code that starts with C07 (Beta Blocking Agents).
4. CALCIUM CHANNEL BLOCKERS	Amlor Zestril	C08CA01 C09AA03	0.0499 0.1145	Any ATC code that starts with C08 (Calcium Channel Blockers). Any ATC code that starts with C00 (Agents acting on the renin-andiotensin
	11000	00111000		system).
6. STATINS 7. ANTIBIOTICS	Zocor Clamoxyl	C10AA01 J01CA04	0.0783 0.0250	Any ATC code that starts with C10 (Lipid modifying agents). Any ATC code that starts with J01 (Antibacterials for systemic use).
8. ANTIRHEUMATICS	Voltaren	J01CR02 M01AB05	0.0445	Any ATC code that starts with M01 (Anti-inflammatory and antirheumatic prod-
	ŝ			ucts).
9. ANALEPTICS	Brufen Prozac	M01AE01 N06AB03	0.0588	Any ATC code that starts with N06 (Psychoanaleptics).
10. Obstructive Airway	Cipramil	R03BA02	0.0507	Any ATC code that starts with R03 (Drugs for obstructive airway diseases).
11 Отивь			0.9695	Any ATC code that starts with A01 (Stomatological menanations) A03 (Dung
			0404.0	Any ALC code that south and the production of the preparations), And (Antiemetics and antinauseants), A05 (Bile and liver therapy), A06 (Drugs for constipation), A07 (Antidiarrheals,
				intestinal anti-inflammatory/anti-infective agents), A08 (Antiobesity prepara- tions, excluding diet products), A09 (Digestives, including enzymes), A11 (Vi-
				tamins), A12 (Mineral Supplements), A13 (Tonics), A14 (Anabolic agents for exstemic use) A15 (Ametric stimulants) A16 (Other alimentary tract and
				procession products), B (Blood and blood forming organs), Cont (Cardiac ther-
				apy), CU2 (Anthrypertensives), CU4 (Peripheral vasodilators), CU5 (Vasoprotec- tives), D (Dermatologicals), H (Systemic hormonal preparations, excluding sex
				hormones and insulins), J02 (Antimycotics for systemic use), J04 (Antimycobac- terials), J05 (Antivirals for systemic use), J06 (Immune sera and immunoglob-
				ulins), J07 (Vaccines), L (Antineoplastic and immunomodulating agents), M02 (Tonical modulet for joint and muscular nain) M03 (Muscle relevante) M04
				(Topical produces for joint and musculat paint), and (Antisout preparations), M05 (Drugs for treatment of bone diseases), M09 (Other
				drugs for disorders of the muculo-skeletal system), N01 (Anesthetics), N02 (Anal- gesics), N03 (Antiepileptics), N04 (Anti-parkinson drugs), N05 (Psycholeptics),
				N07 (Other nervous system drugs), P (Antiparasitic products, insecticides, and repellents), R01 (Nasal preparations), R02 (Throat preparations), R05 (Cough
				and cold preparations), R06 (Antihistamines for systemic use), R07 (Other respiratory system products), S (Sensory organs), V (Various).
EXCLUDED			0.0541	Any ATC code that starts with A02 (Drugs for acid related disorders).
			0.0675	Any ATC code that starts with G (Genito-urinary system and sex hormones).
Notes: Market shares measure https://www.whocc.no/atc.d	red across a ldd_index (a	ll physician accessed 02,	s, using Dl /01/2018).	OD for quantity measure. Sources for the ATC names obtained from

Table 1.1: Classification of ATCs into Product Groups

	OVERALL SAMPLE		NIHDI SAMPLE		IMA SAMPLE	
	Mean	SD	Mean	SD	Mean	SD
	(1)	(2)	(3)	(4)	(5)	(6)
Age (in 2004)	46.839	10.824	47.371	10.787	44.343	10.110
Experience (in 2004)	20.616	10.787	21.166	10.795		
Female	0.288	0.453	0.258	0.438	0.153	0.361
In Group Practice					0.160	0.367
Generic Prescription Rate (in 2004)			0.122	0.072	0.147	0.077
Cheap Prescription Rate (in 2004)	0.186	0.060	0.172	0.066	0.201	0.074
Total DDD (in 2004) 10th percentile 90th percentile	236,334 38,349 459.117	166,169	214,241 34,233 424,318	156,561	137,819 16,575 293.887	104,703
# Transactions (in 2004) 10th percentile 90th percentile	,		5,764 1,016 11.287	4,134	$3,301 \\ 480 \\ 6.922$	2,435
Number of Patients 10th percentile			,		249 74	148
90th percentile					448	
Observations	10,800		1,065		300	

Table 1.2: Physician Descriptives.

Source: Tabulation of NIHDI and IMA Analyses Samples. The baseline generic prescription rate is calculated as the prescription rate of generics (at the physician level) in 2004.

	Full Sample			Generi	GENERIC COMPETITION			
	Mean	SD	Ν	Mean	SD	Ν		
	(1)	(2)	(3)	(4)	(5)	(6)		
Off Patent	0.484	0.500	963,716					
Generic	0.107	0.304	963,716	0.221	0.407	466,843		
Cheap	0.151	0.358	963,716	0.309	0.462	466,843		
Chronic	0.774	0.419	963,716	0.789	0.408	466,843		
Branded Copay				0.281	0.324	$466,\!840$		
Generic Copay				0.150	0.208	$397,\!920$		
Copay Difference				0.133	0.179	$397,\!917$		
Age (in 2004)	64.664	12.81	963,716	64.497	12.71	466,843		
Female	0.616	0.486	963,716	0.616	0.486	466,843		
Increased	0.283	0.450	963,716	0.263	0.440	466,843		
Reimbursement								
Starter	0.267	0.442	963,716	0.244	0.429	466,843		
Daily Dose (DDD)	41.767	38.927	963,716	44.772	39.629	466,843		
Polypharmacy	3.604	2.368	963,716	3.493	2.298	466,843		
Days Between Refill	52.882	44.343	$617,\!888$	55.243	45.018	$303,\!349$		
Adherence	1.043	0.798	424,838	1.040	0.796	242,350		

Table 1.3: Summary Statistics for Patients and Precriptions

Notes: Tabulation of IMA Analysis sample. All copay variables per DDD unit.
	CHRONIC	STADTEDS	LONCE	
	$\frac{ORONIC}{C}$	<u>SIANIERS</u>		<u>ANDING</u>
	Generic	Generic	Generic	Generic
	(1)	(2)	(3)	(4)
Copay Differential	0.034**	0.117***	0.005**	0.008***
	(0.016)	(0.019)	(0.002)	(0.003)
Increased Reimbursement (IR)	-0.013***	-0.012***	-0.004***	-0.004***
	(0.004)	(0.004)	(0.001)	(0.001)
Copay Differential $\times IR$	0.028^{*}	0.042^{**}	0.009^{**}	0.012^{***}
	(0.016)	(0.017)	(0.004)	(0.003)
Female	0.002	0.000	0.000	0.000
	(0.003)	(0.003)	(0.001)	(0.001)
$\operatorname{Generic}_{t-1}$			0.876^{***}	0.901^{***}
			(0.004)	(0.004)
Mean Generic (Pre-Mandate)	0.310	0.310	0.023	0.023
Ν	$242,\!019$	$242,\!019$	951,707	951,707
N Clusters	300	300	300	300
Physician \times Chemical FE	X		X	
Physician \times The rapeutic FE		Х		Х

Table 1.4: Split Sample Reduced Form Coefficients

Notes: *** p < 0.01, ** p < 0.05, * p < 0.1. The outcomes for this regression are whether a physician prescribes a generic prescription drug. The independent variables included in the regressions are discussed in section 1.4.1, and the estimates on the quarterly dummies before and after the announcement of the mandate are shown graphically in Figure 1.5. The analysis sample restricts attention to cases where a generic is available. The first two columns use the sample of prescriptions dispensed for chronic starters, columns three through four focus on prescriptions for chronic longstanding patients. Controls not listed in the table are two indicators for Calcium Channel Blockers and Analeptics in the first 8 months of the sample, as generics were not yet available for these groups at this point. Regressions are weighted by DDD, while standard errors are clustered at the physician level.

	CHRONIC STARTERS			CHRONIC LONGSTANDING		
	Top vs.	Воттом	Above 27% vs	Top v	s. Воттом	
	Median	QUART.	Below 15%	Median	QUARTILE	
	Generic (1)	Generic (2)	Generic (3)	Generic (4)	$\begin{array}{c} \text{Generic} \\ (5) \end{array}$	
Post	0.105***	0.110***	0.118***	0.018***	0.020***	
Post \times High	(0.006) -0.018*	(0.008) - 0.032^{**}	(0.011) - 0.056^{**}	(0.002) - 0.008^{***}	(0.003) - 0.013^{***}	
	(0.009)	(0.015)	(0.026)	(0.003)	(0.004)	
Controls	X	Х	Х	Х	Х	
Physician by Chemical FE	Х	Х	Х	Х	Х	
N Clusters N	$300 \\ 221.588$	$198 \\ 130.582$	$100 \\ 59.034$	$300 \\ 951.707$	$198 \\ 565.276$	

 Table 1.5: Dose-Response Models

Notes: *** p < 0.01, ** p < 0.05, * p < 0.1. The outcomes for this regression are whether a physician prescribes a generic prescription drug. The analysis sample restricts attention to cases where a generic is available. The first two columns use the sample of chronic starters, the final two columns chronic longstanding patients. Controls are the copay differential (at the active ingredient level), an indicator that takes on value on if the patient is on a increased reimbursement schedule, one indicator for female patients, and an interaction between patients on a increased reimbursement schedule and the copay differential. Regressions are weighted by DDD, while standard errors are clustered at the physician level.

	OLS (1)	OLS (2)	IV (3)	IV (4)	IV (5)	IV (6)
			A: Upper/Lower	Median (Full Sam	iple)	
<u>Dep. Variable</u>		$\underline{Adherence_t}$		$\underline{Adherence_{t+1}}$	\overline{A} dherence _{t+2}	$\underline{Adherence_{t+3}}$
Switch	-0.162^{***} (0.009)	-0.161^{***} (0.008)	-0.332^{***} (0.084)	-0.217^{***} (0.069)	-0.097	-0.052 (0.060)
Robust 1st Stage F-test			51.49	41.73	45.88	51.66
Mean Adherence Days Between Refill	1.040 55.243	1.040 55.243	1.040 55.243	1.040 55.243	1.040 55.243	1.040 55.243
Ν	861,022	861,022	861,022	706,156	657, 317	611, 115
N Cluster Controls	298 X	298 X	298 X	295 X	294 X	293 X
Month \times ATC FE	X	X	X	X	X	X
			3: Upper/Lower	Quarter (50% San	nple)	
<u>Dep. Variable</u>		<u>Adherence_t</u>		$\underline{Adherence_{t+1}}$	$\overline{Adherence_{t+2}}$	$\underline{Adherence_{t+3}}$
Switch	-0.155^{***} (0.016)	-0.165^{***} (0.014)	-0.249^{**} (0.133)	-0.193^{*} (0.133)	0.007 (0.126)	0.060 (0.108)
Robust 1st Stage F-test			15.96	13.66	16.69	18.56
Mean Adherence Days Between Refill	1.040 55.243	1.040 55.243	1.040 55.243	1.040 55.243	1.040 55.243	1.040 55.243
N N Clineton	368,199	368,199 140	368,199	301,018 145	280,041 144	260,187
IN Cluster Controls Month × ATC FE	X X	X X	X X	X X	X X	X X
Notes: *** $p < 0.01, **$	p < 0.05, * p	< 0.1. Instru	nents in colum	1 3 through 6 ar	e Low Prescribe	$r \times Post$ and
Lagged Choice \times Post. P	atient-level cont	rols are gender	, whether the p	atient receives an	increased reimbu	irsement, and
whether the patient receive a high or low prescriber a	d a generic at th nd lagged choice	e previous visit interacted wit	t. Baseline contr b low prescribed	ols for the instrur. ۰) are also include	nents (whether th ad Month by act	le patient sees ive inøredient
fixed effects are added to α	ontrol for idiosyn	ncratic time shc	ocks to overall ac	lherence. Column	1 also includes c	ontrols for the
copay differential between i	brand name and	generic drugs.	Standard errors	are clustered at t	he physician level	

Table 1.6: The effect of switching a patient on medication adherence

	Generic	Generic	Generic	Generic	Generic
	(1)	(2)	(3)	(4)	(5)
Starter imes Post	0.111***	0.091^{***}	0.091^{***}	0.092^{***}	0.092^{***}
	(0.003)	(0.003)	(0.003)	(0.003)	(0.003)
$Long standing \times Post$	0.014***	0.014^{***}	0.015^{***}		
	(0.001)	(0.001)	(0.001)		
Long standing imes Post imes					
Recent Lonastandina			-0.001		
(First Prescription after $04/2004$)			(0,001)		
$A_{ae} \subset [35, 50)$			(0.001)	0.014***	
$Age \in [55, 50)$				(0.003)	
$A_{ab} \in [50, 60)$				0.015***	
$Age \in [50, 00)$				(0.013)	
$A_{ab} \in [60, 70)$				0.019***	
$Age \in [00, 10)$				(0.012)	
$A_{ab} \in [70, 80)$				0.012***	
$Age \in [10, 80)$				(0.012)	
$A a \in [80, \infty)$				0.0005)	
$Age \in [60,\infty)$				(0.010)	
Polymbarmaay · 0				(0.003)	0.020***
1 olypharmacy : 0					(0.020)
Polymbarmaau + 1 = 2					(0.005)
$1 \ organized for the formula of t$					(0.014)
Delamberry e en e 2 4					(0.003)
Polypnarmacy: 3-4					(0.012)
					(0.003)
Polypnarmacy: 5-6					$(0.011^{(0,0)})$
					(0.003)
Polypnarmacy: 7+					$(0.010^{-0.01})$
T C	0.000***	0 000***	0 000***	0 000***	(0.003)
$LS imes g_{ijpt-1}$	0.839	0.803^{-10}	$0.803^{-0.00}$	0.803^{-10}	$0.803^{(0,000)}$
	(0.002)	(0.002)	(0.002)	(0.002)	(0.002)
Controls		v	v	v	v
Outrois Dhysician by Chamical FF	v				
N	Λ 1 1057 09	А 1 120 504	А 1 120 504	А 1 120 504	А 1 120 504
N Clustera	1,1957,92	1,139,304	1,139,304	1,139,004	1,139,004
IN UTUSTERS	59,572	30,090	20,090	20,090	90,090

Table 1.7: Pooled Chronic Drugs Reduced Form Results

Notes: *** p < 0.01, ** p < 0.05, * p < 0.1. The outcomes for this regression are whether a physician prescribes a generic prescription drug. The analysis sample restricts attention to chronic drugs and cases where a generic is available. Controls include the copay differential, the copay differential interacted with an indicator for longstanding patients, patient on an increased reimbursement plan, the copay differential interacted with an indicator for patients on an increased reimbursement plan, an indicator for female patients, and two indicators for Calcium Channel Blockers and Analeptics in the first 8 months of the sample, as generics were not yet available for these groups at this point. Regressions are weighted by DDD, while standard errors are clustered at the patient level.

	(1	L)	(2	2)		3)	(4	4)
	Coef.	S.E.	Coef.	S.E.	Coef.	S.E.	Coef.	S.E.
Price Sensitivity								
Δ Copay	-0.72	0.02	-0.74	0.02	-0.76	0.02	-0.77	0.02
\times Longstanding	0.54	0.03	0.60	0.03	0.63	0.03	0.67	0.03
\times Increased Reimbursement (<i>IR</i>)	-0.16	0.03	-0.14	0.03	-0.07	0.03	-0.06	0.032
\times IR \times Longstanding	0.07	0.04	-0.01	0.04	-0.13	0.04	-0.18	0.04
$\frac{\text{Controls}}{\text{Female}}$ IR $Longstanding$ $g(t-1)$	$0.04 \\ 0.05 \\ 2.15 \\ -5.87$	$0.00 \\ 0.00 \\ 0.00 \\ 0.00 \\ 0.00$	$0.04 \\ 0.05 \\ 2.04 \\ -5.87$	$0.00 \\ 0.00 \\ 0.01 \\ 0.00$	$0.03 \\ 0.04 \\ 2.10 \\ -5.87$	$0.00 \\ 0.00 \\ 0.01 \\ 0.00$	0.03 0.04 2.01 -5.87	$0.00 \\ 0.00 \\ 0.01 \\ 0.00$
Patient Considerations								
Longstanding \times Post	0.27	0.01	0.24	0.01	0.22	0.01	0.20	0.01
\times Polypharmacy (2-4 Drugs)			0.04	0.01			0.03	0.01
\times Polypharmacy (5-6 Drugs)			0.07	0.01			0.04	0.01
\times Polypharmacy (7+ Drugs)			0.04	0.01			0.01	0.01
$ \begin{array}{l} \times \ \mathrm{Age} \in [60 - 80) \\ \times \ \mathrm{Age} \in [80 - \infty) \end{array} $					$0.06 \\ 0.20$	$\begin{array}{c} 0.01 \\ 0.01 \end{array}$	$0.06 \\ 0.19$	$\begin{array}{c} 0.01 \\ 0.01 \end{array}$
Ν	270	.987	270.	.987	270.	.987	270	.987
Physician by Chemical FE	2	ζ	2	ζ	2	ζ		X
Baseline Controls			2	ζ.	2	ζ	2	X

 Table 1.8: Structural Parameter Estimates

Notes: Coefficients and standard errors are estimated using the strategy discussed in section 1.5.4.3. The model is estimated on a sample of chronic and non-chronic drugs, where baseline information (on generic use and polypharmacy) is available for chronic longstanding patients. Additionally, I introduce a dummy variable for prescription drugs with atc's starting with C08 and N06 in the first 8 months of 2004, since a generic was not yet available for these product groups.

	(a) Blank Pre	scription Note	(b) Prescription Note with Explanatory Codes				
	BIJLA	<mark>GE 84</mark>	BIJLAGE 84				
-		Naam en voornaam van de voorschrijver	Naam en voornaam van de voorschrijver				
-	DOOR DE VOORSCHRIJVER IN TE VULL Naam en voornaam van de rechthebbende:	EN:	DOOR DE VOORSCHRIJVER IN TE VULLEN: Naam en voornaam van de rechthebbende:				
	Voorbehouden aan het R/ verpakkingsvignet		Voorbehouden aan het verpakkingsvignet R/ 4 5				
	Medische verantwoording voor het voorschrift het octrooi verlopen is :	van een origineel geneesmiddel waarvan	Medische verantwoording voor het voorschrift van een origineel geneesmiddel waarvan het octrooi verlopen is :	-			
	Stempel van de voorschrijver	Datum en handtekening van de voorschrijver:	Stempel van de voorschrijver Datum en handtekening van de voorschrijver: 8				
		Uitvoerbaar vanaf voornoemde datum of vanaf:	Uitvoerbaar vanaf voornoemd vanaf: 9				
	GENEESMIDDELI	ENVOORSCHRIFT	GENEESMIDDELENVOORSCHRIFT				

Figure 1.1: Example of Prescription Note in Belgium

Notes: The left panel shows a simple blank prescription note as used in the Belgian healthcare market. On the right hand side, the numbers refer to the following explanations. 1: Bar code identifying the prescribing physician. 2: Box where prescribing physician writes her or his own name. 3: Box where prescribing physician writes down the name of the patient. 4: Box reserved for patient vignette for administrative purposes. 5: Box where prescribing physician details the name of the drug, the dosage, and the number of packs. Only one drug chemical per prescription is allowed. 6: Box for medical justification for using an brand name prescription when a generic is available (introduced in 2013). 7: Box for an official stamp of the prescribing physicians. 8: Date of prescription. 9: Date when the prescription goes into effect (optional and used when prescription should be explicitly used after a certain date). 10: Area where pharmacies with sufficient ICT infrastructure can print a pharmacy-specific barcode.

Figure 1.2: Differences between Brand Name and Generic Drugs

- (a) Brand Name Package (Zocor)
- (b) Generic Package (Brand: EuroGenerics)





(c) Brand Pill (Zocor 5 mg) (d) Generic Pill (Brand: Accord 5 mg)

Notes: Image from Zocor package retried from https://www.medibib.be/producten/zocor-40-mg-98-tabletten. Image from Eurogenerics Simvastatine package retrieved from

 $https://www.multipharma.be/be_fr/eurogenerics-simvastatine-eg-comp-pell-98-x-40mg-98-pc.html.$

Image from Zocor pill retrieved from https://www.drugs.com/imprints/zocor-msd-726-431.html. Image from generic pill retried from https://www.drugs.com/imprints/s1-22732.html. (all websites accessed 02/02/2018)





Notes: Kernel density of the (overall) prescription rate of generics at the physician level (N=300) before and after the announcement of the Minimum Prescription Rate policy mandate.



Figure 1.4: Descriptive Graphs: Prescription and Switching Rate of Generics

(a) Chronic Starters: Overall

(b) Longstanding Switching: Overall

Notes: This data is a graph of the average prescription rate of generics for different types of patients (chronic starters and longstanding). I show the overall prescription rate (upper panel) and averages across physicians that are in the top/bottom quartile (bottom panel). Overall, the figures display a sudden increase upon announcement of the mandate, with physicians far from the threshold responding more.



Figure 1.5: Impact of the mandate on Starters and Longstanding Patients

Notes: The regression coefficients and details for these event study coefficients are discussed in section 1.4.1 and table 1.4.



(a) Overall



(b) High/Low Prescribers



Notes: The regression coefficients and details for these event study coefficients are discussed in section 1.4.2.



Figure 1.7: Estimated Physician Inertia Before and After Mandate

Notes: This graph shows the IV estimates reported in table 1.6 where t is the first time a patient refills their prescription drug *after* being switched from a branded to a generic version of the same active ingredient. The OLS estimate is reported for time t. The Cluster-Robust 1st Stage F-Statistic and implied change in mean medication adherence are reported below the graph. Additional details are discussed in Section 1.4.3.





Differences in Switching Response across Longstanding Patients

Notes: The estimates reported in this Figure are obtained with the empirical strategy discussed in section 1.4.5 and the coefficient estimates are reported in table 1.7. Sample sizes, controls and clustering details are also found in this section and table.





Notes: This figure shows the smoothed density of physician bias, before and after the mandate. The bias is scaled by the price sensitivity for chronic starters.



Figure 1.10: Adoption Rate of Generics (over 5 years)

Notes: This figure shows the adoption of generics upon patent expiration in the four scenarios discussed in section 1.6. The details of the implementation are discussed in section 1.6 and is based on the structural estimates obtained in the structural estimation.



Figure 1.11: Framework for Policy Simulations

Previous Choice	Data	Model	Model	Model	Model
Baseline, Prices	Data	Data	Data	Data	Data

Figure 1.12: Policy Simulations

(a) Mandatory Generic Substitution (MGS)







Notes: These two graphs show the welfare effect of introducing a Mandatory Generic Substitution (MGS) policy in pharmacies (Figure 1.12a) and the welfare effects of combining a MGS policy with decreases in Patient considerations. Only scenarios with decreases of 30 and 60% are reported. The welfare calculations depend on the welfare weight (x-axis), with the yellow vertical line denoting an estimate of the welfare weight of the Belgian health insurer.

CHAPTER II

Fairness Considerations in Wage Setting: Evidence from Domestic Outsourcing Events in Germany

2.1 Introduction

The impact of fairness considerations in the labor market has been a topic of interest in economics since the seminal paper by Akerlof and Yellen (1988).¹ Ever since, empirical evidence in economics has focused on how these considerations affect job satisfaction (Fehr and Schmidt, 1999; Hamermesh, 2001; Card et al., 2012), job search effort (Card et al., 2012), and labor supply decisions (Cohn et al., 2011; Breza, Kaur and Shamdasani, 2018). It is unclear, however, to what extent employers and firms take these fairness considerations into account when setting wages, and how this can affect labor market outcomes.

In this paper, I fill this gap by studying whether fairness considerations play a role in wage setting. To do so, I investigate the effect of domestic outcourcing events on workers that *remain* in establishments *after* these domestic outsourcing events occur.² Domestic outsourcing is generally defined as the decision of firms to buy local services (such as cleaning or security services) on the market, instead of producing them in-house. I study this question in Germany, where I employ administrative earnings data with detailed occupation and industry codes that links employers to their employees. Using these detailed industry

¹This paper built on a rich tradition in psychology, sociology, and organizational behavior. Durkheim (1895) is considered one of the seminal studies in sociology, while Bicchieri and Muldoon (2011) provides a recent review of this literature.

 $^{^{2}}$ The definition of domestic outsourcing events in this paper is similar to that used in Goldschmidt and Schmieder (2015).

and occupation identifiers, I define domestic outsourcing events when employment in four occupation categories at the establishment level drop to zero. I focus on occupations in security, catering, cleaning, or logistics services.

The main empirical strategy in this paper exploits the timing of these domestic outsourcing events in an event study framework: I compare establishment and worker-level outcomes before and after these events. I find three main results. First, domestic outsourcing events result in an immediate change in the skill ratio in the outsourcing establishment. This ratio is stable both before and after the outsourcing events. On average, outsourcing establishments become more high-skill intensive. Second, holding workers' individual ability constant – using worker-level fixed effects – I find that high skilled workers receive a wage increase of about 5 log points, where low skilled workers face a wage cut of about 1 log point. These changes are not accompanied by changes in investments – suggesting that changes in wages are not explained by substitution or complementarity effects with new investments. Third, these differences are more pronounced in smaller establishments, where workers are more likely to interact with each other.

These empirical findings are consistent with a new theoretical model that describes the outsourcing decision for an employer that faces fairness considerations *acros skill groups* in the wage setting process.³ More specifically, low skilled workers care about the ratio of high skill to low skill wages, and exert less effort when high skill wages increase relative to low skill wages (ie. when this ratio increases). Employers, who produce goods using a CES production function with imperfect substitution between low and high skilled workers, are constrained in how they can set wages for their workers. Domestic outsourcing allows these employers to not only save on the production of services that are being outsourced, but also to change wage setting as the organizational set-up of the establishment is altered. As establishments become more high skilled, they increase the wages of high skilled workers relative to low

³There are other theoretical ways to model fairness in the workplace. This model simply takes a stand on a specific type of fairness considerations where the relative wage gap between different skill groups matters, and does not discard other forms of fairness (such as "internal" fairness norms as in Akerlof and Yellen (1988)).

skilled workers. As a result, domestic outsourcing can increase within-establishment wage inequality among workers who remain in outsourcing establishments.

Several studies have documented that rising assortativeness has been related to the increase in wage inequality in several OECD countries – such as the United Kingdom (Faggio, Salvanes and Van Reenen, 2010; Mueller, Ouimet and Simintzi, 2017), Germany (Card, Heining and Kline, 2013), Sweden (Håkanson, Lindqvist and Vlachos, 2015), Brazil (Helpman et al., 2017), the United States (Song et al., 2019), and studied the role between domestic outsourcing and increasing wage inequality *across* establishments. Building on the work of Dube and Kaplan (2010), Goldschmidt and Schmieder (2015) look at how domestic outsourcing relates to the resorting of workers to different establishments. However, these papers typically do not assess whether there is a role for domestic outsourcing in rising wage inequality within establishments or firms through how employers set wages in response to how these events change the organizational nature of the firm or establishment.

This paper therefore makes two distinct contributions. First, it contributes to our understanding of how fairness considerations play a role in the labor market by looking at how it affects the wage setting process in the labor market. As noted before, much of the previous evidence has focused on how fairness considerations affect worker behavior – either in terms of job satisfaction (Card et al., 2012), job search behavior (Card et al., 2012), or labor supply (Breza, Kaur and Shamdasani, 2018). This paper is one of the first to examine how these fairness considerations play out in how employer set wages and organize their production. This channel also provides an additional motivation for employers to use domestic outsourcing. Apart from the direct cost savings which have typically received most attention in economics research (Dube and Kaplan, 2010; Goldschmidt and Schmieder, 2015), employers can also readjust their wages for workers they decided not to outsource and affect their effort levels.

The second contribution is that it analyzes the potential role of domestic outsourcing in rising *within-firm* or *within-establishment* wage inequality. Whereas the increasing importance of assortativeness in the wage inequality has naturally led researchers to investigate the reallocative effects of domestic outsourcing (Faggio, Salvanes and Van Reenen, 2010; Card, Heining and Kline, 2013; Håkanson, Lindqvist and Vlachos, 2015; Mueller, Ouimet and Simintzi, 2017; Helpman et al., 2017; Song et al., 2019), this paper highlights how domestic outsourcing can change organizational workplace features that affect wage setting and *within-establishment* or *within-firm* wage inequality.

The remainder of this paper proceeds as follows. Section 2.2 discusses the use of domestic outsourcing in several labor markets over time and discusses how these relate to the research questions in this paper. Section 2.3 presents the model, while section 2.4 discusses the data and the setting of the German labor market. Section 2.5 presents how domestic outsourcing is measured for the purposes of this paper and section 2.6 presents the results. Section 2.7 shows the results are robustness to various concerns, while Section 2.8 concludes.

2.2 Background

The increased use of domestic outsourcing services in recent decades has changed the employment relationship in the labor market in important ways, as employers increasingly rely on outside contractors rather than employed workers in the production process. Domestic outsourcing is generally defined as the decision of firms to buy local services (such as cleaning or security) on the market from other firms, instead of producing them in-house. The GDP share of these services almost doubled from 7 to 12 percent between 1982 and 2009 (Yuskavage, Strassner and Medeiros, 2008), and about half of the workers used in the production of manufacturing products are currently employed outside of the manufacturing sector (Houseman, 2014).

Outsourcing firms typically pay higher wages than smaller firms that workers are being outsourced to (Abraham, 1990; Dube and Kaplan, 2010; Goldschmidt and Schmieder, 2015). In particular, recent evidence shows that the outsourced workers on average face substantial wage losses of about 10 to 20 percent (Dube and Kaplan, 2010; Goldschmidt and Schmieder, 2015). This is consistent with the finding that high (low) wage workers are increasingly sorted into high (low) wage firms (Card, Heining and Kline, 2013; Song et al., 2019). In fact, the domestic outsourcing of cleaning, catering, security and logistics services alone explains about 10 percent of the rise in wage inequality in Germany (Goldschmidt and Schmieder, 2015).

While these changes may result in changes in wages through how workers are allocated across employers, it is unclear whether these domestic outsourcing events have impacts on wages through how employers set wages in response to organizational changes. There has been an active and longstanding interest in sociology, psychology and organizational behavior into how workplace organization may drive wage setting. Nevertheless, empirical evidence in economics has largely focused on how fairness considerations drive decisions on the worker side.

Nevertheless, there is descriptive evidence on organizational features possibly playing a role in explaining the rise in wage inequality. Several papers have documented that increasing occupational and education concentration in production units are related to higher levels of wage inequality (Kremer and Maskin, 1996; Handwerker and Spletzer, 2015; Håkanson, Lindqvist and Vlachos, 2015). The underlying drivers of these empirical facts, however, are not that well understood.

2.3 Theoretical Framework

In this section, I build a static model of domestic outsourcing decisions that allows for fairness considerations to impact the on-the-job effort of workers (and hence their marginal productivity). The model has an establishment choosing between two types of labor (high skill and low skill) that each have their labor supply. I follow a recent literature that draws on the IO literature on diversified products to model establishments that offer different wage tuples because of differences in productivity across establishments (Card et al., 2016).

In a first step, I model establishments as cost-minimizers that offer wage tuples to high

and low skill workers as the result of underlying differences in productivity. The establishment employs high and low skill workers both directly (in-house) and through purchasing services on the market (outsourcing). For in-house labor, they face a static labor supply as a result of these differences in wages. Workers observe the wages establishments set for their skill group, but only discover the wages of other skill groups in this establishment once employed.⁴ This has an effect on their productivity in the establishment through fairness considerations: low-skill workers exert less effort on the job when the wage differential between low-skill and high-skill workers is large.

2.3.1 Labor Supply

There are two types of worker on the labor market: high skilled workers (type 1) and low skilled workers (type 2). A type s worker gets an indirect utility from working at an establishment j that offers wage w_{js} that is given by

$$\nu_{ijs} = \sigma w_{js} + \varepsilon_{ijs} \tag{2.1}$$

where ε_{ijs} is some idiosyncratic error term that follows a type I extreme value distribution. It is important to note here the worker does not necessarily observe the wages for other types of workers. Each firm has some degree of market power as workers have some unobserved taste shock. Conditional on wages, these taste shocks as assumed to be independent.⁵ If the number of establishments J is sufficiently large, Card et al. (2016) show these logit choice probabilities simplify to

$$P(\nu_{ijs} \ge \nu_{iks} \quad \forall \ k \neq j) \approx \lambda_s \exp(\sigma w_{js}) \tag{2.2}$$

⁴Alternatively, the decision for low-skill workers to work for an establishment depends solely on the wage low-skill workers get, but their effort once hired depends on both the low-skill and high-skill wages.

⁵Compared to other labor markets, such as the United States, the majority of benefits in Germany is captured through wages. While company cars and other amenities do exist, important benefits such as 401(k)'s are not used in Germany. As a result, the assumption that labor supply decisions can – in large part – be characterized by wage levels and idiosyncratic shocks, is reasonable in this context.

where λ_s is some constant that is different across skill groups.⁶ Finally, the labor supply function an establishment faces can then be written as

$$\ln(L_{js}(w_{js})) = \ln(I_s\lambda_s) + \sigma\ln(w_{js})$$
(2.3)

The assumption that the number of establishments is sufficiently large implies a partial equilibrium framework where there are no strategic interactions between establishments. Given that the fraction of firms deciding to outsourcing is low in any given year, this seems like a reasonable assumption.

Additionally, market conditions allow establishment j to hire some high and low skill labor on the market — \bar{L}_{j1} and \bar{L}_{j2} respectively. The extent to which the establishment uses such services will depend on transaction costs, the availability of different services in local market, and other environmental factors. For these reasons, the firm largely is assumed to take these numbers as given.

2.3.2 Firm Problem

Firms are cost-minimizers that produce a final good using high and low skill labor and need to set wages in order to meet the demand for their product. It is reasonable to allow for low and high skill workers to be imperfect substitutes. Therefore, I model this production function $f_j = f(L_{j1}(w_{j1}), L_{j2}(w_{j2}))$ as a CES production function with two inputs. Following Card et al. (2016), I allow for a productivity shifter T_j that differs across establishments and captures differential technological innovations. A_1 and A_2 capture differential productivity shifters across high and low skill workers.⁷

Following Akerlof and Yellen (1988) and Rees (1993), I assume high wage differentials within the establishment can negatively affect the effort (and hence marginal product) of

⁶It is possible to distinguish for different labor supply elasticities σ_s for different skill groups. Since I am not aware of any studies that highlight these elasticities are dramatically different across skill groups, I choose to simplify in this specific model.

⁷These three productivity shifters are not separately identified, but this notation may clarify how different technological shocks may impact wages. Therefore, I opt to use this notation.

workers. Most research (see, e.g., Card et al. (2012) or Rees (1993)) has suggested that fairness considerations mainly affect workers earning below the mean or the median within the establishment.⁸ As low skill workers typically earn less than high skill workers, I assume the productivity of both these workers is affected by large wage differentials, following the empirical literature (Card et al., 2012). In particular, the productivity wedge can be written as $\tau(w_{j1}, w_{j2})$ where $\tau_1(.,.) < 0$ and $\tau_2(.,.) > 0.^9$ The cost minimization problem when producing the business service in-house can be written as

$$V_j(w_{j1}, w_{j2}) = \min_{w_{j1}, w_{j2}} w_{j1} L_{j1}(w_{j1}) + w_{j2} L_{j2}(w_{j2}) + C(\bar{L}_{j1}, \bar{L}_{j2})$$
(2.4)

s. t.
$$T_j \left\{ A_1 \left[L_1(w_{j1}) + \bar{L}_{j1} \right]^{\rho} + A_2 \left[\tau(w_{j1}, w_{j2}) L_2(w_{j2}) + \bar{L}_{j2} \right]^{\rho} \right\}^{\frac{1}{\rho}} \ge Y_{j1}$$
 (2.5)

It is worth noting that in this context, differential skills are important for two reasons. On the one hand, there are different productivity levels associated to workers of different skill. On the other hand, they offer one way in which workers differ in wage levels, generating fairness considerations. Other reference groups are possible, but using difference in skill levels has the benefit it is a relatively clean and objective measure.

Firms or establishments will decide to outsource when new opportunities make it viable, i.e. when there is a shock to or change in $C(\bar{L}_{j1}, \bar{L}_{j2})$. When the outsourcing environment for an establishment changes in such a way that outsourcing becomes cheaper and outside labor can be contracted, an establishment can alter its employment by increasing the level of outside workers \bar{L}_{j1} and \bar{L}_{j2} .

 $^{^{8}}$ In Card et al. (2012), the median is calculated at the department level, which could be thought of as an establishment. What workers exactly see as their reference group is not something that is clearly laid out in the fairness literature. Therefore, I assume the reference group of interest is the establishment.

⁹Here, $\tau_1(w_1, w_2)$ is shorthand for $\frac{\partial \tau(w_1, w_s)}{\partial w_1}$ and $\tau_2(w_1, w_s)$ is shorthand for $\frac{\partial \tau(w_1, w_s)}{\partial w_s}$.

2.3.3 Wage Setting

In any one time period, the firm minimizes the objective function, leading to the following first order conditions. I suppress the firm subscripts for brevity.

$$(1+\sigma)\mathcal{L}_{1}^{1-\rho} = \mu T f^{1-\rho} \left\{ A_{1} \frac{\sigma}{w_{1}} \right\} + \mu T f^{1-\rho} \left\{ A_{2} \tau_{1}(w_{1}, w_{2}) \left[\frac{\mathcal{L}_{2}}{\mathcal{L}_{1}} \right]^{\rho-1} \frac{L_{2}(w_{2})}{L_{1}(w_{1})} \right\}$$
(2.6)

$$(1+\sigma)\mathcal{L}_{2}^{1-\rho} = \underbrace{\mu T f^{1-\rho} \left\{ A_{2}\tau(w_{1},w_{2}) \frac{\sigma}{w_{2}} \right\}}_{\text{Without fairness}} + \underbrace{\mu_{1}T f^{1-\rho} \left\{ A_{2}\tau_{2}(w_{1},w_{2}) \right\}}_{\text{Fairness effect}}$$
(2.7)

where μ is the Lagrange multipliers on the production constraint in equation 2.5. For simplicity, $\mathcal{L}_1 = L_1(w_1) + \bar{L}_1$ and $\mathcal{L}_2 = \tau(w_1, w_2)L_2(w_2) + \bar{L}_2$ represent the effective labor units in terms of high and low skill labor. This can be thought of as the amount of work that needs to be performed. There is perfect substitution between the actual work being done, which is arguably a reasonable assumption for several outsourcing services, such as catering workers, security guards, and cleaning workers.

In the absence of fairness considerations, $\tau(.,.) = 1$, $\tau_1(.,.) = 0$ and $\tau_2(.,.) = 0$. Therefore, all fairness effects simply drop out, and we are left with the leading terms in all equations. If $\tau_1(.,.) < 0$ and $\tau_2(.,.) > 0$ as assumed, the left hand side of equation 2.6 is driven downwards compared to the scenario when there are no fairness considerations, while the right hand side of equations 2.7 and 2.6 are driven up. Therefore, the effect of fairness considerations predicts wage compression, a prediction that is often hypothesized as an effect of fairness considerations (Bernhardt et al., 2016).

Furthermore, fairness considerations operate as a tax that is carried by high skill workers. This follows from the assumption that workers are paid more (i.e. high skill workers) are typically not affected by fairness considerations (Card et al., 2012). Establishments internalize this knowledge and therefore levy the tax on these high skill workers. However, this model can easily be extended to a scenario where the morale of high skill workers is affected and this decreases overall productivity at the establishment. This could be modeled by an overall productivity wedge for the establishment. However, as long as low skill workers and their morale are affected more by fairness considerations, the main intuitions of the model go through.

Additionally, the labor composition of the establishment also determines the extent to which fairness considerations affect the establishment. If the ratio of low to high skill workers is high, fairness considerations are expected to depress the wage of high skill workers more, as high skill workers need to carry a larger burden.

2.3.4 Assumptions on Fairness and Demand.

I follow Card et al. (2016) and assume firms face an inverse demand function of $P_j = P_j^0(Y_{j1})^{-\frac{1}{\epsilon}}$. Here, ϵ is a market wide-parameter.

In order to get more traction on the effect of fairness considerations, I assume some structure on $\tau(w_1, w_s) = \left(\frac{w_s}{w_1}\right)^a$ where a > 0. If a = 0, there are no fairness effects.¹⁰ This parameterization need not be a deep structural relationship, but can be thought of as a local approximation of the effect of fairness considerations on the marginal productivity of low skilled workers.

2.3.5 Comparative Statics.

When establishments decide to outsource, the wages that the establishment sets will change. Denote the wages before outsourcing as $\{w_1, w_2\}$, whereas the wages after outsourcing are $\{w'_1, w'_2\}$. Taking logs and substracting wages pre-outsourcing from post-outsourcing

¹⁰If a < 0 low skill workers become more productive as their wages is further away from high skill workers. This is not supported by any empirical work, therefore assuming $a \ge 0$ seems relatively innocuous.

wages gives the following relationships¹¹

$$\ln\left(\frac{w_1'}{w_1}\right) = (\rho - 1)\ln\left(\frac{\mathcal{L}_1'}{\mathcal{L}_1}\right) + \ln\left(A_1\sigma - A_2a\left(\frac{\mathcal{L}_2'}{\mathcal{L}_1'}\right)\left(\frac{L_2(w_2')}{L_1(w_1')}\right)^{1+\frac{a}{\sigma}}\xi^a\right) -$$
(2.8)
$$\ln\left(A_1\sigma - A_2a\left(\frac{\mathcal{L}_2}{\mathcal{L}_1}\right)\left(\frac{L_2(w_2)}{L_1(w_1)}\right)^{1+\frac{a}{\sigma}}\xi^a\right)$$
$$\ln\left(\frac{w_2'}{w_2}\right) = \frac{(\rho - 1)}{1 - a}\ln\left(\frac{\mathcal{L}_2'}{\mathcal{L}_2}\right) - \frac{a}{1 - a}\ln\left(\frac{w_1'}{w_1}\right)$$
(2.9)

Under the assumption that "effective" labor units (i.e. \mathcal{L}_1 and \mathcal{L}_2) are constant, two key predictions arise.

1. Wages of high skill and low skill workers move in opposite directions.

This prediction is derived from equation 2.9 in conjunction with the assumptions that a > 0 and the effective labor units are constant.

2. High skill wages increase more when an employer becomes more skill intensive

This prediction is derived from equation 2.8 and discussed in more detail in the appendix. Intuitively, however, it results from all terms within the brackets of the second and third ln terms in equation 2.8 being constant, apart from the labor supply quantities before and after the domestic outsourcing event.

The assumption that effective labor units are constant is a reasonable assumption where services provided are relatively homogenous, easy to provide, and not part of the core business of the establishment. Cleaning or catering services, for instance, is a task where the quantity is relatively well defined and constant where it is reasonable to assume that the amount of cleaning does not change after outsourcing.¹²

¹¹I assume that the functional form of the production function f does not change over time. Additionally, ξ in this context is a constant equal to $\xi = \left(\frac{\lambda_1 I_1}{\lambda_2 I_2}\right)^{1/\sigma}$

¹²For high skill outsourcing, this assumption may be less clearcut. One may expect the change in effective labor units to be relatively important (and increasing) for high skill workers. Under this assumption, we are likely to understate fairness considerations, as part of the wage increase for high skill workers does not only reflect this effect, but also the change in effective labor units after outsourcing.

2.4 Data and Institutional Setting

2.4.1 Data

The data used in this paper combines two data sources from Germany, both made available by the Institute for Employment Research or IAB.¹³ The first data source is the Betriebspanel or Establishment Survey, a representative and yearly survey of establishments in Germany, stratified according to establishment size, industry and federal state. The survey provides each establishment with a unique identifier that is matched to the establishment identification number (EID) that links this survey data to administrative employment data. The sample spans years 1993 through 2010 and consists of about 5,000 establishments at the start of the sample and about 15,000 establishments at the end of the sample.¹⁴ The topics of the survey include, but are not limited to, employment development, production outcomes, investment decisions, unionization information and personnel structure.

The second data source is the Linked IAB or LIAB, a linked employer-employee dataset that augments the Betriebspanel with detailed administrative information from the German Social Security system for every employee in those establishments that are part of the survey. This data is matched using the unique EID identifier. The Social Security system combines data for all establishments and individuals into the Integrated Employment Biographies (IEB), that is built on the integrated notification procedure for health insurance, unemployment insurance, and the statutory pension scheme. Employers have to notify the social security agencies for all employees in a calendar year, using their administrative EID. They provide information on the employment spell (the exact starting and end date of their job), the total earnings, and education, occupation, trainee status, employment type (i.e.

¹³For completeness, IAB stands for Institüt for Arbeitsmarkt- und Berufsforschung der Bundesagentur für Arbeit. The data used in this study are also described in further detail in Alda, Bender and Gartner (2005) or Heining et al. (2013).

¹⁴More specifically, the survey samples about 5,000 establishments from West Germany from 1993 until 1999 and about 10,000 establishments from West Germany from 2000 until 2010. The survey also samples about 5,000 establishments from East Germany from 1996 until 2010. Data past 2010 are not available yet, as the data reporting system underwent some changes. The IAB is working to make the post-2010 data consistent, and information until 2014 should be available soon.

part-time of full-time), and several demographics for each unique employee identifier.¹⁵ If the employment spell lasts longer than one year, an annual report is set up and communicated with social security agencies. In contrast to the IEB, the LIAB therefore does not cover the universe of the German workforce, only those workers that are employed by establishments sampled for the establishment surveys.

There are two models of the LIAB available, a cross-sectional model and a longitudinal model. The cross-sectional model follows establishments and provides detailed information of employment within all these establishments and only follows workers when they leave one establishment for another that is surveyed. When the worker leaves for an establishment not part of the survey, the workers is not in the cross-sectional LIAB any longer. In contrast, the longitudinal model tracks fewer establishments, but follows workers even when they leave. For the purposes of this paper, the cross-sectional model is used, as it maximizes the number of establishments in the sample and provides detailed information to answer the research questions of interest.

The EIDs are assigned by social security agencies on the basis of ownership, industry and municipality. Hethey, Schmieder et al. (2010) discuss some important issues that arise when using these EIDs. For instance, two manufacturing plants or restaurants owned by the same firm, operating in the same authority district (Kreis) will receive one EID. A manufacturing plant and a sales outlet that are run by one firm in the same Kreis, will receive two EIDs. Additionally, new EIDs can be issued when establishments change ownership. One way in which this could be important for my results is when an establishment breaks up in two separate establishments, one "general industry" establishment and one "business service" establishment, which would possibly lead to missing outsourcing events in the data. Mergers, with subsequent outsourcing, could similarly bias my results. Another limitation of the data is that there is top coding of the earnings information.

Appendix B.1 provides details on the data processing used in this paper. I restrict the

 $^{^{15}{\}rm This}$ unique employee identifier is not only unique at the establishment level, but unique for Germany, as it is based on social security numbers.

sample to observations that have non-missing establishment and person identifiers and focus on workers that are between 20 and 60 years old. In order to adjust for top coding, I use imputation techniques that follow other papers that made use of this data (Dustmann, Ludsteck and Schönberg, 2009; Card, Heining and Kline, 2013; Goldschmidt and Schmieder, 2015). The precise details are discussed in appendix B.1.2. After imputing, I drop observations with daily earnings below 10 Deutsche Mark or euros.

For the skill variable, the schooling variable is split up in high and low skill workers. Low skill workers include those workers that have finished middle or high school, with or without a vocational degree. High skill workers have finished either technical university or college. The effects within these skill groups are relatively similar when estimating the models at more granular levels of skill, so this grouping makes does not mask heterogeneous effects across the different skill levels within groups (e.g. those low skill workers with or without a vocational degree).

2.4.2 Institutional Setting

Labor relations and wage setting in Germany differ substantially from the US setting.¹⁶ Collective bargaining agreements are typically set at the industry level and negotiated between the industry and labor unions. Establishments can either agree – covering *all* workers automatically – or they can deviate from these agreements and set up an agreement at the firm or establishment level that union representatives at the establishment agree with and sign off on. Even in the absence of such agreement, establishments can opt out of agreements. When doing so, they are required to pay their existing employees according to previous wage agreements, but need not follow these agreements for new hires.¹⁷

Unionization is different from the collective bargaining agreement, as workers decide

 $^{^{16}\}mbox{For more complete discussions},$ Dustmann et al. (2014) and Fitzenberger, Kohn and Lembcke (2013) provide a good overview

¹⁷Despite the apparent benefits of changing to firm-level agreements, Dustmann et al. (2014) show that the union decline in Germany is primarily driven by firms going from industry level agreements to non-unionized workplaces.

individually to join the union. Workers that are covered by the industry or establishment collective bargaining agreement are therefore not necessarily part of a union and vice versa. Additionally, when it comes to firing workers, Germany does not adhere to employment-atwill which is common in the United States. There are specific laws protecting workers from mass layoffs. There is an upper bound on the number of employees any one establishment can fire within a 30-day period. Any layoffs above these thresholds need the authorization of the employment office, also called the Agentur für Arbeit. The last revision to this law was passed in 2008, with, for example, an upper bound of 5 employees for establishments employing 21 to 59 employees (see Kündigungsschutzgesetz, Section 17).

2.5 Domestic Outsourcing

2.5.1 Measuring Domestic Outsourcing

Several methods to measure domestic outsourcing or contracting out have been used in the literature, and all methods require detailed industry and occupational information to do so. Abraham (1990) compares both high and low wage occupation workers across "general" industries and "business service" industries. Another strand of literature has focused on low skilled occupations such as janitorial or security services. The reason to focus on these occupations is twofold (Goldschmidt and Schmieder, 2015). First, these occupations are easily measured in the data and represent tasks that are fairly consistent over time. Second, the employment share of these occupations in the labor market has remained relatively constant. The employment of other occupations, such as typists or accountants, exhibits strong trends and changing job contents. Dube and Kaplan (2010) use a fixed effects strategy for people moving from a general to a business service industry, acknowledging that different types of workers may sort into different industries. Both of these studies can be performed using CPS or similar data. Both Abraham (1990) and Dube and Kaplan (2010) find that, using this definition, workers take a pay cut of about 10 to 20% when they are outsourced. Linked employer-employee data provide other ways of measuring domestic outsourcing. Similar to Dube and Kaplan (2010), Goldschmidt and Schmieder (2015) study catering, cleaning, security and logistics (CCSL) occupations, but highlight the concern that the outsourcing decision in the previous definition is not necessarily exogenous from an individual's perspective, even when including worker fixed effects.¹⁸ Using the complete IEB covering all German workers since 1975, they exploit the linked nature of their data, and identify events where at least ten people leave one "general industry" establishment to then all show up at a new "business service" establishment in the following year, something they coin *on-site outsourcing.*¹⁹ They contrast this definition to the one used by Dube and Kaplan (2010) and find similar results: workers take a pay cut of about 10 to 15% when they are outsourced.

Similar to Goldschmidt and Schmieder (2015), I exploit the linked character of my data and focus on CCSL occupations, but define outsourcing events differently.²⁰ I build on a set of five descriptive facts, discussed in appendix B.2, to define outsourcing events at the establishment level rather than at the individual level. The first three panels of table B.3 describe the stability of CCSL employment within establishments. First, simple establishment fixed effects explain the majority of the variation in the employment level of these occupations. Second, adding a AR(1) structure on the error component highlights that employment within establishments is highly persistent, as the autocorrelation is close to one. Third, running these regressions with employment shares rather than employment levels decreases the autocorrelation coefficient considerably, indicating that the employment of these occupations does not increase one-to-one with the size of the establishment. Fourth, the final panel of the table highlights that, once the employment in these occupations drops to zero, it is highly unlikely these occupations are insourced again. Finally, figure B.1 highlights that turnover

 $^{^{18}\}mathrm{See}$ Gibbons and Katz (1992) for a more complete discussion.

¹⁹The precise restrictions they impose are the following. At least 10 workers leave a "general industry" establishment and show up at a new "business service" establishment in the following year; the "general industry" establishment does not close down in the following year; this worker flow represents at most 30% of the initial workforce at the originating establishment; and this establishment initially has at least 50 full-time employees.

²⁰I follow the codes used in Goldschmidt and Schmieder (2015). The precise occupational and industry codes are presented in appendix B.2.1, tables B.1 and B.2.

rates are highly stable for these occupations.

Building on this set of facts, I define an outsourcing event at the establishment level as follows. First, the employment in the relevant occupation drops to zero, after it was positive in the year immediately before. Second, the establishment industry code does not switch to a business service or temp industry identifier after the outsourcing event.²¹ Third, the flow of workers that are outsourced, constitute no more than 30% of employment at the moment of outsourcing. Fourth, and finally, the outsourcing establishment employs at least 20 people. Figure 2.1 shows the outsourcing rates (i.e. the fraction of establishments making the decision to outsource) are relatively stable across the sample period and the fraction of establishments that are outsourcing under this definition.²² Overall, the even spread of outsourcing events across the sample period also mitigates concerns of general equilibrium effect in local labor markets.²³

2.5.2 Summary Statistics

Table 2.1 provides some key summary statistics for establishments. The upper panel focuses on establishments the year before outsourcing, while the lower panel focuses on establishments that have never outsourced. Overall, employers that are about to outsource are large and pay slightly higher wages than establishments that do not outsource, consistent with the findings of Goldschmidt and Schmieder (2015). Additionally, they are more likely to be covered by a collective bargaining agreement and tend to have somewhat higher levels of education and productivity, but lower shares of part-time workers.

Table 2.2 provides some summary statistics for workers that remain in outsourcing establishments in the upper panel, and summary statistics for workers that work in establishments that never outsource in the lower panel. Overall, the workers are relatively similar in terms

 $^{^{21}}$ I follow the industry codes used by Goldschmidt and Schmieder (2015), with the slight difference that I don't have access to 5 digit industry codes.

²²This graph possibly underestimates the extent to which establishments are outsourcing. Establishments that decided to outsource prior to 1993 show up as non-outsourcing.

²³In order to analyze these effects in more detail, access to the full underlying administrative data would be necessary and is a useful area for future research.

of wages, education levels and demographics, such as age, gender, nationality and part-time status. However, workers that stay in outsourcing establishments tend to have higher tenure.

2.6 Empirical Strategy and Results

2.6.1 Establishment-Level Outcomes and Structure

I examine the impact of outsourcing events on establishment outcomes using an event study research design. Consider the following econometric model of outsourcing:

$$y_{jt} = \sum_{\Delta = -3}^{4} \delta_{\Delta} \mathbb{I}\{t - t_j^* = \Delta\} + \gamma X_{jt} + \xi_j + \theta_t + \varepsilon_{jt}$$
(2.10)

where y_{jt} is the outcome variable for establishment j at time t. The event study specification measures the dynamic time path of the outcome variable before and after the outsourcing event (which occurs at time t_j^*) conditional on a set of fixed effects (θ_t and ξ_j respectively) and a set of time-varying establishment controls.²⁴ The sample for these establishment-level regressions includes all establishments with an employment size of at least 20 people the year before the outsourcing event takes place.²⁵ The identifying assumption is that the timing of the outsourcing event is random, which can be tested for by verifying that $\delta_{\Delta} = 0$ for $\Delta < 0$.

Figures 2.2a and 2.2b highlight the impact of outsourcing events on the stucture of outsourcing establishments by showing the δ_{Δ} coefficients with 95% cluster-robust confidence intervals for estimating equation 2.10. Both establishment size (measured in number of workers employed) and number of (distinct) occupations employed are relatively constant before and after the outsourcing event, but exhibit and clear and sudden drop in the wake of an outsourcing event. The drop in size and occupations at the establishment highlights that the domestic outsourcing event based on CCSL occupations seems to coincide with

 $^{^{24}}$ There are some cases where an establishments outsources an occupation twice using the definition in this paper. As a result, I focus solely on the *first time* an establishment outsources this occupation.

²⁵Running the regressions on a restricted sample of firms that only decide to outsource provide similar results in terms of magnitude and statistical and economic significance.

a large restructuring of the production process and organizational overhaul. Additionally, the number of occupations decreases by almost 15 log points where total employment only drops by about 10 log points. These numbers suggest that domestic outsourcing events primarily lead to occupations that employ a (relatively) smaller number of workers within the establishment are being purchased on the local labor market (rather than being produced in-house).

Additionally, figure 2.3 shows the effects of domestic outsourcing events on the skill ratio – defined as the number of high skill workers over the number of low skill workers – in outsourcing establishments. On average, the skill ratio increases by about 5 percent. As a result, outsourcing establishments typically become more intensive users of high skilled labor, and outsourcing events result in a clear change in the organizational set-up of the establishment. In the next section, I turn to investigating whether these organizational changes affect the wages of workers employed in these outsourcing establishments. Whereas the identifying assumptions do not seem to fully hold for the employment and occupation regressions, the skill ratio is remarkably stable before and after the outsourcing event – despite large changes in the number of workers and occupations highlighted in the previous paragraph.

2.6.2 Worker-Level Results

I examine the impact of outsourcing events on worker outcomes using an event study research design. Consider the following econometric model of outsourcing:

$$y_{ij(i)t} = \sum_{\Delta = -3}^{4} \delta_{\Delta} \mathbb{I}\{t - t_{j(i)}^* = \Delta\} + \gamma X_{ij(i)t} + \xi_i + \theta_t + \varepsilon_{ij(i)t}$$
(2.11)

Here, $y_{ij(i)t}$ is the log wages worker *i* earns working at establishment *j* in year *t*, while t_j^* is the year the outsourcing decision is made at establishment *j*, with employment for the occupation of interest dropping to zero in $t_j^* + 1$. θ_t represents a year fixed effect, while ξ_i
represents a worker fixed effect. $X_{ij(i)t}$ is a vector of time-varying controls.

The identifying assumption in these worker-level regression warrants a more detailed discussion. If the timing of the outsourcing event is random from the worker's point of view, any changes in wages are attributed to the outsourcing event. Worker fixed effects hold constant the worker's ability and productivity, so changes in wages do not reflect changes in the pool of high or low skill workers. Nevertheless, one may be worried that workers strategically move in (or are hired) just before the domestic outsourcing events occur. Therefore, I restrict the sample to workers who have been at the establishment at least three years before the outsourcing event. The sample here again includes all establishments with an employment size of at least 20 people the year before the outsourcing event takes place.²⁶ As before, I focus only on the first domestic outsourcing event an establishment engages in.

Intuitively, the coefficients δ_{Δ} represent the time path of log wages relative to the timing of the outsourcing decision and conditional on the set of controls. One way to test the identifying assumption is to verify that $\delta_{\Delta} = 0$ for $\Delta < 1$. The estimation of equation 2.11 can be undertaken using standard panel data techniques, provided one of the indicators $\mathbb{I}\{t-t_j^* = \Delta\}$ is normalized for some Δ , as the full set of indicators is perfectly collinear with either the establishment or worker fixed effect. As is standard in this literature, I normalize the indicator where $\Delta = 0$ to zero, as this is when the outsourcing decision is taken, so post-decision coefficients can be interpreted as treatment effects.

An augmented version of equation 2.11 can be used to test for heterogeneity in the wage setting process for the different skill groups. In particular, I test this hypothesis using the following specification, where $Education_{i(e)t}$ is an indicator variable that takes on value one when individual j has education level e, and 0 if not. I collapse the results to three education levels: middle or high school (with or without vocational degree), technical college and

²⁶Running the regressions on a restricted sample of firms that only decide to outsource provide similar results in terms of magnitude and statistical and economic significance.

 $college.^{27}$

$$y_{ij(i)t} = \sum_{\Delta = -3}^{4} \delta_{\Delta} \mathbb{I}\{t - t_{j(i)}^* = \Delta\} + \sum_{e=1}^{2} \alpha_e \times Education_{i(e)t} \times \mathbb{I}\{t > t_{j(i)}^*\} + \gamma X_{ij(i)t} + \xi_i + \theta_t + \varepsilon_{jt}$$

$$(2.12)$$

The skill interactions in this regression are identified off of changes in the wages of workers that have a certain skill level, and move from the non-outsourcing into the outsourcing period within this establishment, controlling for fixed worker unobservable characteristics. Therefore, these are not changes at the establishment across skill groups that are possibly driven by composition, but rather represent wage increases and wage cuts at the individual level. The relative pay increase or decrease for other skill groups is then captured by the α_e coefficients. Finally, the α_e are not identified for both education groups simultaneously, so the low skill workers are chosen as the omitted category. This means that the event study coefficients δ_{Δ} show the time path of wages for low skill workers, and the α_1 coefficient capture the level shift for high skill workers in the aftermath of an outsourcing event. I cluster standard errors at the establishment level.

Figure 2.4a graphically presents the effect of domestic outsourcing on the wages of workers that remain in outsourcing establishment and shows the δ_{Δ} coefficients with 95% clusterrobust confidence intervals for estimating equation 2.11. On average, there is little to no evidence of spillover effects of domestic outsourcing events on the average wages of workers that remain in the establishment. Nevertheless, these results mask substantial heterogeneity across skill groups. Figure 2.4b graphically represents the effects for different education groups, showing the δ_{Δ} coefficients with 95% cluster-robust confidence intervals, but now for estimating equation 2.11. Where low skill workers face wage losses of about one to two log point, high skill workers receive immediate wage increases of about five log points.

Both these effects are not only statistically significant, but also economically significant.

²⁷Similar regressions that distinguish between all six levels of education find relatively similar effects for middle school (with or without vocational) and high school (with or without vocational). Also technical college and college exhibit similar patterns motivating the decision to collapse the education variable to these levels.

Dustmann, Ludsteck and Schönberg (2009) provide a useful starting point to interpret the magnitude of these effects. Using IAB data that also draw from the IEB files, they find that wages at the 15th (85th) percentile of the wage distribution decreased (increased) by about six (ten) percentage points from 1993 to 2010. The immediate effects of domestic outsourcing on the wages of workers staying in establishments represent about a third to a half of this increase. Domestic outsourcing events therefore lead to the same workers being paid substantially different wages just before and after the outsourcing event.

These results, by and large, confirm the first prediction of the model – that in response to an outsourcing event and a change in skill composition, the changes in wages for high and low skill workers move in opposite directions. Finally, it is reasonable to combine medium and high skill workers into one group, as the effect on these two groups is similar and statistically indistinguishable.

2.6.3 Importance of Change in Structure

I augment equation 2.12 by pooling the medium and high skill workers into one group ("High Skill") and regress the change in wages on the change in the ratio of high to low skill workers. This is an explicit test of the first comparative static – that wage increases for high skill workers will be proportional to the change in the skill ratio. As this is essentially an equilibrium relationship, these results should not be interpreted as a causal relationship. However, there is no reason to find a correlation like this in the data if the underlying mechanism is not related to fairness considerations. Table 2.3 presents the results from this empirical appraoch. The first column shows the estimation results from running specification 2.12, whereas the second column presents the relationship between the change in skill workers. The third column presents the relationship between the change in skill intensity and the increase in wages for high skill workers only. The results show a (marginally) significant relationship between the change in skill intensity and both high and low skill wages. As wages for high

and low skill workers are expected to move in opposite directions, the different sign on the coefficients is in line with the theoretical model. Finally, when just focusing on the high skill workers, the results remain relatively similar. Overall, these results are in line with a model where fairness considerations across skill groups matter.

2.7 Robustness Checks

One concern, in line with a large literature on skill-biased or task-biased technological change (Bound and Johnson, 1992; Acemoglu and Autor, 2011), is that changes in investment drive these changes in wages. For instance, if new technologies are complements for high skill workers (or the tasks they perform) and substitutes for low skill workers (or the tasks they perform), changes in investments may change the productivity shifters A_1 and A_2 in the way that we observe in the data. In order to assess whether these changes may be driven by changes in investment, I run regression 2.10 with the log of total investment expenditures as an outcome. Figure 2.6 shows the result from this regression and plots the effects of domestic outsourcing events on this establishment outcome. Overall, there is no evidence of changes in investment levels, as levels are fairly stable across the event study window and not statistically significant. As a result, there is no evidence of a sudden change in investments.²⁸

A second concern is the parametric assumptions imposed in equation 2.12. Specifically, the level shifter according to education level before and after the domestic outsourcing event may mask changes that are not well described by a level shift. In order to allow for more flexibility, I estimate the dynamice time path by education group non-parametrically before and after the domestic outsourcing event (but maintain the group of high and medium skill workers). More specifically, I use the following regression equation.

$$y_{ij(i)t} = \sum_{\Delta = -3}^{4} \delta_{\Delta} \mathbb{I}\{t - t_{j(i)}^* = \Delta\} \times \sum_{e=1}^{2} \alpha_e \times Education_{i(e)t} + \gamma X_{ij(i)t} + \xi_i + \theta_t + \varepsilon_{jt} \quad (2.13)$$

²⁸Unfortunately, it is not possible to get a breakdown in investments into what is being invested in.

Figure 2.5 highlights that, with this flexible approach, the assumption of a level shift across the different skill groups is reasonable, as wages for low skill workers seem to decrease more or less immediately, while wages for high skill workers seem to increase more or less immediately. The standard errors increase compared to the more parametric version, but the overall effects of outsourcing on wages are clear. Furthermore, there are no pre-trends for either skill group, strenghtening the identification assumption.

Finally, additional (omitted) robustness checks confirm that the results are not driven by workers with imputed wages, or part-time workers.

2.8 Conclusion

This paper investigates the effects of domestic outsourcing events on workers that stay in the outsourcing establishment. Most research so far has focused on what happens to wages of those workers that get outsourced at the industry or establishment level. While these studies find substantial wage losses for workers that are being outsourced (Dube and Kaplan, 2010; Goldschmidt and Schmieder, 2015), this paper finds that outsourcing events also have substantial effects on the wages of workers that stay in the establishment. These findings indicate that employers set wages for workers that likely depend on the wages of their coworkers. This finding is underpinned by additional findings, that show the wage increase high skill workers receive in the aftermath of outsourcing events depends on the extent to which the establishment becomes more skill intensive.

These empirical facts can be interpreted through a model that incorporates fairness considerations into wage setting, allowing for wages of workers to depend on the wages of their colleages. In particular, I model fairness considerations as affecting effort, as proposed by Akerlof and Yellen (1988). The reference wage builds on empirical work (see, e.g. Rees (1993); Card et al. (2012)) that fairness considerations primarily affect workers that are paid less than their coworkers. I use skill groups to distinguish between high and low wage workers in the establishment and postulate that effort of low skill workers depends on the wage dispersion between low and high skill workers within the establishment.

The model predicts that wages for high skill workers will increase if more low than high skill jobs are outsourced. Additionally, the wages of low skill workers will move in the opposite direction: when the wages of high skill workers go up, those for low skill workers go down and vice versa. Finally, the wage increase that high skill workers obtain is correlated with the change in skill intensity at the establishment. If the ratio of high to low skill workers increases after the outsourcing event, the wage increase for high skill is expected to be higher.

There are several interesting areas for future research. First, a better understanding which occupations – both for high and low skill workers – are being outsourced is a feasible and interesting avenue for future research. Second, there are several interesting other aspects to fairness that might make for interesting future research. For instance, what is the effect of fairness norms on labor market flows, search behavior, and productivity in the labor market – especially in settings where flows across firms or effort on the job can be measured better. Finally, a better understanding of how fairness norms are shaped (e.g. what is the relevant reference group workers think about when deciding what is fair) would also be a fruitful area for future research.

	Outsourcing Category			
	Catering	Cleaning	Security	Logistics
Year Before Outsourcing				
Median log Daily Wage (\in)	4.314	4.275	4.316	4.256
	(0.329)	(0.332)	(0.335)	(0.358)
Middle/High School	0.158	0.137	0.160	0.127
Middle/High School + Vocational	0.675	0.675	0.670	0.683
Technical College / College	0.095	0.074	0.104	0.096
Missing	0.072	0.104	0.087	0.093
Total Employment	508.9	270.1	344.9	212.0
	(1,158.0)	(717.0)	(532.4)	(573.3)
CBA	0.793	0.665	0.750	0.675
Missing	0.035	0.023	0.034	0.026
Part-Time	0.192	0.177	0.206	0.172
log per capita Profit	6.032	6.875	6.470	6.592
	(8.866)	(8.031)	(8.465)	(8.231)
Missing	0.388	0.234	0.378	0.277
Observations	$1,\!537$	3,407	2,117	2,322
Not Outsourcing				
Median log Wage	$4\ 207$	4 193	4 193	4 200
median log wage	(0.429)	(0.443)	(0.439)	(0.441)
Middle/High School	0 129	0 130	0 131	0 132
Middle/High School + Vocational	0.665	0.663	0.662	0.661
Technical College / College	0.077	0.094	0.092	0.094
Missing	0.113	0.112	0.116	0.113
Total Employment	179.8	182.7	184.0	196.3
I U	(827.6)	(857.2)	(877.6)	(866.5)
CBA	0.566	0.560	0.560	0.570
Missing	0.019	0.019	0.019	0.020
Part-Time	0.210	0.215	0.212	0.217
log per capita Profit	6.217	6.118	6.161	6.191
	(8.354)	(8.408)	(8.372)	(8.363)
Missing	0.211	0.214	0.204	0.216
Observations	183,221	171,929	181,924	181,924

Table 2.1: Summary Statistics for Establishments

Notes: Mean of each variable with standard deviation in parentheses. Statistics are calculated in year before outsourcing for outsourcing establishments and across all observations for establishments that do not outsourced in the sample period. All columns exclude East Germany prior to 1996.

	Outsourcing Category			
	Catering	Cleaning	Security	Logistics
At Outsourcing				
$\overline{\text{Mean log Daily Wage }(\mathbf{\in})}$	3.844	3.830	3.786	3.888
0 0 0 0	(0.480)	(0.472)	(0.500)	(0.535)
Age	41.750	41.729	41.478	42.158
0	(10.019)	(10.100)	(10.156)	(10.077)
Female	0.362	0.363	0.411	0.449
Nongerman	0.068	0.067	0.079	0.048
Part-Time	0.135	0.117	0.138	0.172
Education				
Middle/High School	0.165	0.175	0.181	0.133
Middle/High School + Vocational	0.723	0.712	0.705	0.715
Technical College / College	0.112	0.113	0.114	0.152
Missing	0.029	0.036	0.056	0.050
	0.020	0.000	0.000	0.000
Job Tenure	10.525	10.513	9.527	9.151
000 101110	(7.395)	(7.547)	(7.039)	(7.331)
Establishment Tenure	11.379	11.395	10.241	9.975
	(7.493)	(7.618)	(7.123)	(7.588)
	()	()	()	(*****)
Observations	253,448	311,844	$259,\!916$	135,484
Never Outsourced				
Mean log Daily Wage (€)	3 897	3 915	3 900	3897
Mean log Daily Wage (C)	(0.569)	(0.560)	(0.569)	(0.573)
Age	41 658	(0.500) 41 578	(0.505)	(0.515)
nge	(10.113)	(10, 105)	(10, 106)	(10.141)
Female	0 369	0 361	(10.100) 0.372	0.387
Nongerman	0.071	0.069	0.071	0.071
Part Timo	0.171	0.009 0.139	0.142	0.071
	0.141	0.152	0.142	0.140
Education				
Middle/High School	0.162	0.154	0.164	0.159
Middle/High School + Vocational	0.706	0.714	0.705	0.706
Technical College / College	0.132	0.132	0.131	0.135
Missing	0.045	0.041	0.044	0.043
Job Tenure	9.819	9.852	9.929	9.877
	(7.432)	(7.441)	(7.478)	(7.454)
Establishment Tenure	10.585	10.622	10.712	10.674
	(7.556)	(7.565)	(7.600)	(7.579)
Observations	28,842,142	27,943,626	29,200,157	28,719,570

Table 2.2: Summary Statistics for Workers Remaining in the Establishment

Notes: Mean of each variable with standard deviation in parentheses. The top panel reports statistics that are calculated for each type of outsourcing separately, and covers workers that work in an establishment that outsources catering, cleaning, security or logistics (CCSL) services, but are not employed in the outsourced category. These statistics are reported the year before outsourcing. The second panel reports statistics that are calculated for each type of outsourcing separately, and covers workers that are not employed in the occupation of interest or in the related business service industry. The sample covers workers that are between 20 and 60 years old, and whose log earnings are between 2 and 6.5 for both the top and the bottom panel. All columns exclude East Germany prior to 1996.

	Dependent Variable: $\ln(w_{ij(i)t})$			
	(1)	(2)	(3)	
$High \; Skill imes Outsourcing$	0.0641^{***} (.0084)			
$High \; Skill imes Outsourcing \ imes \Delta Skill Ratio$		0.0167^{*} (0.0100)	0.0189^{*} (0.0106)	
$\begin{array}{l} Low \ Skill \times Outsourcing \\ \times \Delta Skill Ratio \end{array}$		-0.0058^{*} (0.0032)		
$\mathbb{I}\{t-t^*<-5\}$	-0.0044	0.0084	0.0085	
$\mathbb{I}\{t-t^*=-5\}$	-0.0033 (0.0105)	(0.0130) 0.0065 (0.0112)	(0.0103) 0.0065 (0.0112)	
$\mathbb{I}\{t-t^*=-4\}$	-0.0050 (0.0077)	(0.0037) (0.0081)	(0.0037) (0.0081)	
$\mathbb{I}\{t-t^*=-3\}$	-0.0129 (0.0089)	-0.0051 (0.0101)	-0.0050 (0.0101)	
$\mathbb{I}\{t-t^*=-2\}$	-0.0085 (0.0089)	-0.0034 (0.0094)	-0.0033 (0.0094)	
$\mathbb{I}\{t-t^*=-1\}$	-0.0113 (0.0101)	-0.0094 (0.0107)	-0.0094 (0.0107)	
$\mathbb{I}\{t-t^*=1\}$	-0.0125 (0.0068)	-0.0054 (0.0088)	-0.0107 (0.0074)	
$\mathbb{I}\{t - t^* = 2\}$	-0.0198** (0.0083)	-0.0142 (0.0097)	-0.0196^{**} (0.0084)	
$\mathbb{I}\{t - t^* = 3\}$	-0.0247^{**} (0.0099)	-0.0208^{*} (0.0114)	-0.0262^{**} (0.0103)	
$\mathbb{I}\left\{t - t^* = 4\right\}$	(0.0091)	(0.0103)	(0.0203 + (0.0092))	
$\mathbb{I}\left\{t - t = 0\right\}$ $\mathbb{I}\left\{t - t^* > 6\right\}$	(0.0113)	(0.0125) (0.0125)	(0.0210) (0.0115) 0.0288**	
$\mathbb{I}\{\iota - \iota > 0\}$	(0.0512) (0.0147)	(0.0165)	(0.0158)	

Table 2.3: Event Study coefficients Interacted with Change in Share Low over High Skill

Notes: These coefficients provide event study coefficients for the different models where the outcome of interest is the log of worker wages. The event study regression controls for sales, an indicator for whether sales is missing, a second-order polynomial in (establishmet) tenure, and worker and year fixed effects.

Figure 2.1: Incidence of Outsourcing



(a) Fraction of Establishments making Outsourcing Decision



(b) Fraction of Establishments Outsourcing

Notes: The top panel shows the fraction of establishment that decide to engage in outsourcing, broken up by relevant occupational category. The bottom panel shows the fraction of establishments that are currently engaging in outsourcing. Source: author's calculations.





(b) Effect on log(Occupations) at outsourcing establishments

Notes: These graphs plot event study coefficients where the outcome of interest is the log of the number of employees (upper panel) and occupations (lower panel) in the establishment. The event study regression controls for region, establishment and year fixed effects.





Notes: This graph plots the event study coefficients where the outcome of interest is the log of the skill ratio (number of high skill workers over number of low skill workers) in the establishment. The event study regression controls for region, establishment and year fixed effects.



Figure 2.4: Effect of outsourcing on wages of workers that stay.

(a) Effect on wages at the establishments



Effect of Outsourcing on Wages of Remaining Workers

(b) Effect on wages at the establishments by skill group

Notes: These graphs plot event study coefficients where the outcome of interest is the log of worker wages, with the upper panel using the regression specification 2.11 and the lower panel uses the regression specification 2.12. The event study regression controls for age, gender, education, and worker, region, and year fixed effects.





Notes: These graphs plot event study coefficients where the outcome of interest is the log of worker wages using the non-parametric regression equation 2.13. The event study regression controls for age, gender, education, and worker, region, and year fixed effects.





Notes: This graph plots the event study coefficients where the outcome of interest is the log of investments at the establishment level. The event study regression controls for region, establishment and year fixed effects, and sets missing values for investment equal to zero, while controlling for a dummy variable that takes on value 1 if the investment outcome is missing in that year and zero when not missing.

CHAPTER III

Measuring Instructor Effectiveness in Higher Education

3.1 Introduction

Professors and instructors are a chief input into the higher education production process, yet we know very little about their role in promoting student success. There is growing evidence that teacher quality is an important determinant of student achievement in K12, with some school districts identifying and rewarding teachers with high value-added. Yet relatively little is known about the importance of or correlates of instructor effectiveness in postsecondary education. Such information may be particularly important at the postsecondary level, in which administrators often have substantial discretion to reallocate teaching assignments not only within a specific class of instructors (e.g., tenured faculty), but across instructor types (e.g., adjuncts vs. tenured faculty).

There are a number of challenges to measuring effectiveness in the context of higher education. Unlike in K12, there are rarely standardized test scores to use as an outcome. Furthermore, to the extent that college courses and majors intend to teach a very wide variety of knowledge and skills, it is harder to imagine an appropriate outcome as a conceptual matter. The issue of non-random student sorting across instructors is arguably more serious in the context of higher education because students have a great deal of flexibility in the choice classes and the timing of these classes. Finally, one might have serious concerns about the attribution of a particular skill to a specific instructor given the degree to which knowledge spills over across courses in college (e.g., the importance of calculus in intermediate microeconomics or introductory physics, the value of English composition in a history classes where the grade is based almost entirely on a term paper, etc.) For many reasons, the challenge of evaluating college instructors is more akin to the problem of rating physicians (Staiger, 2018).

This paper tackles these challenges to answer two main questions. First, is there variation in instructor effectiveness in higher education? We examine this in a highly standardized setting where one would expect minimal variation in what instructors actually do. Second, how does effectiveness correlate with teaching experience and salary? This informs whether teaching assignment and personnel policies could be used to increase effectiveness and institutional productivity. We examine these questions using detailed administrative data from the University of Phoenix (UPX), the largest university in the world, which offers both online and in-person courses in a wide array of fields and degree programs. We focus on instructors in the college algebra course that is required for all students in BA degree programs and that often is a roadblock to student attainment.

This context provides several advantages. Our sample includes more than two thousand instructors over more than a decade in campuses all across the United States. This allows us to generate extremely precise estimates, and to generalize to a much larger population than has been the case in previous studies. Most students in these courses take a common, standardized assessment that provides an objective outcome by which to measure instructor effectiveness. And, as we describe below, student enrollment and course assignment is such that we believe the issue of sorting is either non-existent (in the case of the online course) or extremely small (in the case of face-to-face or FTF courses).

These institutional advantages possibly come at some cost, however, to generalizability. The UPX does not match the "traditional" model of higher education, in which tenured professors at selective institutions teach courses they develop themselves and have noninstructional responsibilities (such as research). UPX is a for-profit institution with contingent (i.e., non-tenured, mostly part-time) faculty that is focused solely on instruction, and the courses are highly standardized, with centrally prepared curriculum materials and assessments (both online and face-to-face sections). While our findings may not generalize to all sectors of higher education, we believe they are relevant for the growing for-profit sector and possibly less-selective 4-year and community colleges that also have many contingent instructors. A limitation of prior research is that it focuses on selective non-profit or public institutions, which are quite different from the non-selective or for-profit sectors. It is in these settings with many contingent faculty and institutions whose primary purpose is instruction (rather than, say, research) where productivity-driven personnel policies could theoretically be adapted.

We find substantial variation in student performance across instructors. A 1 SD increase in instructor quality is associated with 0.30 SD increase in grades in the current course and a 0.20 SD increase in grades in the subsequent course in the math sequence. Unlike some prior work (Carrell and West, 2010), we find a positive correlation between instructor effectiveness measured by current and subsequent course performance overall and for face-to-face courses. The variation in instructor effectiveness is larger for in-person courses, but still substantial for online courses. These broad patterns and magnitudes are robust to extensive controls to address any possible non-random student sorting, using test scores that are less likely to be under the control of instructors, and other specification checks. These magnitudes are substantially larger than found in the K12 literature and in the Carrell and West (2010) study of the Air Force Academy, but comparable to the recent estimates from DeVry University (Bettinger et al., 2015). Furthermore, instructor effects on future course performance has little correlation with student end-of-course evaluations, the primary metric through which instructor effectiveness is currently judged.

Salary is primarily determined by tenure (time since hire), but is mostly uncorrelated with measured effectiveness or course-specific teaching experience, both in the cross-section and for individual teachers over time. However, effectiveness grows modestly with course-specific teaching experience but is otherwise unrelated to time since hire. Given the disconnect between pay and effectiveness, the performance differences we uncover translate directly to differences in productivity from the University's perspective. These large productivity differences imply that personnel decisions and policies that attract, develop, allocate, motivate, and retain faculty are a potentially important tool for improving student success and productivity at the University of Phoenix. Our study institution – like almost all others – measures faculty effectiveness through student end-of-course evaluations, despite only minimal correlation between evaluation scores and our measures of effectiveness. Thus current practices are not doing a great job of identifying or supporting effective instructors. Though policy-makers and practitioners have recently paid a lot of attention to the importance of teachers in elementary and secondary school, there is surprisingly little attention paid to the importance of instructors or instructor-related policies and practices at the postsecondary level.

The remainder of this paper proceeds as follows. We discuss prior evidence on college instructor effectiveness and our institutional context in Section 3.2. Section 3.3 introduces our administrative data sources and our analysis sample. Section 3.4 presents our empirical approach and examines the validity of our proposed method. Our main results quantifying instructor effectiveness are presented in Section 3.5. Section 3.6 examines how instructor effectiveness correlates with experience. Section 3.7 concludes by discussing the implications of our work for institutional performance and productivity.

3.2 Prior Evidence and Institutional Context

3.2.1 Prior Evidence

There is substantial evidence that teacher quality is an important determinant of student achievement in elementary and secondary education (Rockoff, 2004; Rivkin, Hanushek and Kain, 2005; Rothstein, 2010; Chetty, Friedman and Rockoff, 2014). Many states and school districts now incorporate measures of teacher effectiveness into personnel policies in order to select and retain better teachers (Jackson, Rockoff and Staiger, 2014). Yet little is known about instructor effectiveness in postsecondary education, in part due to difficulties with outcome measurement and self-selection. Standardized assessments are rare and grading subjectivity across professors makes outcome measurement difficult. In addition, students often choose professors and courses, so it is difficult to separate instructors' contribution to student outcomes from student sorting. As a consequence of these two challenges, only a handful of existing studies examine differences in professor effectiveness.

Several prior studies have found that the variance of college instructor effectiveness is small compared to what has been estimated for elementary teachers. Focusing on large, introductory courses at a Canadian research university, Hoffmann and Oreopoulos (2009*b*) find the standard deviation of professor effectiveness in terms of course grades is no larger than 0.08. Carrell and West (2010) examine students at the U.S. Air Force Academy, where grading is standardized and students have no choice over coursework or instructors. They find sizeable differences in student achievement across professors teaching the same courses, roughly 0.05 SD, which is about half as large as in the K12 sector.

Interestingly, instructors that were better at improving contemporary performance received higher teacher evaluations but were less successful at promoting "deep-learning," as indicated by student performance in subsequent courses. Braga, Paccagnella and Pellizzari (2014) estimate teacher effects on both student academic achievement and labor market outcomes at Bocconi University. They also find significant variation in teacher effectiveness, roughly 0.05 SD both for academic and labor market outcomes. They find only a modest correlation of instructor effectiveness in academic and labor market outcomes.

Two recent studies have concluded that instructors play a larger role in student success. (Bettinger et al., 2015) examine instructor effectiveness using data from DeVry University, a large for-profit institution in which the average student takes two-thirds of her courses online. They find a variance of instructor effectiveness that is substantially larger than prior studies in higher education. Specifically, they find that being taught by an instructor that is 1 SD more effective improves student course grades by about 0.18 to 0.24 SD. The estimated variation is 15% lower when courses are online, even among instructors that teach in both formats. Among instructors of economics, statistics, and computer science at an elite French public university, Brodaty and Gurgand (2016) find that a 1 SD increase in teacher quality is associated with a 0.14 or 0.25 SD increase in student test scores, depending on the subject.

A few studies have also examined whether specific professor characteristics correlate with student success, though the results are quite mixed.¹ Using institutional-level data from a sample of U.S. universities, Ehrenberg and Zhang (2005) find a negative relationship between the use of adjuncts and student persistence, though they acknowledge that this could be due to non-random sorting of students across schools. Hoffmann and Oreopoulos (2009b)find no relationship between faculty rank (including adjuncts and tenure-track faculty) and subsequent course enrollment. Two other studies find positive effects of adjuncts. Studying course-taking among students in public four-year institutions in Ohio, Bettinger and Long (2010) find adjuncts are more likely to induce students to take further courses in the same subject. Using a sample of large, introductory courses taken by first-term students at Northwestern University, Figlio, Schapiro and Soter (2015) find that adjuncts are positively associated with subsequent course-taking in the subject as well as performance in these subsequent courses. In their study of the U.S. Air Force Academy, Carrell and West (2010) find that academic rank, teaching experience, and terminal degree are positively correlated with follow-on course performance, though negatively related to contemporary student performance.

There is also evidence that gender and racial match between students and instructors influences students' interest and performance (Bettinger and Long, 2005; Hoffmann and Oreopoulos, 2009a; Fairlie, Hoffmann and Oreopoulos, 2014). Finally, Hoffmann and Oreopoulos (2009b) find that students' subjective evaluations of professors are a much better predictor

¹Much of this evidence is reviewed in Ehrenberg (2012).

of student academic performance than objective professor characteristics such as rank. This echoes the finding of Jacob and Lefgren (2008) that elementary school principals can identify effective teachers, but that observed teacher characteristics tend to explain little of teacher effectiveness.

A limitation of this prior research is that it focuses largely on selective non-profit or public institutions, which are quite different from the non-selective or for-profit sectors that constitute a large and growing share of the postsecondary sector. It is in these settings with many contingent faculty and institutions whose primary purpose is instruction (rather than, say, research) where productivity-driven personnel policies could theoretically be adapted. Students at these types of institutions also have lower rates of degree completion, so facilitating these students' success is thus particularly important policy goal. The one prior study examining a setting similar to ours (Bettinger et al's 2015 study of Devry University) focuses on differences in student performance between online and in-person formats, with very little attention paid to instructors. The simultaneous consideration of multiple outcomes and how the exploration of how effectiveness varies with salary and teaching experience is also novel in the postsecondary literature.

3.2.2 Context: College Algebra at The University of Phoenix

We study teacher effectiveness in the context of the University of Phoenix, a large forprofit university that offers both online and face-to-face (FTF) courses. UPX offers a range of programs, including AA, BA and graduate degrees, while also offering à-la carte courses. We focus on core mathematics courses, MTH208 and MTH209 (College Mathematics I and II), which are a requirement for most BA programs. Below we describe these courses, the process through which instructors are hired and evaluated, and the mechanism through which students are allocated to instructors.² As highlighted above, the context of both the institution and the coursework does not translate to all sectors of higher education: the

 $^{^{2}}$ This description draws on numerous conversations between the research team and individuals at the University of Phoenix.

faculty body is largely contingent and employed part-time and admissions is non-selective.

3.2.2.1 MTH208 and MTH209

BA-level courses at UPX are typically five weeks in duration and students take one course at a time (sequentially), in contrast to the typical structure at most universities. The MTH208 curriculum focuses on setting up algebraic equations and solving single and twovariable linear equations and inequalities. Additionally, the coursework focuses on relating equations to real-world applications, generating graphs, and the use of exponents. MTH209 is considered a logical follow-up course, focusing on more complicated, non-linear equations and functions. Students in our sample take MTH208 after completing about eight other courses, so enrollment in the math course sequence does signify a higher level of commitment to the degree program than students in the most entry-level courses. However, many students struggle in these introductory math courses and they are regarded by UPX staff as an important obstacle to obtaining a BA for many students.

Students can take these courses online or in-person. In the face-to-face sections, students attend four hours of standard in-class lecture per week, typically held on a single day in the evening. In addition, students are required to work with peers roughly four hours per week on what is known as "learning team" modules. Students are then expected to spend 16 additional hours per week outside of class reading material, working on assignments and studying for exams.³

Online courses are asynchronous, which means that a set of course materials is provided through the online learning platform, and instructors provide guidance and feedback through online discussion forums and redirect students to relevant materials when necessary. There is no synchronous or face-to- face interaction with faculty in the traditional sense, but students are required to actively participate in online discussions by substantively posting six to eight times per week over three to four days. One instructor defined a substantive post as having

³There have been recent reductions in the use of learning team interactions in the past two years, but these changes occurred after our analysis sample.

substantial math content:

Substantial math content means you are discussing math concepts and problems. A substantive math post will have at least one math problem in it. Simply talking "around" the topic (such as, "I have trouble with the negative signs" or "I need to remember to switch the signs when I divide by a negative coefficient") will not be considered substantive. (Morris, 2016).

Online participation is the equivalent of the four hours of classes for the FTF sections.⁴

There are differences between the two course modes in terms of curriculum and grading flexibility. Both courses have standardized course curricula, assignments, and tests that are made available to the instructors. Grading for these components is performed automatically through the course software. However, FTF instructors sometimes provide students with their own learning tools, administer extra exams and homework, or add other components that are not part of the standard curriculum. In contrast, online instructors mainly take the course materials and software as given, and interaction with students for these teachers is mainly limited to the online discussion forum. In both online and FTF courses, teachers are able to choose the weights they assign to specific course components for the final grade. As discussed below, for this reason we also use student performance on the final exam as an outcome measure.

3.2.2.2 Hiring and Allocation of Instructors

The hiring and onboarding process of teachers is managed and controlled by a central hiring committee that is hosted at the Phoenix, AZ campus, though much input comes from local staff at ground campuses. First, this committee checks whether a new candidate has an appropriate degree.⁵ Second, qualified candidates then go through a five-week standardized

⁴The posting requirements actually changed over time - for the majority of the time of the study, the requirement was four days a week, two substantive posts per day (i.e., eight posts). In the past several years, it went to six times per week, on at last three days (effectively, allowing for two single post days).

⁵For MTH208 sections, for instance, a minimum requirement might be having a master's degree in mathematics, or a master's degree in biology, engineering or similar coursework, along with a minimum number of credits in advanced mathematics courses and teaching experience in mathematics.

training course they need to pass. This includes a mock lecture for FTF instructors and a mock online session for online instructors. Finally, an evaluator sits in on the first class or follows the online course to ensure the instructor performs according to university standards. Salaries are relatively fixed, but do vary somewhat with respect to degree and tenure.⁶ We should note that the actual hiring process for instructors may deviate from this description for certain campuses or in time periods when positions are particularly difficult to fill.

The allocation of instructors to classes is essentially random for online classes. About 60 MTH208 sections are started weekly and the roster is only made available to students two or three days before the course starts, at which point students are typically enrolled. The only way to sidestep these teacher assignments is by dropping the course altogether and enrolling in a subsequent week. This differs from most settings in other higher education institutions, where students have more discretion over what section to attend. For FTF sections, the assignment works differently, since most campuses are too small to have different sections concurrently and students may need to wait for a few months if they decide to take the next MTH208 section at that campus. While this limits the ability of students to shop around for a better teacher, the assignment of students to these sections is likely to be less random than for online sections. For this reason, we rely on value-added models that control for a host of student-specific characteristics that may correlate with both instructor and student course performance.

3.2.2.3 Evaluation and Retention of Instructors

UPX has in place three main evaluation tools to keep track of the performance of instructors. First, instructors need to take a yearly refresher course on teaching methods, and an evaluator will typically sit in or follow an online section every year to ensure the quality of the instructor still meets the university's requirements. Second, there is an in-

⁶For instance, all else equal, instructors with a Ph.D. can expect a higher salary than instructors with a master's degree. Additionally, tenure in this context refers to the date of first hire at the University of Phoenix. Salary differences are larger among new instructors, and tend to diminish at higher levels of experience.

house data analytics team that tracks key performance parameters. These include average response time to questions asked through the online platform, or indicators that students in sections are systematically getting too high (or too low) overall grades. For instance, if instructors consistently give every student in a section high grades, this will raise a flag, and the validity of these grades will be verified. Finally, additional evaluations can be triggered if students file complaints about instructor performance. If these evaluation channels show the instructor has not met the standards of the university, the instructor receives a warning. Instructors that have received a warning are followed up more closely in subsequent courses. If the instructor performance does not improve, the university will not hire the person back for subsequent courses.

3.3 Data

We investigate variation in instructor effectiveness using data drawn from administrative UPX records. This section describes these records, the sample selection, and descriptive statistics. While the data we analyze has very rich information about the experiences of students and instructors while at the University of Phoenix, information on outside activities is limited.

3.3.1 Data Sources

We analyze university administrative records covering all students and teachers who have taken or taught MTH208 at least once between July 2000 and July 2014. The raw data contains information on 2,343 instructors that taught 34,725 sections of MTH208 with a total of 396,038 student-section observations. For all of these instructors and students, we obtain the full teaching and course-taking history back to 2000.⁷ Our analysis spans 84 campuses (plus the online campus). There is typically one campus per city, but some larger

⁷The administrative records are not available before 2000 because of information infrastructure differences, leading to incomplete teaching and course-taking spells for professors and students respectively.

metropolitan areas have multiple physical locations (branches) at which courses are offered.⁸

3.3.1.1 Instructors

We draw on three information sources for instructor level characteristics. A first dataset provides the full teaching history of instructors that have ever taught MTH208, covering 190,066 class sections. Information includes the campus and location of instruction, subject, the number of credits, and start date and end date of the section.

For each instructor x section observation, we calculate the instructor's teaching load for the current year, as well as the number of sections he or she had taught in the past separately for MTH208 and other courses. This allows us to construct a variety of different experience measures, which we use in the analysis below. As the teaching history is censored before the year 2000, we only calculate the cumulative experience profile for instructors hired in the year 2000 or later.

The second dataset contains self-reported information on ethnicity and gender of the instructor, along with complete information on the date of first hire, the type of employment (full-time or part-time) and the zip code of residence.⁹ A unique instructor identifier allows us to merge this information onto the MTH208 sections.¹⁰ A third dataset contains the salary information for the instructor of each section, which can be merged onto the MTH208 sections using the unique section identifier.

3.3.1.2 Students

Student-level information combines four data sources: demographics, transcript, assessment, and student end-of-course evaluations. The demographics dataset provides information on the zip code of residence, gender, age of the student, program the student is enrolled

⁸There are more than 200 physical locations (branches) corresponding to these 84 campuses.

⁹This instructor dataset also contains information on birth year and military affiliation, though these variables have high non-response rates and are therefore not used for the analysis.

¹⁰The instructor identifier is, in principle, unique. It is possible, however, that an instructor shows up under two different identifiers if the instructor leaves the university and then returns after a long time. While this is a possibility, UPX administrators considered this unlikely to be a pervasive issue in their records.

in, program start, and program end date.¹¹ A unique student identifier number allows us to merge this information onto the course-taking history of the student.

Transcript data contains complete course-taking history including the start and end date of the section, campus of instruction, grade, and number of credits. Every section has a unique section identifier that allows for matching students to instructors. Additionally, student-level information includes course completion, course grade, earned credits, along with a unique student identifier that allows for merging on the student demographics.

For sections from July 2010 to March 2014, or roughly 30 percent of the full sample, we have detailed information on student performance separately by course assignment or assessment, which includes everything from individual homework assignments to group exercises to exams. We use this data to obtain a final exam score for each student when available. Because the data does not have a single, clear code for final exam component across all sections, and instructors have discretion to add additional final exam components, we use a decision rule to identify the "best" exam score for each student based on the text description of the assessment object. Approximately 11% of observations have a single score clearly tied to the common computer-administered final assessment, 77% have a single assessment for a final exam (but we cannot be certain it is from the standardized online system), and the remainder have final exam assessments that are a little more ambiguous. Discussions with UPX personnel indicated that the vast majority of instructors use the online standardized assessment tool with no customization, but unfortunately this is not recorded in the administrative data. Nonetheless, results excluding this latter group are quite similar to analysis with the full sample. Our approach is outlined in Appendix B.

While the analysis focuses on course grades and final test scores, it also considers future performance measures, such as grades and cumulative grade point average earned in the 180 or 365 days following the MTH208 section of interest. Given the linear, one-by-one nature

¹¹Similar to the instructor dataset, demographic data are self-reported. While information on gender and age is missing for less than 1% of the sample, information on ethnicity, veteran status, and transfer credits exhibit much larger non-response rates and are therefore not used for the analysis.

of the coursework, these measures capture the effect instructors have on moving students towards obtaining a final degree.

Finally, for sections taught between March 2010 and July 2014, we obtained student endof-course evaluations. Students are asked whether they would recommend the instructor on a ten point scale. Recommendation scores of 8 or above are considered "good" and are the primary form that the evaluations are used by the University of Phoenix administration. We follow this practice and use a binary indicator for whether the recommendation score is at least 8 as our primary evaluation measure. End of course evaluations are optional for students so have a relatively low response rate. Only 37% of students provide a course evaluation score for MTH208, which is less than half of the students that have a final exam test score for MTH208. While non-random missing evaluations could create bias in our estimates of teacher effectiveness, this bias is also present in the evaluations as used by the institution. Our goal is to see how evaluations *as currently used in practice* correlate with more objective measures of teacher effectiveness.

3.3.1.3 Census Data

In addition to the UPX administrative school records, we use several census data resources to get additional variables capturing the characteristics of students' residential neighborhoods. In particular, we obtain the unemployment rate, median family income, the percentage of family below the poverty line, and the percentage with a bachelor degree or higher of students' home zip code, from the 2004-2007 five-year ACS files.

3.3.2 Sample Selection

Starting from the raw data, we apply several restrictions to obtain the primary analysis sample. We restrict our analysis to the 33,200 MTH208 sections that started between January 2001 and July 2014. We then drop all students with missing data for final grade or unusual grades (0.1% of students) as well as students who do not show up in the student

demographics file (0.3% of remaining students).¹² We then drop all cancelled sections (0.02%) of the sections), sections with fewer than 5 enrolled students who had non-missing final grade and did not withdraw from the course (11.4%) of the remaining sections) and sections for which the instructor is paid less than \$300 (5.2\%) of remaining sections). We believe the final two restrictions exclude sections that were not actual courses, but rather independent studies of some sort. We also drop sections for which the instructor does not show up in the teacher demographics file, which is 3.5% of the remaining sections.

To calculate instructor experience, we use an instructor-section panel that drops observations where there is no salary information (about 3% of sections), the section was cancelled (0.04%), and with less than 5 students (21.7% of the remaining sections) or for which the instructor is paid less than \$300 (8.6% of the remaining sections). As above, these final two restrictions are meant to exclude independent study type courses or other unusual courses that may enter differently into the teacher human capital function.¹³ We then calculate several experience measures based on this sample. We calculate measures of experience such as number of courses taught in the previous calendar year and total cumulative experience in MTH208 specifically and in other categories of classes. The complete cumulative experience measures are only fully available for instructors that were hired after 2000, since the teaching history is not available in prior years.

Finally, we drop data from nine campuses because none of the instructors we observe in these campuses ever taught in another physical campus or online. As discuss below, in order to separately identify campus and instructor fixed effects, each campus must have at least one instructor that has taught in a different location. Fortunately, these nine campuses represent only 2 percent of the remaining sections and 4 percent of remaining instructors.

¹²We keep students with grades A-F, I/A-I/F (incomplete A-F) or W (withdraw). Roughly 0.1% of scores are missing or not A-F or I/A-I/F (incomplete), and we drop these. These grades include AU (audit), I (incomplete), IP, IX, OC, ON, P, QC and missing values.

¹³There are three instructors that are first employed part-time and then employed full-time. As the parttime spells are longer than the full-time spells, we use the part-time demographics only. This restriction only impacts the employment type and date of first hire, as the other demographics are the same for the two employment spells for all three instructors.

The final analysis sample consists of 339,844 students in 26,384 sections, taught by 2,243 unique instructors. The sub-sample for which final exam data is available includes 94,745 students in 7,232 MTH208 sections taught by 1,198 unique instructors. We calculate various student characteristics from the transcript data, including cumulative grade point average and cumulative credits earned prior to enrolling in MTH208, as well as future performance measures. In the rare case of missing single student demographic variables, we set missing to zero and include an indicator variable for missing.

3.3.3 Descriptive Statistics

We report key descriptive statistics for the final analysis sample, spanning January 2001 to July 2014, in Table 3.1 and Table 3.2. We report these statistics for all sections, and for FTF and online sections separately. Table 3.1 reports section and instructor characteristics for the 26,384 MTH208 sections, while Table 3.2 reports student background characteristics and student performance measures. About half of all sections are taught online, and instructors are paid about \$950 for teaching a course, regardless of the instruction mode.¹⁴ Instructors are majority white and male and have been at the university just under five years.¹⁵ They typically have taught more than 40 total course sections since joining the faculty, of which 15 were MTH208 and 10 were MTH209. Instructors teaching online sections tend to specialize more in teaching MTH208 compared to their counterparts teaching FTF sections. Class size is about 13 students and is slightly larger for FTF than online sections. Tables C.1 and C.2 in the appendix report descriptive statistics for the sample for which test scores are available (July 2010 – March 2014). The test score sample is quite similar to the full sample, though the instructors are typically more experienced.

Table 3.1 provides an overview of student characteristics and performance. The students enrolled in these sections tend to be female, around 35 years old, and typically have taken 23

¹⁴The earnings measures are deflated using the national CPI. For each year, the CPI in April was used, with April 2001 as the base.

¹⁵Though omitted from the table, nearly 100% of instructors are part-time.

credits with a GPA of 3.35 prior to beginning MTH208. Students in online sections tend to have earned somewhat fewer credits than their counterparts in FTF sections, and are more likely to have taken MTH208 before. Most students, both in FTF and online sections, are enrolled in a business or general studies program.

Students across both modes of instruction are equally likely to earn a grade of A (about 32%) or B (about 27%) and have similar final exam scores (70%) when available. Consistent with prior work, online students are more likely to withdraw from and less likely to pass MTH208 than students in FTF sections. In terms of student performance after taking MTH208, we find that FTF students are more likely to go on and take MTH209.¹⁶ Students earn about 10.5 credits in the six months following the MTH208 section, with a two-credit gap between FTF and online students. Participation in end-of-course evaluations is similar across formats, though FTF students generally report a greater level of instructor satisfaction.

3.4 Empirical Approach

Our main aim is to characterize the variation in student performance across instructors teaching the same courses. Consider the standard "value-added" model of student achievement given in equation (3.1):

$$Y_{ijkt} = \beta_1 X_i + \beta_2 Z_{jkt} + \phi_t + \delta_c + \theta_k + e_{ijkt}$$

$$(3.1)$$

where Y_{ijkt} is the outcome of student *i* in section *j* taught by instructor *k* during term *t*. The set of parameters θ_k quantify the contribution of instructor *k* to the performance of their students, above and beyond what could be predicted by observed characteristics of the student (X_i) , course section (Z_{jkt}) , campus (δ_k) or time period (ϕ_t) . The variance of θ_k across instructors measures the dispersion of instructor quality and is our primary parameter of interest. We are particularly interested in how the distribution of θ_k varies across outcomes

 $^{^{16}\}mathrm{Conditional}$ on taking MTH209, both online and FTF students typically take this class about a week after the MTH208 section.

and formats, and how effectiveness covaries across outcomes.

Estimation of the standard value-added model in (3.1) must confront three key issues. First, non-random assignment of students to instructors or instructors to course sections could bias value-added models. In the presence of non-random sorting, differences in performance across sections could be driven by differences in student characteristics rather than differences in instructor effectiveness per se. Second, outcomes should reflect student learning rather than grading leniency or "teaching to the test" of instructors. Furthermore, missing outcomes may bias instructor effects if follow-up information availability is not random. Third, our ability to make performance comparisons between instructors across campuses while also controlling for cross-campus differences in unobserved factors relies on the presence of instructors that teach at multiple campuses. We address each of these in turn below.

3.4.1 Course and Instructor Assignment

In many education settings, we worry about non-random assignment of instructors to sections (and students) creating bias in VA measures (Rothstein, 2009; Chetty, Friedman and Rockoff, 2014). In general, we believe that there is relatively little scope for sorting in our setting. Students do not know much about the instructor when they enroll, and instructors are only assigned to specific sections about two days before the start of the course for online sections. Students who have a strong preference with regard to instructor can choose to drop the course once they learn the instructor's identity, but this would mean that they would likely have to wait until the start of the next session to take the course, at which point they would be randomly assigned to a section again. According to UPX administrators, there is no sorting at all in online courses, which is plausible given the very limited interaction students with have with instructors in the initial meetings of the course. UPX admits the possibility of some sorting in FTF courses, but believe this is likely minimal.

To explore the extent of sorting, we conduct two types of tests. First, we test whether observable instructor characteristics correlate with the observable characteristics of students in a section. To do so, we regress mean student characteristics on instructor characteristics, where each observation is a course section.¹⁷ Table 3.3 reports the estimates from three regression models which differ in terms of the type of fixed effects that are included. Once we include campus fixed effects, there are very few systematic correlations between student and instructor characteristics and any significant relationships are economically insignificant. To take one example, consider incoming student GPA, which is the single biggest predictor of student success in MTH208. Whether the instructor was hired in the last year is statistically significantly related to incoming student GPA once campus fixed effects are included, yet this difference is only 0.012 grade points, or 0.3% of the sample mean. Similar patterns are seen for all other observable student and instructor characteristics we examine. Furthermore, this pattern attenuates further when campus-year fixed effects are included. In results not reported here, but available upon request, we continue to find no significant relationship between instructor and student characteristics for subsamples limited to only online sections and to sections with final exam scores.

In addition, we follow the procedure utilized by Carrell and West (2010) to test whether the distribution of student characteristics across sections are similar to what you would get from random assignment within campus and time. In a first step, we take the pool of students in a campus-year cell, randomly draw sections of different sizes (based on the actual distribution), and compute the statistic of interest for these random sections. Similar to test 1, the statistics of interest are average age, fraction male, average prior credits, and average prior GPA. By construction, the resulting distribution of these section-level characteristics is obtained under random assignment of students to sections. In a second step, we take each actual section and compare the actual student average of each baseline characteristic to the counterfactual distribution for the relevant campus-year combination by calculating the p-value. For instance, we take a section, compute the average age, and compute the fraction

¹⁷An alternate approach would be to regress each student characteristic on a full set of course section dummies along with campus (or campus-year) fixed effects, and test whether the dummies are jointly equal to zero. This is equivalent to jointly testing the equality of the means of the characteristics across class sections.

of counterfactual sections with values smaller than the actual value. For each campus-year combination, we therefore obtain a number of p-values equal to the number of sections held at that campus-year combination. In a final step, we test for random assignment by testing the null hypothesis that these p-values are uniformly distributed. Intuitively, we are equally likely to draw any percentile under random assignment, which should result in these p-values having a uniform distribution. If, for instance, we have systematic sorting of student according to age, we would find we are more likely to find low and high percentiles, and the p-values would not exhibit a uniform distribution.

Similar to Carrell and West (2010), we test the uniformity of these p-values using the Chi-square goodness-of-fit test, and a Kolmogorov-Smirnov test with a 5% significance level. We draw counterfactual distributions at the campus-year level, leading to 763 tests of the null hypothesis of uniformity of the p-values. We find that the null hypothesis is rejected in 56 cases using the Chi-square goodness-of-fit test, and in 51 cases using the Kolmogorov-Smirnov test, which is about 6-7%. Given that the significance level of these tests was 5%, we conclude that these tests do not reject the null hypothesis of random assignment of students to sections for these specific observables.

3.4.2 Outcomes

Unlike the elementary and secondary setting in which teacher effectiveness has been studied extensively using standardized test scores, appropriate outcomes are more difficult to identify in the higher education context. Our unique setting, however, allows us to use a standardized testing framework in a higher education institution. Following prior studies in the literature, we examine not only contemporaneous course performance as measured by students' course grades, but also enrollment and performance (measured by grades) in subsequent courses in the same subject.

An important limitation of grades as a measure of course performance is that they reflect, at least in part, different grading practices. This may be particularly worrisome in the context of FTF courses at UPX because many students have the same instructor for MTH208 and MTH209. Thus lenient or subjective grading practices in 208 may be correlated with the same practices in MTH209, meaning that the MTH209 grade is not an objective measure of long-run learning from MTH208. For a subset of our sample, we are able to examine student performance on the final examination for MTH208 and/or MTH209. It also is informative to compare test-based measures to grade-based measures simply because the grade-based measures are easier for the universities to implement. It is informative to know how far from the more "objective" measures using course grades deviates. In order to maximize sample coverage we first look at course grades and credits earned, but then also look at final exam scores (for a smaller sample).

A practical challenge with both grade and test score outcomes is that they may not be observed for students that do not persist to the final exam in MTH208 or who do not enroll in MTH209. Our main analysis imputes values for these outcomes where missing, though we also assess the consequences of this imputation. Our preferred method assumes that students who chose not to enroll in MTH209 would have received a failing grade and those without test scores would have received a score at the tenth percentile of the test score distribution from their MTH208 class. Generally results are not sensitive to imputation method used. We also look directly at the likelihood of enrolling in MTH209 or of having non-missing final exam scores as outcomes.

Persistence is less susceptible to these concerns. Given that roughly one-quarter of the sample either withdraw or fail MTH208, and an equal fraction fail to take MTH209 at any point, it is interesting to look at whether students eventually take MTH209 as an outcome. The number of credits accumulated in the six months following MTH208 is another outcome we examine that is also less susceptible to instructor leniency and missing value concerns.
3.4.3 Cross-Campus Comparisons

A third challenge in estimating instructor effectiveness is that unobservable differences between students across campuses may confound instructor differences. This is the rationale for controlling for campus fixed effects in equation (3.1). But separately identifying campus and instructor effects requires that a set of instructors teach in multiple campuses.¹⁸ For example, if an instructor's students do particularly well, it is impossible to say whether this reflects the contribution of the instructor herself or unobserved campus phenomenon, such as the campus-specific facilities or student peers. Observing instructors across multiple campuses permits the separation of these two phenomenon and permit instructors across campuses to be ranked on a common scale. This is analogous to the concern in studies that attempt to simultaneously estimate firm and worker effects as well as the literature that measures teacher value-added at the K12 level. Most prior work on postsecondary instructors has focused on single campus locations and thus not confronted the cross-campus comparison problem. The existence of the online courses, and the fact that a sizeable fraction of instructors teach both online and at a physical campus, provides the "connectedness" that allows us to separately identify campus and instructor effects. Appendix Table C.3 reports the degree of "switching" that exists across campuses in our data. About 8 percent of the exclusively FTF instructors teach in more than one campus, and about 21 percent of the online instructors also teach at a FTF campus.

3.4.4 Implementation

We implement our analysis with a two-step procedure. In the first step, we first estimate the standard value-added model in (3.1) with OLS including a host of student characteristics, campus fixed effects, and instructor FEs (θ_k). Including θ_k 's as fixed effects permits correlation between θ_k 's and x characteristics (including campus FEs), generating estimates

¹⁸Including fixed effects for each of the 200 physical locations requires instructors that teach at multiple locations within each campus. Within-campus switching is more common than cross-campus switching, and thus location fixed effects are only slightly more challenging to implement than campus fixed effects.

of β_1 , β_2 , ϕ_t , and δ_c that are purged of any non-random sorting by instructors (Chetty, Friedman and Rockoff, 2014). However, the estimated θ_k 's are noisy, so their variance would be an inaccurate estimate of the true variance of the instructor effects. We then construct mean section-level residuals for each outcome

$$\tilde{Y}_{jkt} = \sum_{i \in j} \left(Y_{ijkt} - \hat{\beta}_1 X_i - \hat{\beta}_2 Z_{jkt} - \hat{\phi}_t - \hat{\delta}_c \right)$$
(3.2)

The section-level residuals \tilde{Y}_{jkt} combine the instructor effects (θ_k) with any non-meanzero unobserved determinants of student performance at the student- or section-level. Our fully-controlled first-stage model includes student characteristics (male, age, incoming GPA, incoming credits, indicator for repeat MTH208, number of times taking MTH208, 12 program dummies, years since started program), section averages of these individual characteristics, student zip code characteristics (unemployment rate, median family income, percent of families below poverty line, percent of adults with BA degree in ZIP code, plus missing ZIP) and total section enrollment. We control for aggregate temporal changes in unobserved student characteristics or grading standards by including calendar year and month fixed effects. Campus fixed effects control for any unobserved differences in student characteristics across campuses. Since the campus includes several physical locations for very large metro areas, as a robustness we replace campus fixed effects with effects for the specific physical location at which the class is taught. Finally, we also examine models with various subsets of these control variables and large sets of interactions between them.

In the second step, we use the mean residuals to estimate the variance of the instructor effects θ_k as random effects with maximum likelihood.¹⁹ For a single outcome, not distinguishing by mode, the model is simply $\tilde{Y}_{jkt} = \theta_k + \tilde{e}_{jkt}$. The error term \tilde{e}_{jkt} includes any section-specific shocks and also any non-mean-zero student-level unobserved characteristics,

¹⁹Second stage models are estimated with maximum likelihood using Stata's mixed command. To ensure that estimated variances are positive, this routine estimates the log of the standard deviation of random effects as the unknown parameter during maximization. Standard errors of this transformed parameter are computed using the inverse of the numerical Hessian, then converted back to standard deviation units.

both of which are assumed to be independent across instructors and time. Our preferred approach stacks outcomes and lets effectiveness vary by outcome with an unrestricted co-variance matrix. For instance, for two outcomes (o = grade in MTH208, grade in MTH209) we estimate

$$\tilde{Y}_{jkt}^{o} = \theta_k^{M208}(M208_{ojkt}) + \theta_k^{M209}(M209_{ojkt}) + \tilde{e}_{ojkt}$$
(3.3)

where $M208_{ojkt}$ and $M209_{ojkt}$ are indicators for MTH208 and MTH209 outcomes, respectively.²⁰ The key parameters of interest are SD(θ_k^{M208}), SD(θ_k^{M209}), and Corr(θ_k^{M208} , θ_k^{M209}). The benefit of stacking outcomes and estimating multiple outcomes simultaneously is that the correlation across outcomes is estimated directly. As noted by Carrell and West (2010), the estimate of Corr(θ_k^{M208} , θ_k^{M209}) from (3.3) will be biased in the presence of shocks common to all students in a given MTH208 section if those shocks have a positive correlation across outcomes. For instance, groups of students that are high performing in MTH208 (relative to that predicted by covariates) are also likely to do well in MTH209, independent of the MTH208 instructors' ability to influence MTH209 performance. For this reason, our preferred specification also includes section-specific shocks (random effects μ_{jkt}^{M208} and μ_{jkt}^{M209}) with an unrestricted covariance matrix.

$$\tilde{Y}_{jkt}^{o} = \theta_k^{M208}(M208_{ojkt}) + \theta_k^{M209}(M209_{ojkt}) + \tilde{e}_{ojkt}$$
(3.4)

The $\operatorname{Corr}(\mu_{ojkt}^{M208}, \mu_{ojkt}^{M209})$ captures any common shocks in MTH208 that carry over into MTH209 performance (regardless of instructor), such as unobserved student characteristics or similarities of environment between the classes (such as the same peers). The distribution of θ_k^{M208} and θ_k^{M209} is still estimated by systematic differences in student performance across sections taught by the same instructor, but now the correlation between these two effects nets out what would be expected simply due to the fact that individual students' performance in the

 $^{^{20}}$ All models also include a constant and an indicator for one of the outcomes to adjust for mean differences in residuals across outcomes, which is most relevant when we estimate the model separately by mode of instruction.

two courses are likely to be correlated. Note that since the instructor and section effects are random effects (rather than fixed), their distributions are separately identified. Including section-specific random effects has no bearing on the instructor effects, but does impact the estimated correlation between contemporary and follow-up course effectiveness. Analogous models are estimated separately by mode of instruction.

3.5 Results on Instructor Effectiveness

3.5.1 Main Results for Course Grades and Final Exam Scores

Table 3.4 reports our main estimates of the variances and correlations of MTH208 instructor effects for both grade and test score outcomes, overall and separately by mode of instruction. This base model includes our full set of student and section controls in the first stage, in addition to campus fixed effects. The odd columns report results without correlated section effects.

For the full sample, a one-standard deviation increase in MTH208 instructor quality is associated with a 0.30 and 0.20 standard deviation increase in student course grades in MTH208 and MTH209, respectively. In course grade points, this is a little larger than one grade step (going from a "B" to "B+"). Thus MTH208 instructors substantially affect student achievement in both the introductory and follow-on math courses. These estimates are statistically significant and quite a bit larger than effects found in prior research in postsecondary (e.g. Carrell and West (2010)) and elementary schools (Kane, Rockoff and Staiger, 2008). In Section 1.7, we return to the institutional and contextual differences between our study and these that may explain these differences.

We also find that instructor effects in MTH208 and MTH209 are highly positively correlated (correlation coefficient = 0.70). Including section-specific shocks that correlate across outcomes reduces (to 0.60) but does not eliminate this positive correlation. This tells us that MTH208 instructors that successfully raise student performance in MTH208 also raise performance in follow-on courses. Thus we do not observe the same negative tradeoff between contemporaneous student performance and "deep learning" highlighted by Carrell and West (2010).

Columns (4) and (6) split the full sample by whether the MTH208 section was held at a ground campus (face-to-face) or the online campus. Though slightly more than half of sections are held at ground campuses, they make up three-quarters of the instructors in the full sample. The assignment of students to online sections is de facto randomized, while results from ground sections are more generalizable to non-selective two and four-year institutions and community colleges. Instructor quality is slightly more variable at ground campuses than online (0.31 SD vs. 0.24 SD for MTH208), but with a much larger difference by format when measuring follow-on course performance (0.24 SD vs. 0.04 SD). There are a number of reasons that online instructors may have less variation in quality than face-to-face instructors. First, ground instructors have more discretion over course delivery and are more likely to modify the curriculum. Ground instructors also have more direct interaction with students. Both of these factors may magnify differences in their effectiveness in a ground setting. Second, personnel management is centralized for online sections, while many aspects of hiring, evaluation, and instructor training are done by individual campuses for ground sections. Finally, since faculty are not randomly assigned to section formats (FTF vs. online), variance differences across formats could reflect differences in instructor characteristics. For instance, if teaching experience relates to effectiveness and ground campuses have a greater variance of instructor experience, then this will be reflected in the variance of instructor quality. Furthermore, if there is less non-random sorting of students to instructors (conditional on our extensive control variables) in online sections than in ground sections, this will inflate the estimated variance of instructors at ground campuses. Interestingly, instructor quality in contemporaneous and follow-on course performance are more positively correlated for face-to-face sections than for online sections, though estimates for the latter are quite imprecise and not terribly robust across specifications.

Course grades are problematic as a measure of student achievement to the extent that systematic differences across instructors reflect different grading policies or standards rather than student learning. We address this by examining student performance on normalized final course exams.²¹ Panel B of Table 3.4 restricts analysis to sections that start between June 2010 and March 2014, for which we have such exam scores.²² For FTF sections, the variance of instructor effects is actually larger when using final exam score rather than course grades: 0.49 compared with 0.31. This is consistent with less effective teachers grading more easily than more effective teachers. In contrast, in online sections, the variance of instructor effects is smaller when using final exam score, consistent with less effective teachers grading more harshly. Effectiveness is also highly positively correlated (correlation = 0.61) between contemporaneous and follow-on course exam performance. The weak correlation between contemporaneous and follow-on course performance for online MTH208 sections is also observed with final exam scores (in fact the point estimate of the correlation is negative), though it is imprecisely estimated and generally not robust (in magnitude or sign) across alternative specifications.

One way to interpret the magnitudes is to compare them to outcome differences by student characteristics. On the standardized final exam score, for instance, students that are ten years older score 0.15 SD lower and a one grade-point difference in GPA coming into the class is associated with a 0.46 SD difference in exam scores. So having an instructor that is 1 SD more effective produces a test score change that is larger than the gap between 25 and 35 year-olds and comparable to the performance gap between students entering the class with a 3.0 vs. a 2.0 GPA. So at least compared to these other factors which we know are important – age and prior academic success – instructors seem to be a quite important factor in student success.

²¹Since exams differ in maximum point values across sections and for MTH208 and MTH209, the outcome is the fraction of points earned (out of the maximum). This fraction is then standardized to mean zero and standard deviation one for the individuals with scores across the entire sample.

²²Though not shown in the table, estimates for grade outcomes on the restricted sample of sections with exam scores are nearly identical to those for the full sample in Panel A. Thus any differences between Panels A and B are due to the outcome differences, not the difference in sample.

One candidate explanation for the high positive correlation between instructor effects in contemporaneous and follow-on courses in the FTF setting is that many students have the same instructors for MTH208 and MTH209 at ground campuses. Fully 81% of students in ground sections have the same instructor for MTH208 and MTH209, while fewer than 1% of students taking MTH208 online do. This difference in the likelihood of having repeat instructors could also possibly explain differences between online and face-to-face formats. Having the same instructor for both courses could generate a positive correlation through several different channels. First, instructor-specific grading practices or tendency to "teachto-the-test" that are similar in MTH208 and 209 will generate correlated performance across classes that does not reflect true learning gains. Alternatively, instructors teaching both courses may do a better job of preparing students for the follow-on course.

To examine this issue, Table 3.5 repeats our analysis on the subset of MTH208 face-toface sections where students have little chance of having the same instructor for MTH209. We focus on situations where the instructor was not teaching any classes or MTH208 again in the next three months and where few (<25%) or no students take MTH209 from the same instructor. While instructor quality may influence some students' choice of MTH209 instructor, it is unlikely to trump other considerations (such as schedule and timing) for all students. Thus we view these subsamples as identifying situations where students had little ability to have a repeat instructor for other reasons. Though the number of sections is reduced considerably and the included instructors are disproportionately low-tenure, the estimated instructor effects exhibit a similar variation as the full sample, both for course grades and exam scores. The correlation between MTH208 and 209 instructor effects is reduced substantially for grades and modestly for test scores, but remains positive and significant for both, even with the most restricted sample.²³

²³These specifications all include correlated section shocks across outcomes, though they are not reported in the table. Excluding section shocks makes the instructor effects more positively correlated across outcomes.

3.5.2 Robustness of Grade and Test Score Outcomes

Table 3.6 examines the robustness of our test score results to different first stage models. Our preferred first-stage model includes numerous student characteristics, section averages of these individual characteristics, total section enrollment, campus fixed effects, instructor fixed effects, calendar year fixed effects, and month fixed effects. Even models with only time controls (columns 1) exhibit patterns that are qualitatively similar to our base model, with substantial instructor quality variation, particularly for face-to-face sections. In fact, the extensive controls have little impact on estimates of instructor quality, suggesting minimal systematic non-random sorting of students to instructors based on observed characteristics (and possibly unobserved characteristics too). Even including incredibly flexible studentlevel controls (5) or fixed effects for each physical location of the class (6) has minimal impact on our estimates.²⁴ The only consequential controls we include are campus fixed effects when combined with instructor fixed effects, which increase the estimated variance of instructor effects on MTH208 and MTH209 exam scores and reduce their correlation. For online sections, estimates of instructor effects do not change at all across first stage specifications, but the estimated correlation across current and future course outcomes is not robust and very imprecisely estimated.

Table 3.7 addresses sample selection by assessing the robustness of our estimates to different ways of imputing missing outcomes, overall and separately by instructional mode. For grade outcomes, estimated instructor effects are quite similar regardless of whether MTH209 grades are imputed if a student does not take MTH209. Our preferred method for test scores assumes that students without test scores would have received a score at the tenth percentile of the test score distribution from their MTH208 class. The results are generally quite similar, qualitatively and quantitatively, across imputation methods (including no imputation by only using test scores for the select sample of students with test scores). These results suggest that the substantial differences across instructors and the positive (overall and for

²⁴There are approximately 200 physical locations included in the sample, in contrast to the 75 campuses.

FTF sections) correlation across contemporary and follow-up course outcomes is not driven by non-random selection of students into test score and follow-up course outcomes.

3.5.3 Student Evaluations and Other Outcomes

Though course grades and final exam performance are two objective measures of student learning that can be used to assess instructor quality, end-of-course student evaluations are the primary mechanism for assessing instructor quality at the University of Phoenix and most other institutions. At UPX, end-of-course evaluations are optional; fewer than 50% of students that have a MTH208 final exam score (our proxy for being engaged in the course at the end of the class) also have a completed evaluation. Students are asked how much they would recommend the instructor to another student, on a 1 to 10 scale. Scores equal to 8 or above are considered "good" by the University and we adopt this convention as well, constructing an indicator for whether the student rated the instructor at least an 8 on the 10 point scale. Table 3.8 presents estimates of model (4) with this evaluation score included pairwise along with four different learning outcomes. We also include section-specific shocks that are permitted to correlate between learning and evaluation outcomes. The variance of these section shocks captures section-to-section variability that is not explained by instructors. We do not impute evaluation scores when missing, as our goal is to assess how well the course evaluation system – as it is currently used – captures our more objective measures of instructor effectiveness.²⁵

As with learning outcomes, there is substantial variability across instructors: a onestandard-deviation increase in instructor quality is associated with a 0.219 percentage point increase in the fraction of student evaluations that are positive. This variability is smaller, though still large, among online instructors and is also comparable to the section-to-section variability (0.233). Interestingly, evaluation scores are most positively correlated with grades

²⁵There is the additional complication that it is not entirely clear how missing evaluations should be imputed. In contrast, we are comfortable assuming that students with missing final exam scores (because they dropped out) are likely to have received low exam scores had they taken the exam.

in the current course, suggesting that instructors are rewarded (through higher evaluations) for high course grades or that students experiencing temporary positive grade shocks attribute this to their instructor. Correlations with subsequent course performance and test scores is much weaker (and even negative for MTH209 test scores). Collectively this suggests that end-of-course evaluations by students are unlikely to capture much of the variation in instructor quality, especially for more distant or objective outcomes.

Table 3.9 presents estimates of instructor effects for several different outcomes, both for the full sample and the restricted sample for which test scores are available. There is substantial instructor variability in students' likelihood of taking MTH209 and in the number of credits earned in the six months following MTH208. Both of these are important indicators of students' longer-term success at UPX. A one-standard-deviation increase in MTH208 instructor quality is associated with a five percentage point increase in the likelihood a student enrolls in MTH209 (on a base of 76%), with the variability twice as large for face-to-face MTH208 sections as it is for online ones. A similar increase in instructor quality is associated with a 0.13 SD increase in the number of credits earned in the six months following MTH208, again with face-to-face instructors demonstrating more than twice as much variability as online sections. Total credits earned after MTH208 is an important outcome for students and the university which is unlikely to be manipulated by individual instructors. In Appendix Table C.4 we report correlations between predicted instructor effects measured with these different outcomes for the test score sample, overall and separately by format.²⁶ Most of the outcomes are positively correlated overall and for face-to-face sections. Interestingly, value-added measured by likelihood of taking MTH209 after MTH208 is only weakly correlated with value-added measured by final exam scores. Thus instructors that excel in improving student test scores are unlikely to excel at getting their students to enroll in the

²⁶These correlation matrices are formed by predicting the BLUP instructor effects for different outcomes one at a time and correlating these using section-level data. It would be more efficient to estimate all the effects and the correlations simultaneously as we did for pairs of outcomes (e.g. grades in MTH208 and MTH209 in Table 3.4), but these models did not converge. Consequently, these models do not include section-specific shocks that correlate across outcomes. Thus the correlations reported in Table C.4 differ from those in Table 3.4. Correlations are quite similar for the full sample.

follow-up course.

3.6 Does Effectiveness Correlate with Experience and Pay?

Having demonstrated substantial variation in instructor effectiveness along several dimensions of student success, particularly for face-to-face sections, we now consider how teaching experience and pay correlates with effectiveness. Are more experienced instructors more effective? Are more effective instructors paid more highly? While we do not attempt an exhaustive analysis of these questions, the answers have implications for whether instructional resources are used productively and how overall effectiveness could be improved. Teaching experience – both course-specific and general – may be an important factor in instructor performance given results found in other contexts (e.g., Ost (2014); Papay and Kraft (2015); Cook and Mansfield (2016)).

For this analysis, we focus on instructors hired since 2002 so that we can construct a full history of courses taught across all courses and in MTH208 specifically, not censored by data availability. This results in 18,409 sections (5,970 in the test score sample). Our main approach is to regress section-level residuals \tilde{Y}_{jkt} on observed instructor experience at the time the section was taught:

$$Y_{jkt} = f(Exp_{MTH208,t}) + \theta_k + e_{jkt}$$

$$(3.5)$$

Where f(.) is a flexible function of experience teaching MTH208. Our preferred model includes instructor fixed effects, θ_k , isolating changes in effectiveness as individual instructors gain experience. This model controls for selection into experience levels based on fixed instructor characteristics, but does not control for time-varying factors related to experience and effectiveness. For instance, if instructors tend to accumulate teaching experience when other work commitments are slack, the experience effect may be confounded with any effects of these other work commitments. We also include other dimensions of experience, such as number of sections taught of MTH209 and other courses. Papay and Kraft (2015) discuss the challenges in estimating (3.5) in the traditional K12 setting, given the near collinearity between experience and calendar year for almost all teachers. Many of these issues are not present in our setting, since the timing of when courses are taught and experience is accumulated differs dramatically across instructors. The non-standard calendar of UPX thus facilitates the separation of experience from time effects.

Figures 3.1 and 3.2 present estimates of (3.5) for a non-parametric version of f(.), regressing section mean residuals on a full set of MTH208 experience dummies (capped at 20) along with year, month, and (when noted) instructor fixed effects.²⁷ Figure 3.1 depicts results for course grade outcomes. Effectiveness increases very modestly the first few times instructors teach MTH208, as measured by MTH208 and MTH209 course grades. Interestingly, including instructor fixed effects stabilizes the effectiveness- experience profile, suggesting that less effective instructors are more likely to select into having more MTH208 teaching experience. Figure 3.2 repeats this analysis but for final exam test scores on the restricted test score sample. Estimates are quite imprecise, but do suggest modest growth in MTH208 exam scores as instructors gain experience. Improvement with experience is not as clear-cut for MTH209 test score performance.

To gain precision, Table 3.10 presents estimates from parametric specifications for f(.), while also including teaching experience in other courses and time since hire (in Panel C). We find that teaching MTH208 at least one time previously is associated with a 0.03 to 0.04 SD increase in effectiveness (measured by MTH208 grade), but that additional experience improves this outcome very little. This holds even after controlling for additional experience in other subjects. Instructors' experience impact on follow-on course grades is more modest and gradual. Test score results are much less precise, but do suggest that instructor effectiveness increases with experience for final exams in contemporaneous courses and (very modestly) in follow-on courses. We find that general experience in other subjects has

²⁷Approximately one quarter of the sections are taught by instructors that have taught MTH208 more than 20 times previously. Nine percent have not previously taught MTH208.

little association with effectiveness in MTH208 (not shown). Finally, we find no systematic relationship between teaching experience and instructors' impact on the number of credits their students earn subsequent to MTH208. Whether the instructor was hired in the past year and the number of years since first hire date has no association with most measures of instructor effectiveness (after controlling for MTH208 experience), but is associated with MTH208 test scores.

If pay was commensurate with effectiveness, then the substantial variation in measured effectiveness across instructors would not necessarily translate to productivity or efficiency differences (at least from the institution's perspective). Our discussions with leaders at University of Phoenix suggest that pay is not linked to classroom performance in any direct way, but rather is tied primarily to tenure and experience. We directly examine correlates of instructor salary quantitatively in Table 3.11. Consistent with this practice, effectiveness (as measured by section-level mean residuals in MTH209 grades) is uncorrelated with pay, both in the cross-section and within instructors over time.²⁸ However, years since first hire is the one consistent predictor of the salary instructors are paid for MTH208 courses. Instructors receive approximately \$44 more per course for each year of tenure (approximately 4% higher pay) after fixed instructor differences are accounted for. Overall and course-specific teaching experience have no association with instructor salary.

3.7 Conclusion and Discussion

In this study, we document substantial differences in effectiveness across instructors of required college algebra at the University of Phoenix. A one-standard-deviation in instructor quality is associated with a 0.20 SD increase in course grades and a 0.41 SD increase in final exam scores in the follow-on course, as well as a 0.13 SD increase in the number of credits earned within six months. Variation is much smaller for online sections, yet still measurable

 $^{^{28}}$ It is possible that noise in our estimates of section-specific effectiveness attenuates our estimate of the relationship between effectiveness and pay. We are currently examining this issue, though we note that a finding of no relationship is consistent with the institution's stated pay policy.

and larger than that found in other contexts. Putting these magnitudes in context, having an instructor that is 1 SD more effective produces a test score change that is larger than the gap between 25 and 35 year-olds and comparable to the performance gap between students entering the class with a 3.0 vs. a 2.0 GPA. Instructors are clearly an quite important factor in student success.

It is worth considering what institutional factors may contribute to such large differences across instructors, particularly in contrast to other settings. Prior work in postsecondary has focused on selective and research-oriented public and non-profit universities, courses taught by permanent or tenure-track faculty, institutions operating in a single geographic location, and serving "traditional" students. Our setting focuses on a non-selective for-profit institution where the teaching force is contingent and employed part-time, the student body is diverse, the performance of the teaching force is solely based on teaching and instruction, and courses and testing procedures are highly standardized. It is possible that instructors are a more important factor in the success of "non-traditional" students or that there is more variation in instructor quality among contingent and adjunct faculty than among permanent or tenure-track faculty. The one prior study that finds instructor variation comparable to ours (Bettinger et al., 2015) shares all of these traits with our study institution. Having a better understanding of the importance of faculty at less selective institutions and in settings where most faculty are contingent is important, as these institutions serve a very large (and growing) share of postsecondary students in the U.S.. Finally, it is possible that the fast course pace – five weeks – could magnify the consequences of behavioral differences across instructors. A delay in providing student feedback – even just a few days – could be devastating to students in a five-week course.

This substantial variation across instructors suggests potential to improve student and institutional performance via changes in how faculty are hired, developed, motivated, and retained. Institutions like UPX reflect the sector-wide trend towards contingent faculty (e.g. adjuncts and lecturers), which aimed to save costs and create flexibility (Ehrenberg, 2012). Debate about whether adjuncts are better or worse for instruction than permanent faculty obfuscates the feature that contingent arrangements create opportunities for improving student performance via personnel policies that are not available when faculty are permanent. However, instructor evaluation and compensation systems have not kept up with these changes; our study institution has an evaluation system (student course evaluations) that is similar to that at elite research universities and a salary schedule that varies only with tenure and credentials. Of course the potential for improvement through changes in personnel policies – and how these policies should be designed – depends critically on the supply of instructors available (e.g. Rothstein (2015)). Online and ground campuses likely face quite different labor markets for instructors, the former drawing on instructors across the country, suggesting that personnel policies should differ between them. Better understanding the labor market for postsecondary faculty – particularly at less selective institutions – is an important area for future attention.

Finally, we have focused on the role of individual faculty in promoting the success of students. In fact, differences in instructor effectiveness is one potential explanation for cross-institution differences in institutional performance and productivity that has yet to be explored. Our study suggests it should.

	All S	ections	Face-to-F	ace Sections	Online S	Sections
	n=2	26,384	n=]	13,791	n=12	,593
	Mean	Std. Dev.	Mean	Std. Dev.	Mean	Std. Dev.
Online section	0.477	0.499	0.000	0.000	1.000	0.000
Male	0.735	0.441	0.755	0.430	0.714	0.452
White	0.649	0.477	0.633	0.482	0.664	0.472
Instructor Compensation per Section ($\$$)	955.14	181.61	949.39	211.45	961.45	141.86
Section-average student age	34.887	3.253	34.331	3.375	35.450	2.998
Section-average share male	0.360	0.175	0.373	0.174	0.346	0.174
Section-average incoming GPA	3.348	0.226	3.337	0.243	3.359	0.205
Section-average incoming credits	22.875	8.394	25.564	8.823	19.930	6.768
Section-average repeat 208	0.107	0.110	0.079	0.097	0.138	0.115
Section-average number times taken 208	1.112	0.128	1.086	0.112	1.140	0.139
Section-average time since program start (years)	1.146	0.501	1.200	0.521	1.087	0.472
Section enrollment	12.881	4.404	13.976	5.383	11.681	2.479
Years since first hire	4.783	4.281	5.005	4.811	4.539	3.597
Years since first hire > 1	0.830	0.376	0.804	0.397	0.858	0.349
Total math 208 sections taught prior to this section	15.310	16.792	11.038	13.132	19.988	18.975
Ever taught MTH208 prior to this section	0.920	0.272	0.888	0.316	0.955	0.208
Total sections instructor taught prior to this section	43.213	51.854	46.50149	61.16311	39.61129	38.88616
Total MTH209 sections taught prior to this section	9.871	12.915	10.690	13.170	8.975	12.569
Ever taught MTH209 prior to this section	0.776	0.417	0.873	0.333	0.670	0.470

Table 3.1: Descriptive Statistics for Sections and Instructors (Full Sample)

			Face-t	o-Face		
	All Se	ctions	Sect	ions	Online S	Sections
	n=33	9,844	n=19	2,747	n=14	7,097
	Mean	Std. Dev.	Mean	Std. Dev.	Mean	Std. Dev.
Male	0.359	0.480	0.373	0.484	0.341	0.474
Age	34.816	9.097	34.264	9.127	35.538	9.008
Baseline GPA (0-4)	3.348	0.538	3.348	0.518	3.347	0.563
Credits earned prior to start of Math 208	23.386	18.363	25.714	18.451	20.337	17.79
Fook Math 208 before	0.104	0.306	0.0772	0.267	0.140	0.347
Number of times MTH 208 taken	1.109	0.385	1.084	0.325	1.142	0.448
3S (general studies)	0.211	0.408	0.208	0.406	0.214	0.410
3S in Nursing	0.0496	0.217	0.026	0.159	0.081	0.272
3S in Accounting	0.003	0.057	0.002	0.045	0.005	0.069
3S in Business	0.503	0.500	0.587	0.492	0.393	0.488
3S in Criminal Justice Administration	0.035	0.183	0.047	0.213	0.018	0.133
3S in Education	0.022	0.145	0.013	0.112	0.033	0.179
3S in Health Administration	0.034	0.182	0.034	0.181	0.034	0.182
3S in Human Services	0.033	0.179	0.023	0.150	0.046	0.210
3S in Information Technology	0.028	0.166	0.027	0.162	0.030	0.172
3S in Management	0.041	0 199	0.022	0.148	0.066	0 248
Non-degree program	0.041	0.117	0.022	0.042	0.000	0.240
S in other Program	0.014	0.117	0.002	0.042	0.000	0.150
Fime since program start data (years)	1 160	1 300	1 203	1 334	1 105	1 478
Frade in Math 208	2 457	1 305	2 534	1 333	2 355	1.467
	0.310	0.466	0 323	0.468	0.314	0.464
A / A^{-}	0.268	0.400	0.325 0.275	0.400	0.314	0.404
$D_{+} / D / D_{-}$	0.208	0.445	0.275	0.440	0.258	0.450
D + / D / D	0.174	0.379	0.132	0.354	0.151	0.550
D+ / D / D-	0.075	0.200	0.077	0.207	0.000	0.249
r With drame	0.040	0.207	0.005	0.191	0.054	0.220
Dessed Math 208	0.122	0.327	0.095	0.293	0.150	0.303
Passed Math 208	0.834	0.372	0.007	0.340	0.790	0.407
Viath 208 Final exam score available	0.242	0.429	0.282	0.450	0.191	0.393
Math 208 final exam % correct (if available)	0.708	0.241	0.097	0.240	0.729	0.230
$\frac{100 \text{ Math } 209}{2 \text{ Math } 209}$	0.755	0.430	0.824	0.380	0.004	0.472
Frade in Math 209 (if took it)	2.620	1.240	2.714	1.160	2.404	1.303
A / A-	0.318	0.466	0.328	0.470	0.300	0.458
B+ / B / B-	0.294	0.456	0.304	0.460	0.279	0.449
C + / C / C-	0.201	0.401	0.217	0.412	0.174	0.379
D+ / D / D-	0.074	0.261	0.074	0.262	0.073	0.260
F	0.032	0.176	0.021	0.145	0.049	0.215
Withdrawn	0.068	0.251	0.046	0.209	0.104	0.305
Vlath 209 Final exam score available	0.200	0.400	0.249	0.433	0.136	0.342
Math 209 final exam % correct (if available)	0.691	0.246	0.690	0.245	0.693	0.250
Jredits earned in following 6 months	10.461	5.315	11.401	5.053	9.230	5.397
lave course evaluation	0.117	0.321	0.118	0.323	0.115	0.320
	0.658	0.474	0.693	0.461	0.610	0.488

Table 3.2: Descriptive Statistics	for Students ((Full Sample))
-----------------------------------	----------------	---------------	---

	(1)	(2)	(3)	(4)	(5)	(9)	(2)	(8)	(6)
		Panel A.			Panel B.			Panel C.	
	Outco	me = Averag	e Age	Outcor	ne = Fractio	n Male	Outcome :	= Fraction R	epeating
		mean=34.89			mean=0.36			mean=0.11	
Years since first hire	-0.015	0.009 (0.010)	0.002	0.001 (0.001)	-0.001^{**}	-0.001	-0000-000	0.000	0.000
Years since first hire > 1	0.253^{***}	0.081	0.091	-0.002	0.008*	0.007*	0.011***	0.003	-0.001
Total MTH 208 contions toucht	(0.080)	(0.073) 0.004**	(0.074)	(0.005) -0.001***	(0.004) 	(0.004)	(0.003) 0.001 ***	(0.002)	(0.002)
DUAL MITH 200 SECUOUS LAUGHU Drior to this section	(0000)	(0 003)	-0.002) (0.002)	(0000)	(0000)	(0000)-		00000)	(0000)
Ever taught MTH208	0.155^{*}	-0.076	-0.033	0.003	0.006	0.003	0.025 ***	0.005*	0.008***
prior to this section	(0.084)	(0.080)	(0.078)	(0.005)	(0.005)	(0.005)	(0.003)	(0.003)	(0.003)
Total sections instructor taught	-0.001	-0.001	-0.000	9.60e-05*	$7.69e-05^{**}$	0.000	-7.39e-05***	-0.000	-0.000
prior to this section	(0.001)	(0.001)	(0.001)	(0.000)	(0.000)	(0.000)	(0.00)	(0.000)	(0.000)
Total MTH209 sections taught	GUU.0-	100.0-	100.0	0.000	0.000	0.000*	-0.000	0.000	0.000
Prior to this section Ever tailoht MTH209	(0.004) -0.361***	0.0281	(0.002) 0.0141	-0 00352	-0.0121***	-0.0135***	-0.0206***	0.00304	-0 000
prior to this section	(0.073)	(0.064)	(0.061)	(0.004)	(0.004)	(0.004)	(0.002)	(0.002)	(0.002)
R-squared	0.047	0.121	0.176	0.034	0.105	0.167	0.054	0.13	0.167
		Panel D.			Panel E.			Panel F.	
	Outco	me = Averag	e Age	Outcor	ne = Fractio	n Male	Outcome :	= Fraction R	epeating
		mean=34.89			mean=0.36			mean=0.11	
Years since first hire	0.002^{**}	-0.000	-0.000	0.087^{**}	0.029	-0.007	0.065^{**}	0.022	0.006
	(0.001)	(0.001)	(0.000)	(0.042)	(0.026)	(0.015)	(0.025)	(0.015)	(0.012)
Years since first hire > 1	-0.017***	-0.012***	-0.001	0.174	0.593^{***}	0.192	-0.278**	0.059	0.032
	(0.005)	(0.004)	(0.004)	(0.234)	(0.192)	(0.143)	(0.135)	(0.105)	(0.087)
Total MTH 208 sections taught	-0.000	0.000	0.000	-0.046***	0.024^{***}	0.001	-0.012^{***}	0.019^{***}	0.005***
prior to this section	0.000	0.000)	0.000)	(0.007)	(0.004)	(0.003) 0.356**	(0.004) 0 rar***	(0.003)	(0.002) 0.060***
EVET TAUGNT IN L II 208	0.005)	0.000	-0.002)	(006.0)	0.174 (0.103)	(0.165)	-0.030	0.004	(0 00E)
Total sections instructor taught	0000	0.000	0.000	0.006*	-0.004*	-0.001	(000 0	-0.001	0000-
prior to this section	(0000)	(0.000)	(0.00)	(0.003)	(0.002)	(0.001)	(0.002)	(0.001)	(0.001)
Total MTH209 sections taught	0.000	0.000	0.000	0.013	0.003	0.005	0.023^{***}	0.016^{***}	0.011^{***}
prior to this section	(0.00)	(0.000)	(0.000)	(0.011)	(0.007)	(0.004)	(0.007)	(0.004)	(0.003)
Ever taught MTH209	0.000	-0.002	0.003	1.890^{***}	-0.093	-0.045	0.709^{***}	-0.143	-0.067
prior to this section	(0.004)	(0.004)	(0.004)	(0.191)	(0.165)	(0.112)	(0.117)	(0.104)	(0.063)
R-squared	0.338	0.397	0.440	0.130	0.283	0.429	0.070	0.236	0.359
Observations	23,298	23, 298	23,298	23,298	23, 298	23,298	23, 298	23, 298	23, 298
FE	None	campus	campus- year	None	campus	campus- year	None	campus	campus- year
Notes: Each panel-column is	a separate r	egression of s	section-level s	student averag	e characteris	tics (or total	section enrolln	nent) on inst	ructor

	<u>F I F and Onu</u> (1)	le Combined (2)	$(3) \frac{\mathbf{FTF}}{\mathbf{FTF}}$	(4)	(5)	(6)
Instructor Effect (n	Full Sample no section shocks)	Pε Full Sample (section shocks)	anel A. Outcome = St Full Sample (no section shocks)	andardized Course Full Sample (section shocks)	Grade Full Sample (no section shocks)	Full Sample (section shocks)
						(minoria momona)
SD(MTH208 effect)	0.305	0.300	0.316	0.315	0.246	0.245
	(0.006)	(0.006)	(0.007)	(0.001)	(0.008)	(0.008)
SD(MTH209 effect)	0.201	0.195	0.250	0.243	0.041	0.039
~	(0.005)	(0.005)	(0.006)	(0.006)	(0.005)	(0.005)
Corr (MTH208, MTH209)	0.695	0.596	0.763	0.657	0.374	0.168
	(0.017)	(0.020)	(0.017)	(0.020)	(0.087)	(0.095)
ection Effect en/wrnage affect		790 0		080.0		906 U
		(1 109)		00.200		0.230
SD(MTH209 effect)		(1.102)		0.300		0.298
		(1.058)		(0.192)		(0.149)
Corr (MTH208, MTH209)		0.425		0.478		0.364
~		(3.132)		(0.659)		(0.367)
bservations (sections)	26,384	26,384	13,791	13,791	12,593	12,593
umber of Instructors	2,243	2,243	1,710	1,710	676	676
	Full Sample	Full Sample	Panel B. Outcome = 5 Full Sample	Standardized Test S Full Sample	Score Full Sample	Full Sample
structor Effect (r	no section shocks)	(section shocks)	(no section shocks)	(section shocks)	(no section shocks)	(section shocks)
SD(MTH208 effect)	0.436	0.444	0.482	0.486	0.110	0.135
	(0.012)	(0.012)	(0.014)	(0.014)	(0.014)	(0.012)
SD(MTH209 effect)	0.425	0.408	0.490	0.481	0.100	0.047
	(0.012)	(0.012)	(0.015)	(0.015)	(0.017)	(0.032)
Corr (MTH208, MTH209)	0.680 (0.025)	0.609 (0.027)	0.680 (0.026)	0.597 (0.029)	0.248 (0.204)	-0.066 (0.358)
ection Effect	~	~	~		~	~
SD(MTH208 effect)		0.380		0.384 (0.838)		0.384
SD(MTH209 effect)		(0.003) 0.478		0.439		0.547
		(0.481)		(0.724)		(0.00)
Corr (MTH208, MTH209)		0.294		0.391		0.158
		(0.763)		(1.489)		(0.023)
bservations (sections)	7,232	7,232	4,707	4,707	2,560	2,560
lumber of Instructors	1,198	1,198	938	938	292	292

Table 3.4: Main Course Grade and Test Score Outcomes

				FTF sections	FTF sections
			Not teaching	with $< 25\%$	with 0%
	All FTF	Not teaching	208 next 3	same	same
	sections	next 3 months	months	instructor	instructor
	(1)	(2)	(3)	(4)	(5)
	д	anel A. Outcome = ξ	Standardized Cours	se Grade (Full samp	le)
Instructor Effect					
SD(MTH208 effect)	0.315	0.333	0.318	0.326	0.313
	0.007	0.021	0.007	0.015	0.016
SD(MTH209 effect)	0.243	0.219	0.239	0.159	0.161
	0.006	0.039	0.007	0.022	0.024
Corr (MTH208, MTH209)	0.657	0.333	0.669	0.205	0.14
	0.02	0.137	0.023	0.107	0.118
Observations (sections)	13,791	856	7,224	1,587	1,402
Number of Instructors	1,710	618	1695	805	763
	Pa	nel A. Outcome $=$ St	andardized Test So	core (Test score sam	(ple)
Instructor Effect					
SD(MTH208 effect)	0.486	0.466	0.474	0.464	0.436
	0.014	0.069	0.015	0.035	0.039
SD(MTH209 effect)	0.481	0.296	0.467	0.526	0.486
	0.015	0.093	0.016	0.036	0.042
Corr (MTH208, MTH209)	0.597	(a)	0.597	0.523	0.546
	0.029	(a)	0.033	0.085	0.11
Observations (sections)	4,707	314	2,645	573	513
Number of Instructors	938	255	933	371	351
Notes: Random effects models are	estimated on sectio	n-level residuals. First s	tage models include i	nstructor, campus, yea	r, and month fixed
effects in addition to individual con other than instructor fixed effects.	trols, section averag Individual contro	e controls, and ZIP code s include male, age, inc	controls. Residuals a	re taken with respect to by credits, indicator fo	o all these variables r_reneat_MTH208.
number of times taking MTH208, 1.	2 program dummies	s, years since started prog	gram. Section average	controls include sectio	n averages of these
same characteristics plust total enr	ollment in section.	ZIP controls include the	unemployment rate,	median family income,	percent of families
NTTHPOO was acciented adu	ing) and students t	IN ZIP code from 2004-	ZUUT AUS (plus miss	ang ZIP). Students wh	o did not enroll in b mensentile of the
				were assigned the rol	in percentite of the
Vest score from their 200 section. F All models include full controls in f	vobust standard err first stage implite z	ors clustered by instruct ero MTH209 grade if mi	or m parenuneses. (a, ssing impute 10th nt) murates that convers ile of test scores if miss	gence not acmeveu. sin <i>g</i>
TTT MATATION TINT ANNIATTI MANAGET	man averse, mupule	CID INT TITEON BIGGO TI TAT	ad man and mind time	VITTE OT ACON DONING ADDA TO DIT	mg.

Sections
FTF
id MTH209,
1208 an
or MTF
nstructor fo
Same I
Having
bustness to
.5: Rc
Table 3

		No ir	structor]	FE in first	stage			Instruc	tor FE in	cluded in	first stage	0
	(1)	(2)	(3)	(4)	(2)	(9)	(2)	(8)	(6)	(10)	(11)	(12)
			Panel A.	All Section	ns (just te	st score sa	mple), $n =$	7,232 sect	tions, 1,1	98 instruc	tors	
SD(MTH208 test effect)	0.293	0.263	0.285	0.266	0.266	0.248	0.294	0.442	0.287	0.444	0.44	0.425
~	(0.010)	(0.00)	(0.00)	(0.00)	(0.009)	(0.00)	(0.010)	(0.012)	(0.009)	(0.012)	(0.012)	(0.011)
SD(MTH209 test effect)	0.286	0.21	0.264	0.216	0.217	0.194	0.289	0.432	0.291	0.408	0.413	0.468
	(0.010)	(0.010)	(0.010)	(0.010)	(0.010)	(0.009)	(0.010)	(0.013)	(0.010)	(0.012)	(0.012)	(0.013)
Corr (MTH208, MTH209)	0.725	0.854	0.799	0.865	0.864	0.862	0.722	0.616	0.754	0.609	0.619	0.617
	(0.028)	(0.027)	(0.025)	(0.025)	(0.025)	(0.028)	(0.028)	(0.026)	(0.026)	(0.027)	(0.027)	(0.026)
			Panel B	. FTF Sec	tions (jus	it test score	e sample) -	4,673 sect	tions, 935	instructo	rs	
SD(MTH208 test effect)	0.341	0.304	0.328	0.305	0.305	0.283	0.342	0.480	0.331	0.486	0.482	0.466
	(0.012)	(0.011)	(0.011)	(0.011)	(0.011)	(0.011)	(0.012)	(0.014)	(0.011)	(0.014)	(0.014)	(0.014)
SD(MTH209 test effect)	0.293	0.259	0.293	0.263	0.264	0.236	0.294	0.507	0.296	0.481	0.487	0.546
	(0.012)	(0.011)	(0.012)	(0.011)	(0.011)	(0.011)	(0.012)	(0.015)	(0.012)	(0.015)	(0.015)	(0.016)
Corr (MTH208, MTH209)	0.857	0.896	0.866	0.906	0.906	0.919	0.855	0.601	0.867	0.597	0.606	0.590
~	(0.023)	(0.023)	(0.022)	(0.022)	(0.022)	(0.023)	(0.023)	(0.029)	(0.022)	(0.029)	(0.028)	(0.028)
			Panel C.	Online Se	ctions (ju	ist test sco	re sample)	- 2,559 sec	ctions, 29	2 instruct	ors	
SD(MTH208 test effect)	0.135	0.135	0.135	0.135	0.135	0.135	0.135	0.135	0.135	0.135	0.135	0.135
	(0.013)	(0.013)	(0.012)	(0.012)	(0.012)	(0.012)	(0.013)	(0.013)	(0.012)	(0.012)	(0.012)	(0.012)
SD(MTH209 test effect)	0.036	0.039	0.044	0.044	0.041	0.041	0.042	0.042	0.047	0.047	0.045	0.046
~	(0.042)	(0.039)	(0.034)	(0.034)	(0.036)	(0.036)	(0.037)	(0.036)	(0.032)	(0.032)	(0.033)	(0.033)
Corr (MTH208, MTH209)	-0.200	-0.172	-0.008	-0.082	-0.148	-0.142	-0.156	-0.157	-0.062	-0.066	-0.122	-0.121
	(0.557)	(0.489)	(0.378)	(0.387)	(0.431)	(0.430)	(0.449)	(0.445)	(0.360)	(0.358)	(0.381)	(0.378)
Controls in												
First Stage Model												
indiv. controls	no	no	yes	yes	yes	yes	no	ou	yes	yes	yes	yes
zip controls	no	no	yes	yes	\mathbf{yes}	yes	no	ou	yes	yes	yes	yes
section avg controls	no	ou	yes	yes	yes	yes	no	no	yes	yes	yes	yes
flexible controls	no	ou	no	no	yes	yes	no	no	ou	no	yes	yes
year FE, month FE	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
campus FE	no	yes	no	yes	yes	no	no	yes	ou	yes	yes	no
location FE	no	no	no	no	no	yes	no	no	no	no	no	yes
Notes: Random effects models a Notes: of times taking MTH205	are estimate	ed on secti m dummi	on-level res: es vears sin	iduals. Indi ve started	v controls	include male lection avera	, age, incomi	ng GPA, in Juda sectio	coming cre	dits, indica	tor for repe une charact	at MTH208, eristics plust
total enrollment in section. ZIP	controls ind	clude the 1	unemployme	ent rate, m	edian famil	y income, pe	rcent of fam:	ilies below p	overty line	e, percent of	f adults wit	h BA degree
in ZIP code from 2004-2007 AC	SS (plus mi	ssing ZIP)	. Flexible c	controls inc	lude progré	am-specific c	ubics in inco	ming GPA	and credit	s, cubic int	eractions b	etween GPA
and credits, gender-specific age	cubic, and i	interaction	is between {	gender and	GPA and c	predits. Stud	ents who did	not enroll	in MTH209	9 were assig	gned a zero	(failing) and
suuenus unau uu nuu possess a instructor in parentheses ** In	lest score t dirates that	ur zuo ur model fai	209 were an	erge All m	utu perce odels inclu	de section-sr	est score mo. verific shocks	ui uiteir 200 : and immit	e zero MT	UDUSU SUALIO H200 orade	uaru errors if missinø	ciustereu by immite 10th
ptile of test score if missing.								and min mine		1700 Brack	(Q.11001111 II	mor omduur

\frown	
\mathbf{SS}	
С С	
10	
$\overline{\mathbf{S}}$	
õ	
ţi.	
e	
el	
${\bf \Omega}$	
Ч	
it	
≧	
\sim	
[e]	
pc	
4	
e B	
ğ	
5 to	
Ľ.	
$\mathbf{\tilde{s}}$	
Ę	
<u> </u>	
to	
'n	
lt.	
n	
6G	
Ч	
е	
OĽ	
ŭ	
\mathbf{J}	
\mathbf{st}	
بق	
Г	
of	
- M	
Š	
né	
st	
'n	
q	
Ř	
<u> </u>	
<u>.</u> :	
т. С	
۔ ص	
Эle	
al	
E	

Mis	ssing grade							
	replace	ss for MTH209 d with			Missing grades for	MTH209 replaced	with	
	No butation	Base model: Set Equal to 0 (Failing)	No Imputation	p10 for campus-year of MTH208 section	Base model: p10 for students from MTH208 section	Mean of students from MTH208 section	Minimum of students from MTH208 section	Mean for students who received same grade in MTH- 208 section
	(1)	(2)	(3)	(4)	(5)	(9)	(2)	(8)
Panel A. All Sections					к. У	× •	×.	
Instructor Effect SD(MTH208 effect) 0	0.286	0.286	0.416	0.395	0.444	0.469	0.406	0.402
	0.008) 244	(0.008) 0.305	(0.011)	(0.010)	(0.012)	(0.012)	(0.011)	(0.010) 0 374
	0.008)	(0.007)	(0.011)	(0.010)	(0.012)	(0.014)	(0.012)	(0.011)
$Corr (MTH208, MTH209) \qquad 0$	0.477 0.034)	0.550 (0.030)	0.544	0.614	0.609 (0.027)	(0.531)	(0.623)	0.556
Panel B. FTF Only	(+ 0000	(0000)		(0-0-0)				
Instructor Effect								
SD(MTH208 effect) 0	0.298	0.298	0.445	0.430	0.486	0.503	0.445	0.436
0)	0.009)	(0.00)	(0.013)	(0.013)	(0.014)	(0.015)	(0.013)	(0.013)
SD(MTH209 effect) 0	0.288	0.239	0.457	0.392	0.481	0.572	0.447	0.43
(U Corr (MTH208, MTH209)	J.U1U) J.593	(0.008) 0.597	(0.014) 0.549	(0.012)	(01010) 0.597	(0.017)	(0.014) 0.614	(0.013)
	0.033)	(0.032)	(0.031)	(0.028)	(0.029)	(0.031)	(0.029)	(0.029)
Panel C. Online Only								
Instructor Effect								
SD(MTH208 effect) 0	0.227 (5)	0.225	0.115	0.107	0.135	0.141	0.123	0.118 (0.000)
SD/MTH209 effect)	(a) 1 047	0.028	0.034	0.01	0.042	0.054	(0.012)	0.003
	(a)	(0.013)	(0.024)	(200.0)	(0.032)	(0.022)	(0.029)	(0.029)
Corr (MTH208, MTH209)) -	0.365	-0.296	1	-0.066	0.172	-0.276	0.359
	(a)	(0.234)	(0.403)	(a)	(0.358)	(0.235)	(0.382)	(0.526)

Table 3.7: Robustness to Imputation Method

		FTF and	Online			FTF	Only			Onlin	e Only	
	Mea	sure of Stuc	lent Learni	ing:	Mea	sure of Stue	dent Learni	ing:	Me	asure of Sti	udent Lear	ning:
	MTH208	MTH209	MTH208	MTH209	MTH208	MTH209	MTH208	MTH209	MTH208	MTH209	MTH208	MTH209
	grade	grade	test	test	grade	grade	test	test	grade	grade	test	test
	(1)	(2)	(3)	(4)	(5)	(9)	(2)	(8)	(6)	(10)	(11)	(12)
Offect												
ng effect)	0.286	0.205	0.444	0.410	0.299	0.240	0.487	0.484	0.227	0.028	0.137	0.048
	(0.008)	(0.007)	(0.012)	(0.012)	(0.00)	(0.008)	(0.014)	(0.015)	(0.012)	(0.013)	(0.012)	(0.032)
offect)	0.219	0.219	0.219	0.219	0.240	0.239	0.24	0.240	0.140	0.141	0.141	0.141
	(0.006)	(0.006)	(0.006)	(0.006)	(0.008)	(0.008)	(0.008)	(0.008)	(0.008)	(0.00)	(0.008)	(0.009)
rning, eval)	0.439	0.237	0.084	-0.084	0.390	0.223	0.059	-0.074	0.751	0.597	0.520	-0.605
	(0.033)	(0.042)	(0.039)	(0.041)	(0.039)	(0.047)	(0.044)	(0.045)	(0.041)	(0.293)	(0.084)	(0.435)
sct												
ing effect)	0.271	0.279	0.399	0.490	0.278	0.291	0.400	0.450	0.257	0.262	0.399	0.555
	(0.003)	(0.148)	(0.352)	(0.396)	(0.624)	(0.004)	(0.266)	(0.224)	(0.255)	(0.004)	(0.006)	(0.275)
effect)	0.233	0.233	0.219	0.213	0.246	0.246	0.232	0.228	0.210	0.217	0.200	0.191
	(0.003)	(0.178)	(0.641)	(0.913)	(0.706)	(0.003)	(0.457)	(0.442)	(0.313)	(0.004)	(0.004)	(0.797)
rning, eval)	0.174	0.040	0.119	0.001	0.156	0.041	0.102	0.001	0.214	0.041	0.153	0.001
	(0.015)	(0.054)	(0.452)	(0.017)	(0.799)	(0.019)	(0.27)	(0.021)	(0.534)	(0.023)	(0.024)	(0.026)
ns (sections)	7,267	7,267	7,267	7,267	4,707	4,707	4,707	4,707	2,560	2,560	2,560	2,560
Instructors	1,201	1,201	1,201	1,201	938	938	938	938	292	292	292	292
m effects models an ZIP code controls. repeat MTH208, n reollment in section SS (plus missing ZI the test score from the loft by the of test	re estimated on Residuals are umber of time 1. ZIP controls IP). Students 1 their 208 sec	n section-leve taken with J s taking MTH s include the who did not tion. Robust	I residuals. F respect to all 1208, 12 prog unemployme enroll in MT standard er	7)rist stage mod I these variable gram dummies, ent rate, media fH209 were ass rrors clustered	els include instr s other than in , years since st n family incom signed a zero (f by instructor i	ructor, campi- structor fixeo- arted program (e), percent of failing) and in parenthese	us, year, and d effects. Inc m. Section av f families bel students that s. All mode	month fixed efft lividual controls rerage controls i ow poverty line, c did not posses ls include full c	sets in addition s include male, nclude section percent of ad s a test score ontrols in first	a to individua age, incomir averages of lults with BA for 208 or 20 t stage, impu	al controls, se ng GPA, inco these same o degree in Z 09 were assig nte zero MT	ection average ming credits, haracteristics IP code from gred the 10th H209 grade if

Table 3.8: Relationship between Course Grade or Test Effect and Teaching Evaluation

	Outcome				
	Pass MTH208	Take MTH209	Credits earned 6 months		
Panel A. Full Sample					
SD (instructor effect) - overall	0.073	0.051	0.126		
(n = 26,384)	(0.002)	(0.002)	(0.004)		
SD instructor effect - FTF	0.080	0.062	0.154		
(n = 13,791)	(0.002)	(0.002)	(0.005)		
SD instructor effect - online	0.059	0.031	0.059		
(n = 12,593)	(0.002)	(0.002)	(0.004)		
Panel B. Test Score Sample					
SD (instructor effect) - overall	0.072	0.059	0.130		
(n = 7,267)	(0.002)	(0.003)	(0.006)		
SD instructor effect - FTF	0.077	0.069	0.150		
(n = 4,707)	(0.003)	(0.003)	(0.007)		
SD instructor effect - online	0.056	0.032	0.040		
(n = 2,560)	(0.004)	(0.004)	(0.011)		

Table 3.9: Instructor Effects for Alternative Outcomes

Notes: Random effects models are estimated on section-level residuals. First stage models include instructor, campus, year, and month fixed effects in addition to individual controls, section average controls, and ZIP code controls. Residuals are taken with respect to all these variables other than instructor fixed effects. Individual controls include male, age, incoming GPA, incoming credits, indicator for repeat MTH208, number of times taking MTH208, 12 program dummies, years since started program. Section average controls include section averages of these same characteristics plust total enrollment in section. ZIP controls include the unemployment rate, median family income, percent of families below poverty line, percent of adults with BA degree in ZIP code from 2004-2007 ACS (plus missing ZIP). Robust standard errors clustered by instructor in parentheses. First stage model with full controls.

	Outcome: Section-level mean residual for								
					Credits				
	MTH208	MTH209	MTH208	MTH209	Earned				
	grade	grade	test	test	6 months				
	(1)	(2)	(3)	(4)	(5)				
	A. Linear, Only MTH208 Experience, Instructor FEs								
Taught MTH208 previously	0.0384***	0.006	0.069**	0.019	-0.016				
	(0.011)	(0.011)	(0.034)	(0.038)	(0.010)				
Times taught MTH208	0.000	0.000	-0.003	-0.003	0.001				
0	(0.001)	(0.001)	(0.004)	(0.004)	(0.001)				
	B. Piecewise, Only MTH208 Experience, Instructor FEs								
Times taught $MTH208 = 1$	0.031***	-0.002	0.067*	0.020	0.000				
	(0.012)	(0.012)	(0.036)	(0.042)	(0.012)				
Times taught $MTH208 = 2$ to 5	0.041***	0.008	0.078^{*}	0.045	-0.020*				
	(0.012)	(0.012)	(0.040)	(0.044)	(0.011)				
Times taught $MTH208 = 6$ to 10	0.040***	0.008	0.137**	-0.001	-0.005				
	(0.016)	(0.015)	(0.054)	(0.056)	(0.014)				
Times taught MTH208 = 11 to 15	0.041**	0.001	0.169**	0.043	-0.001				
10	(0.020)	(0.018)	(0.066)	(0.068)	(0.017)				
Times taught MTH208 = 16 to	0.040*	-0.009	0.159**	0.077	0.017				
20	(0.004)	(0.000)	(0,070)	(0.001)	(0.010)				
	(0.024)	(0.020)	(0.079)	(0.081)	(0.019)				
Times taught MTH208 > 20	0.035	-0.005	0.131	0.113	0.043*				
	(0.028)	(0.023)	(0.089)	(0.096)	(0.023)				
	C. Linear, Control for MTH209 experience, other math,								
	non-mat	n experience li	nearly, time sir	nce hire, Instru	actor FEs				
Taught MTH208 previously	0.028**	-0.005	0.059	-0.045	-0.025**				
	(0.014)	(0.013)	(0.048)	(0.055)	(0.012)				
Times taught MTH208	0.000	0.000	-0.008	-0.003	0.001				
	(0.001)	(0.001)	(0.005)	(0.005)	(0.001)				
Taught MTH209 previously	0.015	0.014	-0.014	0.081^{*}	0.015				
	(0.015)	(0.013)	(0.054)	(0.049)	(0.012)				
Times taught MTH209	0.002	0.001	0.001	0.009**	-0.000				
	(0.001)	(0.001)	(0.005)	(0.004)	(0.001)				
Years since first hire date	0.002	-0.005	0.019	0.038	0.023				
	(0.016)	(0.016)	(0.048)	(0.056)	(0.016)				
First hire more than one year ago	0.017	0.017	0.084***	-0.001	0.0014				
	(0.012)	(0.012)	(0.032)	(0.033)	(0.011)				

Table 3.10: Correlates of Instructor Effectiveness

Notes: Section mean residuals are regressed on teaching experience, instructor fixed effects, and year and month fixed effects. Sample restricted to 18,409 sections (5970 for test scores) taught by instructors hired since 2002. First stage model include instructor, campus, year, and month fixed effects in addition to individual controls, section average controls, and ZIP code controls. Residuals are taken with respect to all these variables other than instructor fixed effects. Individual controls include male, age, incoming GPA, incoming credits, indicator for repeat MTH208, number of times taking MTH208, 12 program dummies, years since started program. Section average controls include the unemployment rate, median family income, percent of families below poverty line, percent of adults with BA degree in ZIP code from 2004-2007 ACS (plus missing ZIP). Students who did not enroll in MTH209 were assigned a zero (failing) and students that did not possess a test score for 208 or 209 were assigned the 10th percentile of the test score from their 208 section. Robust standard errors clustered by instructor in parentheses. First stage model with full controls. All sections, faculty hired since 2002.

	Outcome: Total Salary Paid for MTH208 Section (\$1,000) (mean=1.077)					
	(1)	(2)	(3)	(4)	(5)	
Section-level mean residual	-0.005	0.003	0.006	0.007	0.006	
for MTH209 grade	(0.006)	(0.005)	(0.005)	(0.004)	(0.004)	
Years since first hire date		0.030***	0.027***	0.044***	0.046^{***}	
		(0.001)	(0.001)	(0.004)	(0.004)	
First hire more than one year ago		0.010***	0.008**	0.006	0.005	
		(0.004)	(0.004)	(0.004)	(0.004)	
Total sections taught previously		0.001***	0.000***	0.000	· · · ·	
		(0.000)	(0.000)	(0.000)		
Taught MTH208 previously				. ,	0.002	
					(0.004)	
Times taught MTH208					-0.001**	
					(0.000)	
Times taught MTH209					0.000	
					(0.000)	
Times taught other math courses					-0.000	
					(0.000)	
Times taught nonmath courses					0.000	
					(0.000)	
Constant	1.038	0.919	0.907	0.953	0.951	
	(0.004)	(0.007)	(0.007)	(0.013)	(0.013)	
R-squared	0.265	0.536	0.565	0.713	0.714	
Fixed effects	None	None	Campus	Instructor	Instructor	

Table 3.11: Correlates of Instructor Salary

Notes: Sample restricted to 18,080 sections taught by instructors hired since 2002.All specifications also include year and month fixed effects. Section-level residuals include the full set of individual and section controls and campus fixed effects, imputing zero MTH209 grades for students that did not enroll. Robust standard errors clustered by instructor in parentheses. All sections, faculty hired since 2002.



Notes: Dashed lines denote 95% CI with standard errors clustered by instructor. Section mean residuals are regressed on MTH208 teaching experience (capped at 20), instructor fixed effects (bottom row), and year and month fixed effects. Sample restricted to 18,418 sections taught by instructors hired since 2002. First stage model includes full controls (see text).



Figure 3.2: Relationship between Instructor Effectiveness (Test Scores) and Teaching Experience

Notes: Dashed lines denote 95% CI with standard errors clustered by instructor. Section mean residuals are regressed on MTH208 teaching experience (capped at 20), instructor fixed effects (bottom row), and year and month fixed effects. Sample restricted to 18,418 sections taught by instructors hired since 2002. First stage model includes full controls (see text).

APPENDICES

APPENDIX A

Appendix to Quantifying Sources of Persistent Prescription Behavior: Evidence from Belgium

A.1 Institutional Setting

A.1.1 The Belgian Healthcare Market

The health care market in Belgium is financed through a withheld tax (at a rate of 13.07%) which applies to gross wages. This tax is used for health, disability, and unemployment insurance. Additional funds to finance shortfalls are earmarked and financed through specific taxes (e.g. tobacco taxes) or other financing means. The health care market is organized through a heavily regulated insurance market in which the Mandated Health Insurance is sold.

A.1.2 The Minimum Prescription Rate (MPR)

This section provides some additional descriptive numbers on the introduction of the MPR. Below is an overview of the average prescription rate of generics going back to 2004 which is based on data provided by the NIHDI in Belgium. The micro-data I employ is not

available going back to before 2004, but these data do provide some insight as to what the impact of the MPR was.



Figure A.1: Stylized Facts: Overall Prescription Rate 2000-2010

Notes: data used for this graph were provided by NIHDI, and plots the overal prescription rate of generics between 2000 and 2010.

Overall, the graph suggests that there is a steady increase in the use of generics (for instance, because of the arrival rate of generics as patents expire), but that this steady increase was relatively stable before the introduction of the MPR.

Finally, I also show a graph similar to Figure 1.4 but dividing the data into physicians in the top and bottom quartile of the baseline prescription rate of generics. Comparing these numbers to Figure 1.4 shows that physicians further from the threshold (e.g. bottom quartile) are much more likely to increase the prescription rate of generics in the wake of the policy mandate.

Figure A.2: Descriptive Graphs: Prescription and Switching Rate of Generics



(a) Chronic Starters: Top/Bottom Median

(b) Longstanding Switching: Top/Bottom Median

Notes: This data is a graph of the average prescription rate of generics for different types of patients (chronic starters and longstanding). I show the averages across physicians that are above/below the median (middle panel). Overall, the figures display a sudden increase upon announcement of the mandate, with physicians far from the threshold responding more.

A.1.3 Licensing of "Free Professions"

Practicing physicians in Belgium are subject to an employment regime of "free professions", a regime that refers to non-merchant occupations that perform intellectual or nonmanual labor services both for a direct customer and the society as a whole. Other examples of free professions include, among others, veteranarians, accountant, pharmacists, architects, nurses. For a more complete discussion on exact status definitions, see 2005/36/EG Directory of the European Parliament and the European Council. People with a medical degree might choose not to practice medicin and pursue other career paths that are not "free occupations" in diverse sectors. A notable exception is practicing physicians that are affiliated with universities and university hospitals: they are typically directly employed by the state and are therefore in paid employment, although they do need to fulfill licensing requirements. These physicians are typically specialists and not primary care physicians. Access to "free professions" is regulated through occupational licensing programs that operate in similar ways to similar programs in other countries in the European Union or the United States. Upon licensing, primary care physicians are typically self-employed in a solo-practice, or self-employed in a cooperative group practice.

A.1.4 Prescription Filling and Processing

The central document in this process is the prescription written out by a physician (see Figure 1.1 for an example). The bar code in the top left identifies the physician (who is forced to order his prescription books at a central provider who prints the bar code). The physician writes the specific product name in the field denoted by box 5 in Figure 1.1b. The patient then takes this prescription to a pharmacist who provides the drug as written on the prescription and scans the product barcode upon dispensing. Pharmacists in this period were required to follow the physician's prescription, although some changes to this procedure have been made. The patient then inserts their electronic health insurance cards (identifying their health insurance records) and pays for the prescription drug. Unless the prescription drug is a particular drug (e.g. because of cost) or the patient is on an increased reimbursement plan, the patient pays the full price. The patient then uses a "vignet" (akin to a sticker with identifying information on the patient) which is then submitted to their mutual fund who reimburses the patient.

Typically, a patient visits their physician to obtain a prescription. Prescriptions are valid for three months from the date of prescription (which is posted in box 8 in Figure 1.1b). It is possible for a physician to allow for this start date to be in the future, e.g. when the physician wants to provide a prescription in February and June while not requiring the patient to return. This future start date is denoted in box 9. However, physicians typically prefer patients to come back for a visit when needing a new prescription, as they receive only a fee for a visit (not for a prescription).

Prescriptions on INN (Active Ingredient)

There was a program that was introduced in 2005 at the time of the mandate that allowed physicians to prescribe on INN (International Nonproprietary Names). However, the fraction of prescription that used these was low (around 1-2%) and the take-up rate was the lowest among primary care physicians, for whom it was well below 1%. This program has become more popular in recent years though.

A.1.5 Pricing and Price changes

The Belgian healthcare system uses a reference pricing system (RPS) for prescription drugs, detailed in further detail in Appendix A.1.5, which was introduced in 2001 (Farfan-Portet et al., 2012; Cornelis, 2013).¹ An RPS consists of two elements. The first element is the set of clusters, or groups of prescription drugs that are considered equivalent from the perspective of the policymaker. Belgium has a "generic RPS" or an "RPS at the molecular level," where all drugs that have the exact same active ingredient (i.e. are bio-equivalent) form one cluster (Vrijens et al., 2010; Farfan-Portet et al., 2012).²

The second element is the Reference Price (RP), which is the maximum price manufacturers of generic drugs can charge within a cluster.³ The RPS then fixes the reimbursement within a cluster to be the RP multiplied by the copay rate. As a result, the insurer reimburses a fixed amount, regardless of the prescription decision. If a drug is priced above the RP, the difference between the price and this fixed reimbursement is therefore fully borne by the patient. Generics and branded drugs that charge the RP are considered "cheap", while

¹Similar systems are used in other countries. Dylst, Vulto and Simoens (2012), Simoens (2012) and Farfan-Portet et al. (2012) provide a more complete discussion on this system and differences across the countries that have implemented such systems.

 $^{^{2}}$ In contrast, therapeutic equivalence – defined at the ATC4 level – only requires drugs to treat similar conditions. Bio-equivalence implies that brand-name simvastatin Zocor would be in a cluster with generic simvastatins, but not atorvastatins (such as Lipitor or generic equivalents). All these drugs would be in the same cluster when using therapeutic equivalence.

³This reference price is based on a well-defined estimate of the production cost of the brand-name multisource drug.

multisource drugs that charge more than the RP are considered "expensive".⁴ Reference prices were decreased by four percent across all prescription drugs with generic competition in June 2005.⁵

Figure A.4 provides a graphical overview of how it works. The Reference Price is based on the "ex-factory" price, a well-defined estimate of the production cost of the brand-name drug.⁶ This price applies to the entire cluster and is used for calculating the levels of reimbursement and copay. The minimum level of copay is the Reference Price multiplied by the copay rate, the reimbursement amount for any drug in the cluster is the difference between the Reference Price and this minimum level of copay. For instance, if the copay rate is 25%, the reimbursement amount that the insurer pays for any drug in the cluster is $75\% \times \text{RP}$, while the copay for patients is $Price - 75\% \times RP$.⁷

As shortly touched on before, Reference Prices were decreased by four percent across all prescription drugs with generic competition in June 2005. This decreased the price level, both for generic and brand name drugs. However, under the influence of the mandate, there was an incentive for brand name drugs to decrease their prices further in order to fall under the mandate. Figure A.3a plots the coefficients of an event-study regression at the prescription drug level as in equation A.1.

$$\ln(P_{pt}) = \sum_{m=-M}^{M} \beta_m \mathbb{I}\{t - t^* = m\} + \xi_p + \varepsilon_{pt}$$
(A.1)

where t^* is June 2005 and ξ_p are product fixed effects. The coefficients β_m trace the dynamic path of prices around June 2005. I cluster standard errors at the manufacturer level and

⁴On-patent drugs are considered expensive.

⁵Appendix A.1.5 shows that the price gap between generic and brand name drugs remained constant. Nevertheless, certain brand name drugs did change status to cheap. As this appendix shows, most of these changes happened after the mandate was announced and were unexpected by physicians.

⁶This is not the price that was charged when the drug was on-patent, but is rather a cost estimate of manufacturing, transportation, packaging, and other factors. The Reference Price is typically set a certain percentage below the "ex-factory" price. See Vrijens et al. (2010) for more details.

⁷These copayment rates did not change over the sample period and therefore do not affect the empirical analysis. Drugs are only reimbursed for pre-specified uses, that do not necessarily include all possible uses mentioned in the prescription drug leaflet.

set M to 10. On-patent drugs did not change prices. Overall, these results suggest that the price gap between generic and brand name prescription drug remained fairly stable over the study period. Nevertheless, the *levels* of copays and reimbursements have changed by about four percent for generics and brand name drugs with generic competition. As a result, the *price gap* between both drug groups is relatively stable. Figure A.3b shows the average (smoothed) price gap between off-patent branded and generic prescription drugs, and we indeed find that the average price gap does exhibit some variation, but is not strongly affected by the introduction of the change in the Reference Pricing System.





Notes: Figure A.3a shows the regression coefficients β_m from regression equation A.1 for three distinct product groups: on-patent drugs (unaffected), branded off-patent drugs, and generic drugs. Figure A.3b shows the smoothed copay differential between branded off-patent and generic prescription drugs at the product group level (as defined in table 1.1). These numbers are smoothed and show some variation over tim, but no systematic change in the effect of the mandate.

The limited effect of the changes in the RP system are supported in Figure A.3b, that plots the differential between the price of brand name and generic drugs for selected main product groups. Most price changes at the product group level are within a two to four percent change, and are therefore relatively small. This graph was computed as follows: the average price of generic and brand name products is computed at the level of the active
ingredient. Then, to purge the data of level differences, I regress these price differences on an active ingredient fixed effect and compute the average price differential for each product group in each month. Figure A.3b presents the Lowess-smoothed version of these differences.



Figure A.4: Determination of Status Prescription Drug.

Copay for Patient: Price - Cluster Reimbursement

A.2 Data

The flow of the data collection is shown graphically in Figure A.5. The source of the data is the pharmacy, where the prescription and patient health care card are read and provide information on the physician and patient identifier are recovered. The pharmacy then sells the prescription drug and scans the product's bar code upon dispensing. The copay is directly identified (and stored) when the patient inserts their health care. As a result, if a patient does not fill out the slip and recover the reimbursement, this is not in the data.

After the prescription is read in at the pharmacy, the data are then uploaded and made available to a billing service provider, who aggregates and delivers this data to the relevant mutual fund on a quarterly basis.⁸ These data are heavily scrutinized and reviewed for quality and accuracy at all steps in this process. For instance, certain checks on the copay and reimbursement are made. The mutual funds receive the verified data and reimburse their patients. As these mutual funds still need to reimburse, these mutual funds have access to patient identifiers.

In a final step, these data are shared with the NIHDI, who use it for risk-adjustment formulas and reimbursement of the mutual funds. While information is still at the patient-level, mutual funds anonymize the data before sending them along to NIHDI as NIHDI in principle does not require knowledge of patients' identities to reimburse mutual funds. Physician identifiers still uniquely identify physicians for the NIHDI, as they use this information to provide feedback reports to physicians and use this for general follow-up and control.

As noted in Figure A.5, the different mutual funds have also organized themselves to create the InterMutualistic Agency (IMA) where patient identifiers are still available and used for research purposes. As a result, this graph provides a clear overview of the data I use (and the advantages of this data).

⁸The pharmacist can choose among licensed billing service providers that are approved by the NIHDI.

Figure A.5: Processing and collection flow of the data



A.2.1 Sample selection NIHDI.

I drop transactions for which a negative DDD is recorded, as this is indicative of data error (10,860 observations or 0.025 percent of the sample). Additionally, I drop transactions referring to prescription drugs that have ATC codes starting either with "A02" (acid reflux medication) or "G" (mostly birth control pills), since administrative reporting for these prescription drugs was not consistent throughout. However, results are robust to keeping these groups in the sample. These transactions represent about 8.56 percent of the original sample. I drop all transactions in 2009 (representing 7,000,844 observations or about 18 percent of the remaining sample) as an increase in the MPR was announced for 2010. Finally, observations with negative prices (61 or 0.0001 percent of the remaining sample) are dropped. The final sample consists of 31,775,509 transactions.

A.2.2 Sample selection IMA.

The IMA dataset consist of 25,449,736 transactions covering about 152,589 patients and 44,872 physicians, of which 300 physicians form the "core" sample for whom I have the full transaction history for all patients over 35 years old. I drop transactions where the physician prescribes a preparation made by a pharmacist rather than a manufactured prescription drug (N=1,173,648 or 4.6%), prescription drugs for which no product information is available (N=283,073 or 1.2%) and transactions for which the patient ID could not be linked to the census information (N=9,728 or 0.04%). This yields 23,983,287 transactions, that reduces to a sample of 6,440,115 when I focus on the core sample of 300 physicians.

For starters, I also exclude product groups for which a generic was not yet introduced. This is primarily analeptics (ATC code N06) and Calcium Channel blockers (C08). They both go off-patent in July 2004, and are then added in to the sample.

A.2.3 Market Descriptives.

I first use the NIHDI to provide an overview of several market characteristics. It is not necessary to differentiate between chronic starters and longstanding patients in the sections below, and – being a 10% random sample of physicians – the NIHDI dataset provides a better overview of the market. Figure A.6 provides information about the market for prescription drugs in Belgium over the sample period, with panel A.6a providing prescription shares of the different product groups over time: the prescription shares of the main product groups have stayed relatively constant over time. Panel A.6b displays the growth (measured in DDD) of the different product groups, normalized to be one in the first month of the sample period (January 2004). This picture higlights that there is a steady growth in some of the product groups, and the MPR and other policy interventions do not seem to have altered growth rates of prescription volume.

In a second step, I discuss the market for active ingredients. I first describe the extent to which an active ingredient is dispensed in different administration methods. Figure A.7 describes this in larger detail. The histogram reports the number of administration methods (at the active ingredient level) on the horizontal axis, and reports the share of active ingredients on the vertical axis. Taking a look at unweighted data, about 75% of products have one single administration method, and about 20% have at most 2. As a result, most products are dominated by a single administration method. When adjusting for the number of daily doses that are being prescribed, this number becomes even more stark. About 99% of active ingredients are then dominated by a single administration method. Those active ingredients for which more than one administration method can be found is typically in the Antirheumatics class (results not reported).

In a third step, I investigate the number of manufacturers that dominate the market at the active ingredient level. The histogram in Figure A.8 shows the extent to which the larger manufacturers dominate the (generic) market. The horizontal axis shows the rank of the manufacturer according to market size (for the generic prescriptions being sold). In other words, the leftmost bin reports the average market share for the largest generic manufacturers. The number of manufacturers can be relatively large. There are some generic markets with up to eleven competitors. However, the market is largely captured by the larger manufacturers. Especially when weighing by quantity, the top two generic manufacturers typically account for about 85 to 90% of the generic market.

A.2.4 Sample Selection and Definitions

In order to answer the research questions in this research paper, it is necessary to distinguish between, on the one hand, non-chronic and chronic drugs, and, on the other hand, starters and longstanding patients. Figure A.9 shows how I do this. I start 6.5 million transactions written by my core sample of 300 physicians (the 4.1 million refers to the sample when restricting my sample to data points between 2004 and 2007). I divide the chronic and non-chronic drugs as decribed in the main paper. I then define starters as those patients who were prescribed their first prescription less than 90 days ago. I define starters at the active ingredient level. To be more specific, a patient who switched from astorvastatin to simvastatin is defined as a new patient. This is a reasonable definition, as a central concern in the paper is whether a patient may be confused when being switching at the active ingredient level. However, the results are robust to changing this to the therapeutic level.

The figure clearly highlights the censoring problem I encounter in January 2004. Therefore, I only start defining chronic starters starter 1 April 2004. All patient prescriptions noted before this date are defined at chronic longstanding. I motivate this cut-off by looking at the arrival rate of chronic starters, displayed in Figure A.9b. Changing the cut-off from 90 to 60 (or 120) days does not substantially affect the results in my papers (results not displayed).

When a patient is prescribed an active ingredient more than 3 months ago, the patient moves from the green field to the orange field. As a result, including longstanding patients whose initial choice was affected by the mandate (the grey field in the figure) may lead to a misinterpretation on the probability that a longstanding patient is switched. Therefore, these observations are discarded from the sample. Finally, these issues do not arise when looking at non-chronic drugs, therefore the full sample of these drugs can simply be retained.

Figure A.6: Market for Product Groups in Belgium

(a) Market share for product groups over time (measured in DDD).



Market Share of Different Product Groups

(b) Index of Market demand for product groups over time (measured in DDD).



Notes: Author's calculations from NIHDI data sample using product group definitions in table 1.1.



Figure A.7: Dominance of Administration Method at Active Ingredient Level

Notes: Author's calculations from NIHDI data sample

Figure A.8: Dominance of Administration Method at Active Ingredient Level



Notes: Author's calculations from NIHDI data sample

Figure A.9: Definition of Starters and Longstanding Patients



(a) Sampling Scheme

(b) Distribution of First Day Since Prescribed Within Product Group



A.3 Additional Descriptives and Reduced Form Evidence

A.3.1 Additional Descriptives

This section describes several key features of the prescription behavior of physicians in 2004 (before the mandate was announced). The data reveal substantial variation in the fraction of generics a physician prescribes, as highlighted in Figure 1.3. As often documented in this literature, differences in patient characteristics or disease profiles do not explain this variation in prescription behavior. Table A.1 statistically tests for differences in patient composition across high and low prescribers and documents that there are no statistically significant or economically meaningful differences in patient mix across these two physician types.

It is possible that physicians face patients with similar demographics, but different disease profiles. If the availability of generics differs across health conditions, the patient mix a physician sees could explain differences in prescription behavior. In order to investigate this, I group active ingredients into larger product groups that represent large, salient prescription drug groups. Table 1.1 provides an overview. These are typically dominated by one or two active ingredients for which a generic is available (e.g. amlodipine for Calcium Channel Blockers). The aggregation therefore mostly has the advantage that it groups several smaller active ingredients that are prescribed infrequently, while indicating the prescription behavior of physicians across larger, more important active ingredients.

Figure A.10 plots the market share of different product groups (y axis) in relation to the physicians baseline prescription ranking (x axis). The fraction of prescription drugs physicians write within product groups are remarkably stable across this ranking. Differences in the availability of generics across product groups are therefore unlikely to explain the differences in prescription rates of generics.

In order to test whether physicians consistently prescribe brand name across different active ingredients, I zoom in on the prescription behavior of physicians across different product groups. For each physician, I compute the 2004 generic prescription rate within a product group, and then investigate the correlation of these prescription rates across product groups.⁹ A correlation coefficient close to one suggests that physicians whose prescription rate of generics is above the average in one product group, are likely to prescribe above the average prescription rate in the other product group. A correlation coefficient close to zero suggests prescribing an above-average fraction of generics is not predictive of the physician's prescription behavior in the other product group. Figure A.11 reports this information through a heatmap, where fields in the color yellow denote correlations closer to one, and fields in the color dark blue denote correlations closer to zero (or negative). The correlation coefficients across product groups are typically positive, and range from 0.2 to 0.4, with some values up to 0.5. The overall picture that emerges is one where the prescription rate of generics in one product group is somewhat predictive of the behavior in another group. The correlations, however, are not suggestive of clear high-prescribing and low-prescribing physicians.

⁹In order to focus on the choice between an off-patent brand name drug and a generic, I compute these correlations only for active ingredients where a generic was available. In particular, I focus on active ingredients for which generics were available before the announcement of the mandate percentage in June 2005.

	BASELINE		TOP VS.		TOP VS.	
			Воттом		Воттом	
	FRACT	ΓION	Med	IAN	Quar	TILE
	(1)	(2)	(3)	(4)	(5)	(6)
Intercept	0.205***	0.202***	0.586***	0.551***	0.543***	0.506***
	(0.005)	(0.004)	(0.051)	(0.043)	(0.064)	(0.057)
Increased	0.001	0.001	-0.006	-0.006	-0.008	-0.008
Reimbursement	(0.002)	(0.002)	(0.014)	(0.014)	(0.018)	(0.018)
Female	-0.001	-0.001	-0.010	-0.010	-0.016	-0.016
	(0.001)	(0.001)	(0.009)	(0.008)	(0.011)	(0.011)
Starter	0.001	0.001	0.006	0.005	0.011	0.011
	(0.002)	(0.001)	(0.013)	(0.012)	(0.017)	(0.017)
Age (in 2004)	0.000		0.000		0.000	
	(0.000)		(0.001)		(0.001)	
Polypharmacy (in 2004)	0.000		-0.001		-0.002	
	(0.000)		(0.003)		(0.004)	
Age (in 2004)						
$\in [35, 50)$		0.002		0.018		0.023
		(0.003)		(0.028)		(0.036)
$\in [50, 60)$		0.000		0.006		-0.001
		(0.002)		(0.022)		(0.029)
$\in [60, 70)$		0.002		0.009		0.017
		(0.002)		(0.018)		(0.024)
$\in [70, 80)$		0.001		0.011		0.007
		(0.002)		(0.015)		(0.019)
Polypharmacy (in 2004)						
0		0.001		0.025		0.006
		(0.003)		(0.025)		(0.034)
1 - 2		0.000		0.005		0.004
		(0.003)		(0.022)		(0.029)
3 - 4		-0.001		0.000		-0.007
		(0.002)		(0.017)		(0.024)
5 - 6		-0.002		0.013		-0.011
		(0.002)		(0.017)		(0.023)
Ν	466,843	466,843	466,843	466,843	275,927	$275,\!927$
N Clusters	300	300	300	300	300	300

Table A.1: Balance of Patients

Notes: *** p < 0.01, ** p < 0.05, * p < 0.1. The dependent variable for these regression is the prescription of cheap drugs in 2004 (Columns 1 and 2), whether the physician is in the top (1) or bottom (0) median of cheap prescribers in 2004 (Columns 3 and 4), and whether the physician is in the top (1) or bottom (0) quartile of cheap prescribers in 2004 (Columns 5 and 6). The analysis sample restricts attention to cases where a generic is available. Standard errors are clustered at the physician level.

Figure A.10: Fraction of Product Group Prescription as a function of Baseline Prescription (in deciles)



Notes: This graph shows the prescription shares of 11 different product groups (as defined in table 1.1 in order to aggregate active ingredients and facilitate interpretation). The x-axis ranks physician by baseline prescription rate from lowest quintile (left) to highest quintile (right). The figure shows that physicians at different quintiles have patients with similar disease profiles.



Figure A.11: Within-Physician Correlations of Generic Prescription Rates across Product Groups

Notes: This graph uses NIHDI data to calculate the prescription rate of generics for the major active ingredients highlighted across 10 product groups (as shown in table 1.1). I then compute the correlation of this prescription rate across product groups. A high and positive correlation therefore indicates that a physician that prescribes a high share of generics is also very likely to prescribe a high share of generics in other product groups. A near-zero correlation suggests the prescription behavior of a physician for one product group is not predictive of its behavior in another product group.

A.3.2 Distribution and Change in Prescription Rates

While the distribution before 2004 cannot be plotted, Appendix A.3.1 plots the average prescription rate of generics and shows the prescription behavior of physicians is relatively stable. Figure A.12 shows a smoothed histogram of the prescription rate of generics for active ingredients for which a generic was available, both before and after the announcement of the mandate. The prescription rates are computed at the physician by product group level (as defined above), and weighted by daily doses. First, the histogram highlights that very few physicians prescribe exclusively brand name or generic prescription drugs even within product groups, but rather prescribe a mixture of both generics and brand name drugs (both before and after the announcement of the mandate). Second, the histogram shows an overall increase in the prescription rate of generics, with a particularly change at low generic prescription rates; in line with the objectives of the mandate, there is a stark decrease in physicians prescribing shares of generics within product groups below 20 percent.

Figure A.12: Kernel Density of Generic Prescription Rate (Physician by Product Group Level)



Notes: This graph uses IMA data and bins the average prescription rate of a physician by product group combination, both before and after the announcement of the mandate. The "before" graph shows that physicians tend to mix within product groups, and do not simply prescribe only generics or only brand name drugs (5% of physician by product group combinations do prescribe a zero share). The "after" graph shows a clear increase in the use of generics, particularly in the bottom, that pushes the histogram towards generics. However, there is still no clear bunching on either extremes.

A.3.3 Robustness Checks

Non-Chronic Drugs and Flexible controls. Prescriptions for non-chronic drugs serve as a reasonable robustness check for the physician response to chronic starters. Switching costs do not apply to non-chronic drug users, and therefore physicians are likely to treat these patients as chronic starters. The figures below indeed confirm that the response for non-chronic drugs mirrors that of chronic starters. Additionally, including additional flexible controls for demographics does not substantially change the results.

Physician Biases. The results below in Figure A.13 show that including physician by therapeutic class essentially leads to the same results as those presented in the paper. Using product group fixed effects, however, leads to estimates that are similar in direction, but are somewhat different in magnitude. For completeness, the regression coefficients (excluding the β coefficients) are list in table A.2.

	Chronic Starters			Chronic Longstanding			
	(1)	(2)	(3)	(4)	(5)	(6)	
Copay Differential	-0.034	0.117	-0.21	0.005	0.008	-0.004	
	(0.016)	(0.019)	(0.018)	(0.002)	(0.003)	(0.003)	
Increased Reimbursement (IR)	-0.013	-0.012	-0.011	-0.004	-0.004	-0.003	
	(0.004)	(0.004)	(0.004)	(0.001)	(0.001)	(0.001)	
Copay Differential $\times IR$	0.028	0.042	-0.021	0.009	0.012	-0.001	
	(0.016)	(0.017)	(0.018)	(0.004)	(0.003)	(0.003)	
Female	0.002	0	0.002	0	0	0	
	(0.003)	(0.003)	(0.003)	(0.001)	(0.001)	(0.001)	
$\operatorname{Generic}_{t-1}$				0.876	0.901	0.92	
				(0.004)	(0.004)	(0.003)	
Ν	$242,\!019$	$242,\!019$	$242,\!019$	951,707	951,707	951,707	
N Clusters	300	300	300	300	300	300	
Physician \times Chemical FE	Х	Х	Х	Х	Х	Х	

Table A.2: Robustness Checks Level of Fixed Effects

Notes: Coefficients are estimated using the strategy discussed in section 1.5.4.3.

Figure A.13: Descriptive Graphs: Prescription and Switching Rate of Generics

- (a) Chronic Starters: Active Ingredient
- (b) Longstanding Switching: Active Ingredient



Event Study Coefficient for Chronic Drugs (Chronic Starters)

A.3.4 Physician Shopping

This section investigates whether patients respond to the mandate by "shopping" for physicians who are willing to prescribe brand name drugs despite the mandate. As patients take, on average, 3 to 4 chronic prescription drugs, it might actually be costly for them to switch physicians when they are switched on one specific drug (as it risks changes in the other drugs the patient takes). Additionally, patients tend to prioritize convenience when choosing providers (e.g. distance). However, they might also consider provider personality or practice style. Even though brand awareness is low and patients may not necessarily select physicians they see according to the number of generics they prescribe, these prescription patterns might be correlated with the physician's personality traits that matter to patients. As a result, this section investigates in more detail whether physician shopping is a concern.

Figure A.14 plots the probability that a patient sees a different physician from the one they saw during their previous visit. Overall, there is a reasonably high amount of switching, as patients regularly see a physician on call or when their regular physician is on holiday (with clear bumps in the summer months). However, we see no evidence of physician shopping: patients of high prescribers are not less likely to switch in the aftermath of the policy mandate and vice versa. As a result, this does not point to evidence of physician shopping in response to the mandate.

I also test this concern in a regression framework. If patients resort to physician shopping, I expect to uncover two patterns in the data. First, longstanding patients who visit a low prescriber are likely to switch. Second, starters are now more likely to look for a high prescriber if they prefer receiving brand name drugs. As a result, we expect high prescribers to see an increase in the fraction of starters after the policy mandate goes into effect – especially since physicians primarily change their habits for starters.

The regression results in Table A.3 below show that there is no evidence of physician shopping the data. Column 1 highlights that physician close to the threshold (above the median of the 2004 generic prescription rate distribution) are not more likely to see starters





Notes: This graph plots the probability (at the prescription level) that a patient's current prescription is written by a physician that did not write the patient's previous prescription.

than physicians far from the threshold. Column 2 shows that longstanding patients visiting physicians far from the threshold (as defined in Column 1) exhibit no increase in switching physicians compared to those visiting physicians close to the threshold.

	(1)	(2)
Post imes High	$0.0056 \\ (0.0057)$	0.0010 (0.0007)
N N Clusters Physician × Chemical FE	1,188,993 300 X	889,829 300 X
Controls	Post, High	$Post, High, \\ Generic_{t-1}$

Table A.3: Robustness Checks Level of Fixed Effects

Notes: Column 1 reports the coefficients of a regression in which a binary indicator of whether the prescription was written for a starter is regressed on physician by chemical fixed effects, a post indicator (taking on value 1 in months after June 2005), an indicator for whether the physician is a high prescriber or not, and an interaction between these two indicators. Column 2 reports the coefficients of a regression in which a binary indicator taking on value one if a patient sees a different physician between prescriptions is regressed on the same two indicators and interaction used in the regression in Column 1. Additionally, the lagged generic choice is also used as a control.

A.3.5 Robustness Checks to Quality of Dispensed Drugs

Some additional robustness checks regarding the quality of drugs being dispensed are posted below. I use an empirical strategy that is similar in spirit to equation 1.2, but uses several different outcomes. There are a couple of concerns beyond the use of on-patent drugs. At the active ingredient level, manufacturers have introduced prescription drugs that release the active ingredients in more gradual ways (also known as "extended release" formulations), there may be differences in the potency of drugs that are being prescribed. Additionally, changes in the administration method may matter as they may affect the extent, speed or quality with which the active ingredient is absorbed. Finally, there is a certain class of drugs for which small changes in dosis or small differences in how the body absorbs the active ingredient can have severe consequences in effectiveness or side effects. These drugs are typically referred to as Narrow Therapeutic Index drugs, with Warfarin being a particularly famous example.

The graphs in Figure A.15 below show event study coefficients for four key outcome variables for chronic starters. The graph in panel Figure A.15a shows that the prescription rate of extended release formulations does not change over the sample period. The graph in panel Figure A.15b shows that the potency of drugs was not affected by the announcement or the introduction of the policy mandate. The graph in panel Figure A.15d shows active ingredients are typically dominated by one single administration method, and, therefore, changes in administration method are only a minimal worry. The graph in panel Figure A.15c shows, similarly, that the use of NTI drugs was not substantially affected by the introduction of the policy mandate. The coefficients are listed in table A.4.

A.3.6 Robustness Checks to Effect of Switching Prescription Drugs on Medication Adherence.

This section gathers some additional evidence on the effect of switching a patient's prescription drugs on his or her medication adherence. Table 1.6 collects several results that

	Chronic Starters		Chronic Longstandi	
	(1)	(2)	(3)	(4)
Copay Differential	0.007	0.015	0.007	0.015
	(0.007)	(0.010)	(0.007)	(0.010)
Increased Reimbursement (IR)	0.001	-0.003	0.001	-0.003
	(0.001)	(0.005)	(0.001)	(0.005)
Copay Differential $\times IR$	-0.026	-0.001	-0.026	-0.001
	(0.010)	(0.018)	(0.010)	(0.018)
Female	-0.002	-0.035	-0.002	-0.035
	(0.001)	(0.004)	(0.001)	(0.004)
Ν	242,019	$242,\!019$	$242,\!019$	242,019
N Clusters	300	300	300	300
Physician \times Chemical FE	X	Х	Х	Х

Table A.4: Robustness Checks Quality Dispensed Drugs

2

Ξ

Notes: Coefficients are estimated using the strategy discussed in section 1.5.4.3.

strengthen the interpretation of the IV results discussed in the paper. I focus on the full sample, exploiting differences between physicians with a baseline prescription rate above or below the median of the distribution of baseline generic prescription rates.

Column 1 repeats the exercise of the Instrumental Variable strategy in the text, but estimates the causal effect of switching on medication adherence *before* being switched. This addresses the concern that the effect might be spurious, or that the switching is driven by a change in medication adherence. As the results show, switching has no effect on pre-switch adherence.

Another concern is that the medication adherence results are the result of patients that have hoarded prescription drugs in the past. Patients may exhibit poor medication adherence and therefore have multiple prescription drug doses at home. Upon being switched, they first decide to use up this stock of prescription drugs before filling their generic prescription drugs (either because they do not like the switch or suddenly realize they have a stock of prescription drugs at home). This would imply that the use of prescription drugs does not actually change, but that patients substitute to using a stock of prescription drugs they have



(a) Extended Release drugs

(b) Potency Prescribed



at home. While this results in a decrease in measured medication adherence, there is no change in "actual" medication adherence.

Column 2 and 3 address this concern by splitting the data into patients that exhibited high levels of medication adherence (Column 2) and patients that exhibited low levels of medication adherence before the introduction of the mandate (Column 3). Patients that exhibit low levels of medication adherence are likely to have stocks of prescription drugs lying around at home, while those who exhibit high levels of medication adherence are unlikely to have a large stock of prescription drugs at home. As a result, if hoarding is driving the IV estimates, I expect to find that a change in prescription drugs primarily changes medication adherence for patients exhibiting low levels of medication adherence.

Column 2 and 3 show that the point estimate of the effect of switching a patient's

prescription drug is indeed somewhat larger for patients exhibiting a low level of medication adherence, but that, by an large, the effect is fairly similar. These findings therefore suggest that the evidence for hoarding as the primary driver of changes in medication adherence is small.

	IV	IV	IV
	(1)	(2)	(3)
Dep. Variable	<u>Adherence_{t-1}</u>	$\underline{Adherence_t}$	
Switch	$0.020 \\ (0.160)$	-0.209^{*} (0.112)	-0.266^{***} (0.066)
Robust 1st Stage F- test	205.64	24.77	41.47
Ν	514,316	$515,\!409$	310,040
N Cluster	293	294	296
Controls	Х	Х	Х
Month \times ATC FE	Х	Х	Х

Table A.5: The effect of switching a patient on medication adherence

Notes: *** p < 0.01, ** p < 0.05, * p < 0.1. Instruments in column 1 through 3 are Low Prescriber × Post and Lagged Choice × Post. Patient-level controls are gender, whether the patient receives an increased reimbursement, and whether the patient received a generic at the previous visit. Baseline controls for the instruments (whether the patient sees a high or low prescriber, and lagged choice interacted with low prescriber) are also included. Month by active ingredient fixed effects are added to control for idiosyncratic time shocks to overall adherence. Standard errors are clustered at the patient level.

A.3.7 Robustness Checks to Patient Heterogeneity

The graphical results highlight that older patients using multiple prescription drugs are less likely to be switched. As these are risk factors for confusion and possible drug-drug interactions, these results line up with the results in Table 1.7.

Overall, Column 1 and 2 suggest the prescription rate increases by about 7 and 1.5 percentage points for chronic starters and longstanding patients respectively, similar to the

results documented in section 1.4.1. Interacting $L_{jpt} \times Post_t$ with different demographic characteristics of the patient provides a useful framework to investigate which patient observables predict which longstanding patients are switched at higher or lower rates.

First, I investigate whether whether the duration of use is an important predictor of longstanding patients being switched. One may, for instance, hypothesize that patients exhibit brand loyalty to the specific prescription drug they use, especially since boxes in Belgium differ across brand name and generic drugs. Column 3 in Table 1.7 provides the results from a formal test of this hypothesis by comparing the switching rate of patients that have been "longstanding" for only a couple of months to those that have been for at least a year. In particular, I compare patients that started using prescription drugs in a therapeutic class in the year between April 2004 and April 2005 ("recent longstanding") and patients that were using a prescription drug within a therapeutic class at least since April 2004 ("legacy longstanding").¹⁰ The coefficient estimate on the interaction term suggest that recent longstanding patients. However, the effect is rather small, especially comparing the effect size between starters and longstanding patients. Therefore, the results suggest that there is an immediate lock-in effect.

Second, I investigate whether this immediate lock-in effect could result from risks of confusing patients or adverse interactions with other prescription drugs. Patients that take multiple prescription drugs might experience negative interactions between different active or inactive ingredients when a prescription drug is changed, or might get confused more easily when one (or multiple) prescription drugs change appearance. Older patients might also get confused more easily when prescription drugs change appearance, especially if it is used to follow their treatment plan. In particular, I investigate whether a patient's age or

¹⁰I use April 2005 as cut-off since these patients are "longstanding" by the time the mandate is announced. The April 2004 cut-off is a natural result of the censoring inherent in my dataset. This censoring makes it impossible to contrast patients that have been longstanding for at least 2 years to those who have been at least 3 years. However, the small differences between the longstanding patients of less than a year to those of more than a year alleviates those concerns substantially.

polypharmacy profile (ie. the number of prescription drugs the patient takes on a regular basis) recorded in 2004 predict the probability of a longstanding patient being switched. Columns 4 and 5 in Table 1.7 indeed uncover differences in switching rates that are consistent with these hypotheses. Older patient cohorts are less likely to be switched compared to younger patient cohorts: a longstanding patient in their forties or fifties in 2004 is about 50% more likely to be switched than a patient in their eighties in 2004. More strikingly, patients that had no history of polypharmacy were about twice as likely to be switched than a longstanding patient taking five or more drugs on a regular basis.

A.3.8 Machine Learning Algorithm

Equation A.2 provides a simple framework to think about how to predict the change in switching from brand name drugs to generic drugs. The change in probability that patient j is switched from a branded to a generic version of prescription drug p at time t is set up as a function of patient characteristics x_{jpt} , without imposing a predefined functional form on f(.).

$$\Delta Switch_{jpt} = f(x_{jpt}) \tag{A.2}$$

It is possible to parameterize this with functional forms, as I did in the previous section, or to use more flexible feature selection or machine learning methods to see which variables predict switching. I pursue the second strategy in this section. Details of regression tree and random forest algorithms are provided in A.3.8.

Regression Tree. Regression trees use a single decision tree to predict who is switched, but the statistics package made available by the data provider does not apply regression trees on the change in an outcome variable. Therefore, I compute switching rates before and after the mandate and bin these by age, gender polypharmacy, type of longstanding patient (recent or long) and whether the patient is on an increased reimbursement scheme or not. As this is now a continuous rather than a binary measure, it is necessary to use a regression tree rather than a decision tree model.

Random Forest. Random Forests allow for the flexible approach of decision trees, but minimize the risk of overfitting the data. They do so by allowing for multiple regression or decision trees, and then average out over the different predictions to get a final prediction. The upside of this method is that it is more robust, but the downside is there is no clear deicision rule that can be backed out. I use the methodology proposed by Su et al (2009) and Radcliffe and Surry (2011) to see how variable predict the change in the probability of being switched in response to the mandate announcement.

The random forest algorithm builds on the Random Forest literature going back to

Breiman (2001). The uplift algorithm used in this paper builds on algorithms proposed in Su et al. (2009) and Radcliffe and Surry (2011). In this algorithm, the training data is used to both generate the trees and estimate the uplift inside the different leaves. This differentiates this approach from the "honest" sampling approach as proposed in Athey and Imbens (2016) and Athey et al. (2019). In this sampling approach, the training data is split into a sample that generates the trees, and a separate sample where the uplift of different leaves is estimated. This has the added value that confidence intervals on the uplift can be computed, which is not possible with the algorithm proposed here. As the machine learning algorithm in this paper is mostly a robustness check, the uplift algorithm is sufficient for these purposes.

Once the trees have been generated, the selection of which decision rules to retain build on the selection rule in Radcliffe and Surry (2011). In essence, at each possible split, the following interaction regression is run.

$$Generic_{ijpt} = \alpha + \beta Post_t + \gamma Up_{jpt} + \eta Post_t \times Up_{jpt}$$
(A.3)

In this regression $Generic_{ijpt}$ is an indicator taking on value 1 if a generic is prescribed and value 0 if not. The indicator $Post_t$ takes on value 1 after the mandate is announced, and 0 before. Finally, Up_{jpt} is an indicator variable indicating that splits the observations at a certain node (e.g. patients over 55 years old against those younger than 55 years old). These splits were randomly created during the first step of the random forest, so the goal of these regressions is to retain those splits where the predictive power of the split is sufficiently high. As a result, those splits where the parameter η has a (absolute value of the) t-stat that is sufficiently large will be retained. Further details regarding the specific outcomes in this paper are to be added.

Table A.6 provides an overview of the results. Whereas the magnitudes of the numbers are not comparable across methods, a higher number suggests a variable is more important for predicting the outcome of interest. The results from both the regression tree and random forests model confirm the more parametric results from the previous section. In particular, a patient's polypharmacy levels and age are important features that predict whether a physician will switch them from a brand name to a generic prescription drug. Whether the patient is a recent switcher or not is not that important and carries about the same weight as the gender of a patient, and is less important than whether a patient receives an increased reimbursement rate.

	(1)	(2)	(3)
	Δ Generic Switch	Generic Switch	
	Regression Tree	Random Forest	
	Variable Importance (Higher is more Informativ		
	2.100	2 1 2 2	
Polypharmacy	3.139	2,102	2,076
Age	4.369	$1,\!673$	4,608
Recent Switcher	1.952	686	649
Increased Reimburse-	1.533	725	918
ment			
Female	2.116	593	$1,\!436$
Days Unemployed			1,366
(2004)			
Days Unable to work			706
(2004)			
Days Disabled (2004)			702
. ,			
Ν	$15,\!697$	1,059,820	1,059,820

Table A.6: Predicting Generic Switching Using Feature Selection Methods

Notes: The results in column 1 of this table are based on binned regression tree methods, where variables are binned as described in section 1.4.5. The outcome in column 1 is the change in the switching rate from brand name to generic drugs and the model is a regression tree. Variable importance is measured using the outcome "Variable Importance" (higher is more predictive). The results in column 2 through 4 of this table use the sample of prescription drugs dispensed for longstanding patients. The model is an random forest with uplift (Radcliffe and Surry, 2011). This model predicts which characteristics predict a change in the outcome variable for some treatment, which in my setting is the announcement of the mandate ($Post_t = 1$ or 0.). Variable importance here is measured by the number of decisions rules over the different trees (higher is more predictive).

APPENDIX B

Appendix to Fairness Considerations in Wage Setting: Evidence from Domestic Outsourcing Events in Germany

B.1 Data Processing

B.1.1 Data Creation and Variable Construction

I draw on two main datasets. In a first step, I collect the relevant survey responses from the Betriebspanel data files over the different years and save the yearly survey datasets. The specific survey questions are discussed in subsection 3 of this appendix section. In a second step, I read in establishment-level LIAB data for every year, with detailed information. I drop observations for which there is a missing establishment or person identifier, and restrict the sample to include only people ages 20 to 60 years old. At this point, I define parttime workers and drop wages that fall above the top coding limit in any given year and perform the data imputation method, discussed in subsection 2 of this appendix section. After imputing these wages, I save a worker-level file with information on the employment and demographics of the worker, and then collapse this file to an establishment-level file. I merge the survey responses to these establishment level files. In a third step, I append all the worker-level datasets and establishment level datasets in order to obtain the panel structure. The establishment level dataset is used to define the outsourcing events, therefore they contain information on total number of workers in the different occupations, and other necessary variables that enable me to create outsourcing event indicators. Two variables need special attention:

- Education: Originally, the education variable takes on seven values: middle school

 middle school with a vocational degree (2), high school (3), high school with a vocational degree (4), technical university (5), university (6), and missing (.z). I combine
 middle school and high school (1 and 3) as the number of people with high school de grees was very small for certain outsourcing events, and overall in the workforce. This
 was problematic both for data review of summary statistics and estimation purposes.
- 2. **Part-time**: The part-time indicator is based off of the **stib** variable. Workers are coded as working part-time when this variable takes on value 8 or 9, as is the standard when working with this data.

B.1.2 Imputation

As mentioned in the text, I follow standard imputation techniques closely, but not exactly: I miss two variables that Card, Heining and Kline (2013) use in their imputation method. The imputation algorithm is as follows. I first divide the age variable into 4 age bins (20-30 years; 31-40 year; 41-50 years; 51-60 years). I then run several tobit specifications within each year for all year, gender, education group, part-time, and age bin combinations. This yields $23 \times 2 \times 7 \times 2 \times 4 = 2,576$ separate tobit models. The variable in the tobit models are: age, the fraction of censored wages in the establishment of employment, an indicator whether the establishment employs more than 10 people, an indicator whether the establishment is a oneperson establishment, the fraction of full-time workers at the establishment of employment (along with a quadratic of this variable), and, finally, the mean of the uncensored wages within the establishment of employment. I then impute wages building on the estimated tobit model, and using a random uniform draw u for each censored observation. In particular, I follow Card, Heining and Kline (2013) and drop censored values, imputing the upper tail by setting it equal to $y_{imp} = X'\beta + \hat{\sigma}\Phi^{-1}(k + u \times (1 - k))$ where y_{imp} stands for imputed value, X is the vector of observables associated with the observation, and $\hat{\sigma}$ represents the estimated standard deviation of the tobit model. Φ^{-1} stands for the inverse normal, u is the random uniform draw, $k = \Phi[(c - X'\beta)/\hat{\sigma}]$, and c is the value at which wages are censored.

B.2 Details on measuring domestic outsourcing

B.2.1 Industry and Occupation Codes

The occupation codes are consistent throughout the sample period. The industry codes have 4 3-digit variables: the digit codes based on the 1973, 1993, 2003, or 2008 codes. Focusing on the first three covers all workers, so I report the industry codes for these classifications only. I code an establishment being part of a certain business service industry if either of these industry variables takes on a relevant value. For instance, if an establishment is a business service firm only under the 1973 classification code, but not for any of the other classifications, I classify it as a business service establishment. The overview of the occupation codes can be found on the next page in table B.1, while the overview of the industry codes can be found on the page after that, in table B.2. These largely follow Goldschmidt and Schmieder (2015), but not fully, as I don't have five-digit industry codes to my disposal.

B.2.2 Descriptive facts on outsourcing

The first three facts describe the stability of CCSL employment at the establishments level, using a fixed effects regression where the employment for each occupation at the establishment level is regressed on a set of establishment fixed effects. Since the population of interest here is establishments that employ these occupations, all establishments not employing the occupation of interest are dropped from the sample.¹ The first panel of table B.3 shows that simple establishment fixed effects explain the majority (about 90 to 95%) of the variation in the employment level of these occupations. Since these numbers may be hard to interpret, I impose an AR(1) structure on the error to test the persistent of employment, presented in the second panel of figure B.3. An autocorrelation coefficient close to one provides evidence that employment within the establishment is highly persistent and stable. As the second panel of table highlights, the autocorrelation for all occupations is

¹Adding in the establishments that do not employ these occupations, or have outsourced these occupations, would mechanically increase the persistence of employment of these occupations.
about 0.75, indicating the employment level is relatively stable. The third panel repeats this exercise, but for employment shares rather than employment levels. While the fixed effects still explain a majority of the variance, the estimated autocorrelation coefficients are substantially lower. The finding that employment levels are more stable than employment shares indicate that employment of these occupations does not increase one-to-one with the size of the establishment. For instance, a manufacturing plant may need only one security agent, regardless of whether it employs one hundred or two hundred workers.

Another way to consider the stability of these occupations is by considering the turnover rates at the establishment level. Figure B.1 shows this graphically: they plot the turnover rates at the establishment level with the share of the workforce leaving on the horizontal axis, and the frequency on the vertical axis.² As the pictures show, cleaning and security jobs in particular seem to be very stable, but also catering and logistics show spikes around zero. Finally, the bottom panel of table B.3 shows the rate at which establishments end up rehiring the occupation after outsourcing, sometimes dubbed "insourcing".³ For all CCSL occupations, this probability is fairly small and hovers around 8%.

 $^{^{2}}$ As the object of interest here involves the stability of turnover rates before establishments engage in outsourcing or contracting out, the outsourcing events are precluded from this sample. Including them would mechanically generate a spike at -1. The turnover rates are calculated for all establishments that either have positive employment for the specific occupation or have not engaged in outsourcing of the occupation just yet. The rationale here is similar to that of the fixed effects regressions discussed above.

³In contrast to the four descriptive facts above, these probabilities are based on the sample of establishments that decided to outsource. Employment in the occupation of interest was positive at some point in time, but has fallen to zero due to outsourcing. I then compute the probability of seeing positive employment in the relevant occupation any given year after outsourcing.

		Table B.1: Occupation Codes for different Business Service Occupations
Category	Code	Description (EN)
Catering	411	Köche (Cooks)
_	412	Fertiggerichte-, Obst-, Gemüsekonservierer, -zubereiter (Ready-made meals-, fruit- and vegetable-processing
_		machine operators)
_	911	Gastwirte, Hotelliers, Gaststättenkaufleute (Hoteliers, innkeepers, restaurateurs, and management assistants
_		in hotels and restaurants)
_	912	Kellner, Stewards (Waiters, waitresses, stewards, stewardesses and buspersons)
_	913	Übrige Gästebetreuer (Porters, bartenders, and other hotel and restaurant attendants)
Cleaning	923	Hauswirtschaftliche Betreuer (Valets, chambermaids, and other housekeeping attendants)
_	933	Raum-, Hausratreiniger (Dishwashers, room and domestic cleaners)
_	934	Glas-, Gebäudereiniger (Windows, frontages and building cleaners)
_	936	Fahrzeugreiniger, -pfleger (Car washers, vehicle cleaners, car and vehicle carers)
	937	Maschinen-, Behälterreiniger un verwandte Berufe (Machinery, plant, tube and container cleaners)
Security	791	Werkschutzleute, Detektive (Factories security offices, store, hotel and other detectives)
_	792	Watchpersons, custodians, attendants, and related workers
_	793	Pförtner, Hauswarte (Door-, gatekeepers, and caretakers)
Logistics	714	Kraftfahrzeughführer (Car, taxi, bus, (heavy) truck and other motor vehicle drivers)
_	741	Lagerverwalter, Magaziner (Stocks administrators, and clerks)
	742	Transportgeräteführer (Lift, lifting-trucks, and other materials handling equipment operators)
_	743	Stauer, Möbelpacker (Longshoreman, furniture removers)
	744	Lager-, Transportarbeiter (Stock, loading, and other transport workers)

• $\left(\right)$ ζ F ٤ ζ \langle 2 -E

Category	Code	Year	Description (EN)
Catering	703	1973 - 1993	Gast- und Speisewirtschaften (Restaurants)
	553	1993 - 2003	Restaurants, Cafes, Eisdielen und Imbißhallen (Restaurants)
	554	1993 - 2003	Sonstiges Gaststättengewerbe (Bars)
	555	1993 - 2003	Kantinen und Caterer (Canteens and catering)
	553	2003 - 2010	Speisengeprägte Gastronomie (Restaurants)
	554	2003 - 2010	Getränkegeprägte Gastronomie (Bars)
	555	2003 - 2010	Kantinen und Caterer (Canteens and catering)
Cleaning	721	1973 - 1993	Reinigung von Gebäuden, Räumen, Inventar (Industrial cleaning)
	747	1993 - 2003	Reinigung von Gebäuden, Inventar und Verkehrsmitteln (Industrial cleaning)
	747	2003 - 2010	Reinigung von Gebäuden, Inventar und Verkehrsmitteln (Industrial cleaning)
Security	861	1973 - 1993	Bewachung, Aufbewahrung, Botendienste (Security and storage activities; courier services)
	746	1993 - 2003	Detekteien und Schutzdienste (Investigation and security activities)
	746	2003 - 2010	Wach- und Sicherheitsdienste sowie Detekteien (Investigation and security activities)
Logistics	651	1973 - 1993	Güterbeförderung mit Kraftfahrzeugen (Carriage of goods by motor vehicles)
	670	1973 - 1993	Spedition, Lagerei, K"uhlhäuser (Forwarding agencies, storage and refrigerating storage
			houses)
	602	1993 - 2003	Sonstiger Landverkehr (Other land transport)
	631	1993 - 2003	Frachtumschlag und Lagerei (Cargo handling and storage)
	632	1993 - 2003	Sonstige Hilfs- und Nebentätigkeiten für den Verkehr (Other supporting transport activi-
			ties)
	634	1993 - 2003	Spedition, sonstige Verkehrsvermittlung (Activities of other transport agencies)
	602	2003 - 2010	Sonstiger Landverkehr (Other land transport)
	631	2003 - 2010	Frachtumschlag und Lagerei (Cargo handling and storage)
	632	2003 - 2010	Sonstige Hilfs- und Nebentätigkeiten für den Verkehr (Other supporting transport activi-
			ties)
	634	2003 - 2010	Spedition, sonstige Verkehrsvermittlung (Activities of other transport agencies)
Temp	865	1973 - 1993	Arbeitnehmerüberlassung (Labour recruitment and provision of personnel)
	745	1993 - 2003	Gewerbsmäßige Vermittlung und Überlassung von Arbeitskräften (Labour recruitment
			and provision of personnel)
	745	2003 - 2010	Personal- und Stellenvermittlung, Überlassung von Arbeitskräften (Labour recruitment
			and provision of personnel)

Table B.2: Industry Codes for different Business Service Industries

			Outs	ourcing	; Category			
	Cateri	ng	Cleanii	ng	Securi	ty	$\operatorname{Logisti}$	cs
		Variano	e Decomp	osition	of Employ	yment I	Levels	
	Variance	%	Variance	%	Variance	%	Variance	%
Between	45.143	0.993	26.068	0.871	18.358	0.948	48.375	0.905
Within	3.912		10.048		4.287		15.641	
	Variance	Decom	position of	' Emplo	yment Le	vels wit	h AR(1) I	Error
ρ	0.731		0.823		0.739		0.752	
Between Within	Variance 54.466 2.912	% 0.997	Variance 28.068 6.000	% 0.956	Variance 22.205 2.971	% 0.982	Variance 54.565 11.782	% 0.955
	Variance	Decom	position of	Emplo	yment Sha	ares wit	h AR(1) I	Error
ρ	0.303		0.467		0.497		0.409	
Between Within	Variance 0.110 0.030	% 0.930	Variance 0.085 0.032	% 0.879	Variance 0.053 0.018	% 0.899	Variance 0.119 0.034	% 0.925
P(Insource)	0.0615	Proba	ability of I 0.0912	nsourci	ng after O 0.0807	utsour	cing 0.0849	

Table B.3: Descriptives of Employment

Notes: Panel one through three report a variance decomposition based on a regression of employment levels or shares on establishment fixed effects, where the estimation sample only includes establishments with strictly positive employment in the occupation of interest. The between variance is accounted for by differences between establishments, the within variance is accounted for by differences within establishments. The percentage reports the fraction of variance that is explained between firms. Panel two through three additionally impose an AR(1) model on the error term and report a point estimate for the autocorrelation coefficient. Standard errors are not reported yet, as Stata does not readily report these, but will be calculated for future versions of this paper. Panel four reports the probability of seeing positive employment in the occupation of interest in any given year, after the establishment has outsourced this category according to my outsourcing measure.





Notes: Frequency graphs for the turnover rate in the different occupations of interest. The sample for which these turnover rates are calculated include only establishments with strictly positive employment in the occupation of interest, and do not include the year when the employment in the relevant occupation drops to zero.

B.3 Proofs

I start from equations 2.8 and 2.9 which are given by

$$\ln\left(\frac{w_1'}{w_1}\right) = (\rho - 1)\ln\left(\frac{\mathcal{L}_1'}{\mathcal{L}_1}\right) + \ln\left(A_1\sigma - A_2a\left(\frac{\mathcal{L}_2'}{\mathcal{L}_1'}\right)\left(\frac{L_2(w_2)}{L_1(w_1')}\right)^{1+\frac{a}{\sigma}}\xi^a\right) - \qquad (B.1)$$
$$\ln\left(A_1\sigma - A_2a\left(\frac{\mathcal{L}_2}{\mathcal{L}_1}\right)\left(\frac{L_2(w_2)}{L_1(w_1)}\right)^{1+\frac{a}{\sigma}}\xi^a\right)$$
$$\ln\left(\frac{w_2'}{w_2}\right) = \frac{(\rho - 1)}{1 - a}\ln\left(\frac{\mathcal{L}_2'}{\mathcal{L}_2}\right) - \frac{a}{1 - a}\ln\left(\frac{w_1'}{w_1}\right) \qquad (B.2)$$

Define the employment ratio of high skill to low skill workers as $\eta = \frac{L_2(w_2)}{L_1(w_1)}$ and the post-outsourcing skill ratio as η' . I first rewrite equation B.1 as⁴

$$\ln\left(\frac{w_1'}{w_1}\right) = (\rho - 1)\ln\left(\frac{\mathcal{L}_1'}{\mathcal{L}_1}\right) + \ln\left(A_1\sigma - A_2a\left(\frac{\mathcal{L}_2'}{\mathcal{L}_1'}\right){\eta'}^{1+\frac{a}{\sigma}}\xi^a\right) - \ln\left(\underbrace{A_1\sigma - A_2a\left(\frac{\mathcal{L}_2}{\mathcal{L}_1}\right){\eta'}^{1+\frac{a}{\sigma}}\xi^a}_{\equiv b(w_2,w_1)}\right)$$

Then maintaining the assumption on \mathcal{L}'_k and \mathcal{L}_k for $k \in \{1, 2\}$ and applying a first-order Taylor approximation to this equation around η results in

$$\ln\left(\frac{w_1'}{w_1}\right) \approx \ln\left(A_1\sigma - A_2a\left(\frac{\mathcal{L}_2}{\mathcal{L}_1}\right)\eta^{1+\frac{a}{\sigma}}\xi^a\right) - \\ \ln\left(A_1\sigma - A_2a\left(\frac{\mathcal{L}_2}{\mathcal{L}_1}\right)\eta^{1+\frac{a}{\sigma}}\xi^a\right) + \\ \underbrace{\frac{A_2a\xi^a}{b(w_2,w_1)}\frac{\mathcal{L}_2}{\mathcal{L}_1}\eta(w_2,w_1)^{\frac{a}{\sigma}}(\eta'-\eta)}_{>0}$$

A more detailed and precise Taylor approximation could state this in terms of changes in wages, rather than in changes in the skill ratio, however this is left out of the

⁴The assumption that $\mathcal{L}_1 = \mathcal{L}'_1$ and $\mathcal{L}_2 = \mathcal{L}'_2$ allow to have *b* not depend on these magnitudes.

APPENDIX C

Appendix to Measuring Instructor Effectiveness in Higher Education

C.1 Additional Tables

	All Se	ections	Face-to-F	lace Sections	Online	Sections
	n=7	7,267	n=	=4,707	n=2	2,560
	Mean	Std. Dev.	Mean	Std. Dev.	Mean	Std. Dev.
Online section	0.352	0.478	0.000	0.000	1.000	0.000
Male	0.683	0.465	0.699	0.459	0.656	0.475
White	0.641	0.480	0.633	0.482	0.652	0.476
Section-average student age	34.367	3.355	33.697	3.478	35.598	2.715
Section-average share male	0.381	0.179	0.412	0.191	0.323	0.137
Section-average incoming GPA	3.200	0.205	3.185	0.222	3.227	0.168
Section-average incoming credits	24.529	7.151	25.200	7.767	23.295	5.649
Section-average repeat 208	0.112	0.106	0.091	0.101	0.152	0.103
Section-average number times taken	1.124	0.130	1.105	0.125	1.159	0.131
Section-average time since program start (years)	1.232	0.518	1.196	0.510	1.297	0.525
Section enrollment	13.038	4.284	12.702	5.159	13.655	1.600
Years since first hire	6.271	5.008	5.908	5.450	6.939	3.987
Years since first hire > 1	0.832	0.374	0.802	0.399	0.887	0.317
Total math 208 sections taught prior to this section	19.661	20.900	13.704	15.689	30.615	24.542
Ever taught MTH208 prior to this section	0.937	0.244	0.911	0.285	0.984	0.126
Total sections instructor taught prior to this section	59.854	66.590	58.833	75.495	61.733	45.869
Total MTH209 sections taught prior to this section	14.014	16.765	13.139	15.680	15.621	18.490
Ever taught MTH209 prior to this section	0.805	0.396	0.896	0.306	0.639	0.480

Table C.1: Descriptive Statistics for Sections and Instructors (Test Sample)

			Face-te	o-Face		
	All Se	<u>ections</u>	Sect	ions	Online S	Sections
	n=33	39,844	n=19	2,747	n=14	7,097
	Mean	Std. Dev.	Mean	Std. Dev.	Mean	Std. Dev.
Male	0.384	0.486	0.419	0.493	0.323	0.468
Age	34.319	9.411	33.57	9.3	35.601	9.46
Baseline GPA (0-4)	3.206	0.576	3.195	0.565	3.227	0.594
Credits earned prior to start of Math 208	24.533	17.534	25.256	16.69	23.296	18.827
Took Math 208 before	0.112	0.316	0.089	0.285	0.152	0.359
Number of times MTH 208 taken	1.124	0.407	1.103	0.36	1.16	0.475
BS (general studies)	0.164	0.371	0.159	0.366	0.173	0.378
BS in Nursing	0.044	0.206	0.017	0.131	0.09	0.287
BS in Accounting	0.009	0.094	0.005	0.071	0.015	0.123
BS in Business	0.382	0.486	0.467	0.499	0.236	0.425
BS in Criminal Justice Administration	0.1	0.3	0.124	0.33	0.058	0.234
BS in Education	0.028	0.166	0.013	0.115	0.054	0.226
BS in Health Administration	0.091	0.288	0.092	0.288	0.09	0.287
BS in Human Services	0.044	0.204	0.036	0.186	0.057	0.232
BS in Information Technology	0.043	0.203	0.046	0.21	0.038	0.191
BS in Management	0.055	0.228	0.027	0.162	0.103	0.304
Non-degree program	0.013	0.114	0.003	0.056	0.031	0.172
BS in other Program	0.025	0.155	0.009	0.095	0.051	0.221
Time since program start date (years)	1.234	1.596	1.197	1.425	1.297	1.85
Grade in Math 208	2.385	1.361	2.405	1.324	2.352	1.422
A / A-	0.283	0.451	0.275	0.447	0.296	0.457
B+ / B / B-	0.277	0.448	0.283	0.451	0.267	0.442
C+ / C / C-	0.189	0.392	0.203	0.402	0.167	0.373
D+ / D / D-	0.092	0.289	0.099	0.299	0.08	0.272
F	0.052	0.221	0.05	0.217	0.055	0.227
Withdrawn	0.106	0.308	0.09	0.286	0.135	0.342
Passed Math 208	0.842	0.365	0.861	0.346	0.81	0.392
Math 208 Final exam score available	0.854	0.354	0.894	0.308	0.785	0.411
Math 208 final exam % correct (if available)	0.707	0.241	0.696	0.246	0.728	0.23
Took Math 209	0.779	0.415	0.833	0.373	0.686	0.464
Grade in Math 209 (if took it)	2.467	1.249	2.524	1.187	2.347	1.361
A / A-	0.265	0.442	0.265	0.442	0.265	0.441
B+ / B / B-	0.296	0.457	0.307	0.461	0.273	0.445
C + / C / C-	0.22	0.414	0.233	0.423	0.192	0.394
D + / D / D-	0.102	0.302	0.107	0.309	0.091	0.288
F , , ,	0.04	0.195	0.031	0.174	0.057	0.232
Withdrawn	0.067	0.25	0.049	0.215	0.105	0.306
Math 209 Final exam score available	0.67	0.47	0.758	0.428	0.518	0.5
Math 209 final exam % correct (if available)	0.69	0.245	0.691	0.243	0.688	0.251
Credits earned in following year	10.947	5.348	11.561	5.078	9.897	5.628
Have course evaluation	0.369	0.483	0.342	0.474	0.416	0.493
Course evaluation: Recommend instructor	0.661	0.473	0.694	0.461	0.614	0.487
			0.0001	0.101		

Table C.2: Descriptive Statistics for Students (Test Score Sample)

	Total F7	F cam	puses ta	aught a	t_
0	1	2	3	4	Total
0	$1,\!498$	110	10	1	$1,\!619$
534	126	14	3	0	677
534	1624	124	13	1	$2,\!296$
	0 0 534 534	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

Table C.3: How much switching is there between online and FTF campuses?

Notes: Number of MTH208 faculty by online and FTF participation.

	4	All sections, r	estricted to t	est and evalu	uations samp	le $(N = 7, 135)$	sections)		
Test MTH208 100 <t< th=""><th></th><th>Test MTH208</th><th>Test MTH209</th><th>Grade MTH208</th><th>Grade MTH209</th><th>Credits earned 6mo</th><th>Pass MTH208</th><th>Take MTH209</th><th>Good eval MTH208</th></t<>		Test MTH208	Test MTH209	Grade MTH208	Grade MTH209	Credits earned 6mo	Pass MTH208	Take MTH209	Good eval MTH208
	Test MTH208	1.000							
$ \begin{array}{cccc} \mbox{and MIT208} & 0.329 & 0.271 & 1.000 \\ \mbox{Grade MIT209} & 0.329 & 0.081 & 0.406 & 1.000 \\ \mbox{Pass MIT209} & 0.329 & 0.081 & 0.406 & 1.000 \\ \mbox{Pass MIT209} & 0.329 & 0.017 & 0.387 & 0.429 & 0.554 & 1.000 \\ \mbox{Pass MIT209} & 0.127 & 0.014 & 0.382 & 0.0207 & 0.167 & 0.134 & 1.000 \\ \mbox{Pass MIT208} & 0.109 & -0.042 & 0.382 & 0.207 & 0.167 & 0.354 & 0.138 & 1.000 \\ \mbox{Tale MIT208} & 0.109 & -0.042 & 0.382 & 0.207 & 0.167 & 0.354 & 0.138 & 1.000 \\ \mbox{Tale MIT209} & 0.127 & 0.014 & 0.382 & 0.207 & 0.167 & 0.354 & 0.138 & 1.000 \\ \mbox{Tale MIT208} & 1.000 & 1.000 & 1.000 & 0.013 & 1.000 & 0.0100 & 0.000 & 0.$	Test MTH209	0.574	1.000						
	Grade MTH208	0.529	0.271	1.000	000				
	Grade IVI H209 Credits earned fimo	0.332 0.232	0.081	0.500 0.401	1.000 0.466	1 000			
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Dass MTH208	0.393	0.127	0.827	0.429	0.542	1.000		
	Take MTH209	0.127	0.014	0.385	0.628	0.515	0.514	1.000	
	Good evaluation in MTH208	0.109	-0.042	0.382	0.207	0.167	0.354	0.138	1.000
	F.	TF sections,	restricted to	test and eval	uations sam	ple (N $= 4,58$	1 sections)		
Test MTH208 M11120 M111200 M111200 <th< td=""><td></td><td>Test MTH908</td><td>Test Мттироо</td><td>Grade</td><td>Grade</td><td>Credits</td><td>Pass</td><td>Take MTTH200</td><td>Good eval</td></th<>		Test MTH908	Test Мттироо	Grade	Grade	Credits	Pass	Take MTTH200	Good eval
Tast MTH200 0.613 1.000 Grade MTH208 0.536 0.349 1.000 Grade MTH209 0.338 0.349 1.000 Grade MTH209 0.338 0.346 0.119 0.471 1.000 Credits earned 6mo 0.3300 0.186 0.471 1.000 1.000 Pass MTH208 0.074 0.034 0.736 0.640 0.563 1.000 Good evaluation in MTH208 0.074 0.034 0.307 0.211 0.143 0.663 1.000 Good evaluation in MTH208 0.074 0.034 0.307 0.211 0.143 0.663 1.000 Task MTH209 0.074 0.034 0.307 0.211 0.143 0.663 1.000 Task MTH208 0.074 0.307 0.211 0.143 0.653 0.065 1.000 Test Test Test Test Test Test Test Test Test Test<	Test MTH208	1.000	CO211 1 141		CO711 1 141	0000		00711 T 111	
	Test MTH209	0.613	1.000						
	Grade MTH208	0.536	0.349	1.000					
	Grade MTH209	0.338	0.307	0.598	1.000				
	Credits earned 6mo	0.346	0.119	0.457	0.471	1.000			
	Pass MTH208	0.3900	0.186	0.791	0.504	0.603	1.000		
	Take MTH209	0.097	0.026	0.336	0.640	0.509	0.489	1.000	
	Good evaluation in MTH208	0.074	-0.034	0.307	0.211	0.143	0.268	0.062	1.000
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	On	line sections.	restricted to	test and eve	aluations san	$rac{1}{r}$ $ m Plote (N = 2,5)$	54 sections)		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		Test	Test	Grade	Grade	Credits	Pass	Take	Good eval
Lest MTH209 1.000 Test MTH209 0.059 1.000 Test MTH208 0.426 -0.299 1.000 Grade MTH209 0.227 0.297 0.184 1.000 Grade MTH209 0.227 0.297 0.184 1.000 Grade MTH209 0.230 -0.064 0.544 0.558 1.000 Task MTH209 0.3385 -0.322 0.910 0.204 0.624 1.000 Task MTH209 0.282 -0.120 0.558 0.710 0.660 0.591 1.000 Good evaluation in MTH208 0.365 0.185 0.185 0.423 1.000	SOCIETA ASST	1 000	<u>60711111</u>		<u>EUZUTM</u>	earned 0000	007111 IM	<u>60711111</u>	<u>00711 T IN</u>
Test MTH209 0.059 1.000 Grade MTH208 0.426 -0.299 1.000 Grade MTH209 0.227 0.297 0.184 1.000 Grade MTH209 0.227 0.297 0.184 1.000 Grade MTH209 0.230 -0.064 0.544 0.558 1.000 Deres MTH209 0.230 -0.021 0.5144 0.558 1.000 Take MTH209 0.2322 0.910 0.2044 0.521 1.000 Good evaluation in MTH208 0.385 -0.123 0.558 0.710 0.660 0.591 1.000		000.1	000						
Grade M1 H208 0.420 -0.299 1.000 Grade MTH209 0.227 0.297 0.184 1.000 Grade MTH209 0.230 -0.064 0.544 0.558 1.000 Tase MTH208 0.385 -0.322 0.910 0.204 0.591 1.000 Take MTH209 0.282 -0.120 0.558 0.710 0.660 0.591 1.000 Good evaluation in MTH208 0.365 -0.153 0.658 0.185 0.349 0.633 0.423 1.000	Test MTH209	0.059	1.000	0000					
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Grade MTH208	0.420	-0.299	1.000	1 000				
Description Distribution Distribution </td <td>Gradits samed fmo</td> <td>0.930</td> <td>-0 064</td> <td>0.104 0 544</td> <td>1.000 0.558</td> <td>1 000</td> <td></td> <td></td> <td></td>	Gradits samed fmo	0.930	-0 064	0.104 0 544	1.000 0.558	1 000			
Take MTH209 0.282 -0.120 0.535 0.710 0.660 0.591 1.000 Good evaluation in MTH208 0.365 -0.153 0.658 0.185 0.633 0.423 1.000	Pass MTH208	0.385	-0.322	0.910	0.204	0.624	1.000		
Good evaluation in MTH208 0.365 -0.153 0.658 0.185 0.349 0.633 0.423 1.000	Take MTH209	0.282	-0.120	0.535	0.710	0.660	0.591	1.000	
	Good evaluation in MTH208	0.365	-0.153	0.658	0.185	0.349	0.633	0.423	1.000
	<i>Notes:</i> Random effects models a BLUPs for random instructor e	re estimated or ffects for each	i section-level re pair of outcom	es. First stage	tcome at a tim models inclue	e. Tables show J le instructor, ca	pair-wise correl mpus, year, ar	ations between nd month fixed	l predicted l effects in
Notes: Random effects models are estimated on section-level residuals one outcome at a time. Tables show pair-wise correlations between predicted BLUPs for random instructor effects for each pair of outcomes. First stage models include instructor, campus, year, and month fixed effects in	addition to individual controls, instructor fixed effects. Individu	section average ual controls in	controls, and 2 clude male, age	ZLP code contro , incoming GP	ols. Residuals A, incoming c	are taken with 1 redits, indicato	respect to all th r for repeat M'	hese variables TH208, numbe	other than er of times
<i>Notes:</i> Random effects models are estimated on section-level residuals one outcome at a time. Tables show pair-wise correlations between predicted BLUPs for random instructor effects for each pair of outcomes. First stage models include instructor, campus, year, and month fixed effects in addition to individual controls, section average controls, and ZIP code controls. Residuals are taken with respect to all these variables other than instructor fixed effects. Individual controls include male, age, incoming GPA, incoming credits, indicator for repeat MTH208, number of times	taking MTH208, 12 program du plust total enrollment in section	mmies, years si n. ZIP contro	nce started pro s include the u	gram. Section	average contrc rate, median	ls include sectio familv income.	n averages of t percent of fam	hese same cha iilies below po	racteristics vertv line.
<i>Notes:</i> Random effects models are estimated on section-level residuals one outcome at a time. Tables show pair-wise correlations between predicted BLUPs for random instructor effects for each pair of outcomes. First stage models include instructor, campus, year, and month fixed effects in addition to individual controls, section average controls, and ZIP code controls. Residuals are taken with respect to all these variables other than instructor fixed effects. Individual controls include male, age, incoming GPA, incoming credits, indicator for repeat MTH208, number of times taking MTH208, 12 program dummies, years since started program. Section average controls include the unemolovement rate. median family income, percent of families below poverty line.	percent of adults with BA degr	ee in ZIP code	from 2004-200	7 ACS (plus n	nissing ZIP). S	students who di	d not enroll in	MTH209 wer	e assigned
<i>Notes:</i> Random effects models are estimated on section-level residuals one outcome at a time. Tables show pair-wise correlations between predicted BLUPs for random instructor effects for each pair of outcomes. First stage models include instructor, campus, year, and month fixed effects in addition to individual controls, section average controls, and ZIP code controls. Residuals are taken with respect to all these variables other than instructor fixed effects. Individual controls include male, age, incoming GPA, incoming credits, indicator for repeat MTH208, number of times taking MTH208, 12 program dummies, years since started program. Section average controls include section averages of these same characteristics plust total enrollment in section. ZIP controls include the unemployment rate, median family income, percent of families below poverty line, percent of adults with BA degree in ZIP code from 2004-2007 ACS (plus missing ZIP). Students who did not enroll in MTH209 were assigned	a zero (failing) and students th	at did not pos	sess a test scor	e for 208 or 20	19 were assign	ed the 10th per	centile of the t	test score from	their 208
<i>Notes:</i> Random effects models are estimated on section-level residuals one outcome at a time. Tables show pair-wise correlations between predicted BLUPs for random instructor effects for each pair of outcomes. First stage models include instructor, campus, year, and month fixed effects in addition to individual controls, section average controls. Residuals are taken with respect to all these variables other than instructor fixed effects. Individual controls include male, age, incoming GPA, incoming credits, indicator for repeat MTH208, number of times taking MTH208, 12 program dummies, years since started program. Section average controls include section averages of these same characteristics plust total enrollment in section. ZIP controls include the unemployment rate, median family income, percent of families below poverty line, percent of adults with BA degree in ZIP code from 2004-2007 ACS (plus missing ZIP). Students who did not enroll in MTH209 were assigned a zero (failing) and students that did not posses a test score for 208 or 209 were assigned the 10th percentile of the test score from their 208	section. Robust standard errors	clustered by in	istructor in pai	entheses. All r	nodels include	full controls in	first stage, im	pute zero MTF	1209 grade
<i>Notes:</i> Random effects models are estimated on section-level residuals one outcome at a time. Tables show pair-wise correlations between predicted BLUPs for random instructor effects for each pair of outcomes. First stage models include instructor, campus, year, and month fixed effects in addition to individual controls, section average controls. Residuals are taken with respect to all these variables other than instructor fixed effects. Individual controls include male, age, incoming GPA, incoming credits, indicator for repeat MTH208, number of times taking MTH208, 12 program dummies, years since started program. Section average controls include section averages of these same characteristics plust total enrollment in section. ZIP controls include the unemployment rate, median family income, percent of families below poverty line, percent of adults with BA degree in ZIP code from 2004-2007 ACS (plus missing ZIP). Students who did not enroll in MTH209 were assigned a zero (failing) and students that did not possess a test score for 208 or 209 were assigned the 10th percentile of the test score from their 208 section. Robust standard errors clustered by instructor in parentheses. All models include full controls in first stage, impute zero MTH209 grade	if missing impute 10th ntile of i	test score if mi	seina						

Table C.4: Correlation across Outcomes (Restricted to Test Sample)

C.2 Final Exam Score Determination

For sections from July 2010 to March 2014, we have detailed information on student performance separately by course assignment or assessment, which includes everything from individual homework assignments to group exercises to exams. We use this data to obtain a final exam score for each student when available. Because the data does not have a single, clear code for final exam component across all sections, and instructors have discretion to add additional final exam components, we use a decision rule to identify the "best" exam score for each student based on the text description of the assessment object. Ideally, this measure would capture computer-administered tests, since instructors do not have discretion over these. We therefore define a quality measure, ranging from 1 (best) to 4 (worst), that indicates how clean we believe the identification of these test scores to be. Once a student in a certain section gets assigned a test score, it is marked and not considered in later steps, so students get assigned a single quality measure and the assigned test score is of the highest quality available Group 1 consists of the computer-administered common assessments available to all UPX instructors. To identify these assessments, we flag strings that contain words or phrases associated with the computer testing regime (e.g., "Aleks", "MyMathLab" or "MML") as well as words or phrases indicating a final exam (e.g., "final exam," "final examination," "final test"). If a student has an assessment that meets these criteria, we use the score from this assessment as the student's final exam score.¹ Specifically, we use the fraction of test items answered correctly as our measure of student performance. Roughly 11% of student-sections in our test score subsample have a final exam score with this highest level of quality, both for MTH208 and MTH209 test scores. Some students have a single assessment with a word or phrase indicating a final exam (e.g., "final exam,"

¹In extremely rare cases (less than 4 percent of the sample), students will have more than one assessment that meets these criteria, in which case we sum the attained and maximal score for these components, and calculate the percentage score. This is, in part, because for many cases, there was no grade component that could be clearly identified as the test score (e.g. a student may have "Aleks final exam: part 1" and "Aleks final exam: part 2"). About 3.75% of these cases have two assessments that meet the criteria. The maximum number of components for a student is five.

"final examination," "final test"), but no explicit indication that the exam was from the standardized online system. If the assessment does not contain any additional words or phrases indicating that the test was developed by the instructor (e.g., "in class," "instructor generated," etc.), we are reasonably confident that it refers to the standardized online system. Hence, we use this assessment score as the student's final exam, but we consider these assessments as Group 2 for the purpose of exam quality. Another 77 percent of student-sections fall into this category for the MTH208 and MTH209 sections. The third group looks at strings such as "test," "quiz," and "course exam." While quizzes and tests may sometimes refer to weekly refresher assessments, these strings identify final test scores reasonably well after having considered decision rules 1 and 2. About 9% of the student-sections fall into this category for both section types. The fourth and final group selects a grade component as a final test score if the title includes both "class" and "final." Another 2 percent of the sample gets assigned a test score of this quality for both the MTH208 and MTH209 sections.

BIBLIOGRAPHY

BIBLIOGRAPHY

- Abraham, Katharine G. 1990. "Restructuring the employment relationship: The growth of market-mediated work arrangements." New developments in the labor market: Toward a new institutional paradigm, 85.
- Acemoglu, Daron, and David Autor. 2011. "Skills, tasks and technologies: Implications for employment and earnings." In *Handbook of labor economics*. Vol. 4, 1043–1171. Elsevier.
- Akerlof, George A, and Janet L Yellen. 1988. "Fairness and unemployment." The American Economic Review, 78(2): 44–49.
- Alda, Holger, Stefan Bender, and Hermann Gartner. 2005. "The linked employeremployee dataset of the IAB (LIAB)." IAB Discussion Paper.
- Athey, Susan, and Guido Imbens. 2016. "Recursive partitioning for heterogeneous causal effects." *Proceedings of the National Academy of Sciences*, 113(27): 7353–7360.
- Athey, Susan, Julie Tibshirani, Stefan Wager, et al. 2019. "Generalized random forests." The Annals of Statistics, 47(2): 1148–1178.
- Baicker, Katherine, Amitabh Chandra, Jonathan S Skinner, and John E Wennberg. 2004. "Who You Are And Where You Live: How Race And Geography Affect The Treatment Of Medicare Beneficiaries: There is no simple story that explains the regional patterns of racial disparities in health care." *Health affairs*, 23(Suppl2): VAR–33.
- Baicker, Katherine, Sendhil Mullainathan, and Joshua Schwartzstein. 2015. "Behavioral hazard in health insurance." *The Quarterly Journal of Economics*, 130(4): 1623–1667.
- Bernhardt, Annette, Rosemary Batt, Susan N Houseman, and Eileen Appelbaum. 2016. "Domestic Outsourcing in the United States: A Research Agenda to Assess Trends and Effects on Job Quality."
- Berry, Steven, James Levinsohn, and Ariel Pakes. 1995. "Automobile prices in market equilibrium." *Econometrica: Journal of the Econometric Society*, 841–890.
- Bettinger, Eric, Lindsay Fox, Susanna Loeb, and Eric Taylor. 2015. "Changing Distributions: How Online College Classes Alter Student and Professor Performance. CEPA Working Paper No. 15-10." Stanford Center for Education Policy Analysis.

- Bettinger, Eric P, and Bridget Terry Long. 2005. "Do faculty serve as role models? The impact of instructor gender on female students." *American Economic Review*, 95(2): 152–157.
- Bettinger, Eric P, and Bridget Terry Long. 2010. "Does cheaper mean better? The impact of using adjunct instructors on student outcomes." The Review of Economics and Statistics, 92(3): 598–613.
- Bicchieri, Cristina, and Ryan Muldoon. 2011. "Social norms."
- Bosworth, Hayden B, Bradi B Granger, Phil Mendys, Ralph Brindis, Rebecca Burkholder, Susan M Czajkowski, Jodi G Daniel, Inger Ekman, Michael Ho, Mimi Johnson, et al. 2011. "Medication adherence: a call for action." *American heart journal*, 162(3): 412–424.
- Bound, John, and George Johnson. 1992. "Changes in the Structure of Wages in the 1980's: An Evaluation of Alternative Explanations." *The American Economic Review*, 82(3): 371–392.
- Braga, Michela, Marco Paccagnella, and Michele Pellizzari. 2014. "The academic and labor market returns of university professors." Bank of Italy Temi di Discussione (Working Paper) No, 981.
- Breiman, Leo. 2001. "Random forests." Machine learning, 45(1): 5–32.
- Breza, Emily, Supreet Kaur, and Yogita Shamdasani. 2018. "The morale effects of pay inequality." *The Quarterly Journal of Economics*, 133(2): 611–663.
- Brodaty, Thibault, and Marc Gurgand. 2016. "Good peers or good teachers? Evidence from a French University." *Economics of Education Review*, 54: 62–78.
- Bronnenberg, Bart J, Jean-Pierre H Dubé, and Matthew Gentzkow. 2012. "The evolution of brand preferences: Evidence from consumer migration." *American Economic Review*, 102(6): 2472–2508.
- Card, David, Alexandre Mas, Enrico Moretti, and Emmanuel Saez. 2012. "Inequality at work: The effect of peer salaries on job satisfaction." *The American Economic Review*, 102(6): 2981–3003.
- Card, David, Ana Rute Cardoso, Jörg Heining, and Patrick Kline. 2016. "Firms and Labor Market Inequality: Evidence and Some Theory."
- Card, David, Jörg Heining, and Patrick Kline. 2013. "Workplace Heterogeneity and the Rise of West German Wage Inequality." *Quarterly Journal of Economics*, 128(3).
- Carone, Giuseppe, Christoph Schwierz, and Ana Xavier. 2012. "Cost-containment policies in public pharmaceutical spending in the EU." Available at SSRN 2161803.

- Carrell, Scott E, and James E West. 2010. "Does professor quality matter? Evidence from random assignment of students to professors." *Journal of Political Economy*, 118(3): 409–432.
- **Center for Workforce Studies.** 2013. "State Physician Workforce Data Book." American Association of Medical Colleges.
- Chandra, Amitabh, Benjamin Handel, and Joshua Schwartzstein. 2018. "Behavioral Economics and Health-Care Markets."
- Chandra, Amitabh, David Cutler, and Zirui Song. 2011. "Who ordered that? The economics of treatment choices in medical care." In *Handbook of health economics*. Vol. 2, 397–432. Elsevier.
- Chetty, Raj, John N Friedman, and Jonah E Rockoff. 2014. "Measuring the impacts of teachers I: Evaluating bias in teacher value-added estimates." *American Economic Review*, 104(9): 2593–2632.
- Choudhry, Niteesh K, Thomas D Denberg, and Amir Qaseem. 2016. "Improving adherence to therapy and clinical outcomes while containing costs: opportunities from the greater use of generic medications: best practice advice from the Clinical Guidelines Committee of the American College of Physicians." Annals of internal medicine, 164(1): 41–49.
- CMS. 2015. "National Health Expenditures 2015 Highlights."
- **CMS.** 2018. "Speech: Remarks by CMS Administrator Seema Verma at the Pharmacy Quality Alliance Annual Meeting."
- Cohn, Alain, Ernst Fehr, Benedikt Herrmann, and Frédéric Schneider. 2011. "Social Comparison in the Workplace: Evidence from a Field Experiment." Working paper series/Department of Economics, , (07).
- Cook, Jason B, and Richard K Mansfield. 2016. "Task-specific experience and taskspecific talent: Decomposing the productivity of high school teachers." Journal of Public Economics, 140: 51–72.
- **Cornelis, Koen.** 2013. "Het geneesmiddelenbeleid inzake goedkopere geneesmiddelen in België." Federaal Kenniscentrum voor de Gezondheidszorg.
- Costa-Font, Joan, Alistair McGuire, and Nebibe Varol. 2014. "Price regulation and relative delays in generic drug adoption." *Journal of health economics*, 38: 1–9.
- Crawford, Gregory S, and Matthew Shum. 2005. "Uncertainty and learning in pharmaceutical demand." *Econometrica*, 73(4): 1137–1173.
- **Darby, Michael R, and Edi Karni.** 1973. "Free competition and the optimal amount of fraud." *The Journal of law and economics*, 16(1): 67–88.
- **Dickstein, Michael J.** 2011*a*. "Efficient provision of experience goods: Evidence from antidepressant choice."

Dickstein, Michael J. 2011b. "Physician vs. patient incentives in prescription drug choice."

- **Dube, Arindrajit, and Ethan Kaplan.** 2010. "Does outsourcing reduce wages in the low-wage service occupations? Evidence from janitors and guards." *Industrial & labor relations review*, 63(2): 287–306.
- Durkheim, Emile. 1895. The rules of sociological method. Vol. 8.
- Dustmann, Christian, Bernd Fitzenberger, Uta Schönberg, and Alexandra Spitz-Oener. 2014. "From sick man of Europe to economic superstar: Germany's resurgent economy." *The Journal of Economic Perspectives*, 28(1): 167–188.
- **Dustmann, Christian, Johannes Ludsteck, and Uta Schönberg.** 2009. "Revisiting the German Wage Structure." *The Quarterly Journal of Economics*, 124(2): 843–881.
- **Dylst, Pieter, Arnold Vulto, and Steven Simoens.** 2012. "Reference pricing systems in Europe: characteristics and consequences." *Generics Biosimilars Initiative J*, 1: 127–31.
- Ehrenberg, Ronald G. 2012. "American higher education in transition." Journal of Economic Perspectives, 26(1): 193–216.
- Ehrenberg, Ronald G, and Liang Zhang. 2005. "Do tenured and tenure-track faculty matter?" *Journal of Human Resources*, 40(3): 647–659.
- Ellis, Randall P, and Thomas G McGuire. 1986. "Provider behavior under prospective reimbursement: Cost sharing and supply." *Journal of health economics*, 5(2): 129–151.
- Emanuel, Ezekiel J, Peter A Ubel, Judd B Kessler, Gregg Meyer, Ralph W Muller, Amol S Navathe, Pankaj Patel, Robert Pearl, Meredith B Rosenthal, Lee Sacks, et al. 2016. "Using behavioral economics to design physician incentives that deliver high-value care." Annals of internal medicine, 164(2): 114–119.
- Faggio, Giulia, Kjell G Salvanes, and John Van Reenen. 2010. "The evolution of inequality in productivity and wages: panel data evidence." *Industrial and Corporate Change*, 19(6): 1919–1951.
- Fairlie, Robert W, Florian Hoffmann, and Philip Oreopoulos. 2014. "A community college instructor like me: Race and ethnicity interactions in the classroom." *American Economic Review*, 104(8): 2567–91.
- Farfan-Portet, Maria-Isabel, Carine Van de Voorde, France Vrijens, and Robert Vander Stichele. 2012. "Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription data." The European Journal of Health Economics, 13(3): 301–313.
- Farrell, Joseph, and Paul Klemperer. 2007. "Coordination and lock-in: Competition with switching costs and network effects." *Handbook of industrial organization*, 3: 1967–2072.

- Fehr, Ernst, and Klaus M Schmidt. 1999. "A theory of fairness, competition, and cooperation." The quarterly journal of economics, 114(3): 817–868.
- Feng, Josh. 2019. "History-Dependent Demand in Chronic Drug Markets: Evidence and Implications." Available at SSRN 3316426.
- Figlio, David N, Morton O Schapiro, and Kevin B Soter. 2015. "Are tenure track professors better teachers?" *Review of Economics and Statistics*, 97(4): 715–724.
- Finkelstein, Amy, Matthew Gentzkow, and Heidi Williams. 2016. "Sources of geographic variation in health care: Evidence from patient migration." *The quarterly journal of economics*, 131(4): 1681–1726.
- Fitzenberger, Bernd, Karsten Kohn, and Alexander C Lembcke. 2013. "Union density and varieties of coverage: the anatomy of union wage effects in Germany." *Industrial* & Labor Relations Review, 66(1): 169–197.
- Fraeyman, Jessica, Lies Peeters, Guido Van Hal, Philippe Beutels, Guido RY De Meyer, and Hans De Loof. 2015. "Consumer choice between common generic and brand medicines in a country with a small generic market." Journal of managed care & specialty pharmacy, 21(4): 288–296.
- Gagne, Joshua J, Niteesh Kumar Choudhry, Aaron Seth Kesselheim, Jennifer Milan Polinski, David Hutchins, Olga S Matlin, Troyen Anthony Brennan, Jerry Lewis Avorn, and William Shrank. 2014. "Comparative effectiveness of generic and brand-name statins on patient outcomes."
- Gibbons, Robert, and Lawrence Katz. 1992. "Does unmeasured ability explain interindustry wage differentials?" The Review of Economic Studies, 59(3): 515–535.
- Glombiewski, Julia A, Yvonne Nestoriuc, Winfried Rief, Heide Glaesmer, and Elmar Braehler. 2012. "Medication adherence in the general population." *PLoS One*, 7(12): e50537.
- Goldschmidt, Deborah, and Johannes F Schmieder. 2015. "The Rise of Domestic Outsourcing and the Evolution of the German Wage Structure." National Bureau of Economic Research.
- Grennan, Matthew, Kyle Myers, Ashley Swanson, and Aaron Chatterji. 2018. "Physician-Industry Interactions: Persuasion and Welfare." National Bureau of Economic Research Working Paper 24864.
- Grimshaw, Jeremy M, Martin P Eccles, John N Lavis, Sophie J Hill, and Janet E Squires. 2012. "Knowledge translation of research findings." *Implementation science*, 7(1): 50.
- Grosse-Tebbe, Susanne, and Josep Figueras. 2005. Snapshots of health systems.

- Haas, Jennifer S, Kathryn A Phillips, Eric P Gerstenberger, and Andrew C Seger. 2005. "Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997–2000." Annals of internal medicine, 142(11): 891– 897.
- Håkanson, Christina, Erik Lindqvist, and Jonas Vlachos. 2015. "Firms and skills: the evolution of worker sorting." Stockholm University, Department of Economics.
- Hamermesh, Daniel S. 2001. "The Changing Distribution of Job Satisfaction." Journal of Human Resources, 36(1).
- Handel, Benjamin R. 2013. "Adverse selection and inertia in health insurance markets: When nudging hurts." *American Economic Review*, 103(7): 2643–82.
- Handwerker, Elizabeth Weber, and James Spletzer. 2015. "The Role of Establishments and the Concentration of Occupations in Wage Inequality." US Census Bureau Center for Economic Studies Paper No. CES-WP-15-26.
- Heckman, James J. 1981. "Heterogeneity and state dependence." In *Studies in labor* markets. 91–140. University of Chicago Press.
- Heining, Jörg, Theresa Scholz, Stefan Seth, et al. 2013. "Linked employer–employee data from the IAB: LIAB cross-sectional model 2, 1993–2010 (LIAB QM2 9310)." FDZ-Datenreport, 2: 2013.
- Hellerstein, Judith K. 1998. "The importance of the physician in the generic versus tradename prescription decision." The Rand journal of economics, 108–136.
- Helpman, Elhanan, Oleg Itskhoki, Marc-Andreas Muendler, and Stephen J Redding. 2017. "Trade and inequality: From theory to estimation." The Review of Economic Studies, 84(1): 357–405.
- Hethey, Tanja, Johannes F Schmieder, et al. 2010. "Using worker flows in the analysis of establishment turnover–Evidence from German administrative data." *FDZ Methoden*-report, 6(en): 43.
- Hoffmann, Florian, and Philip Oreopoulos. 2009*a*. "A professor like me the influence of instructor gender on college achievement." *Journal of human resources*, 44(2): 479–494.
- Hoffmann, Florian, and Philip Oreopoulos. 2009b. "Professor qualities and student achievement." The Review of Economics and Statistics, 91(1): 83–92.
- Houseman, Susan. 2014. "Trade, Competitiveness and Employment in the Global Economy." *Employment Research*, 21(1): 1.
- Huber, Carola A, Thomas D Szucs, Roland Rapold, and Oliver Reich. 2013. "Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications." *BMC public health*, 13(1): 1030.

- Iizuka, Toshiaki. 2012. "Physician agency and adoption of generic pharmaceuticals." American Economic Review, 102(6): 2826–58.
- Illanes, Gastón. 2016. "Switching Costs in Pension Plan Choice."
- IQVIA. 2019. "The Global Use of Medicine in 2019 and Outlook to 2023."
- Ivers, Noah, Gro Jamtvedt, Signe Flottorp, Jane M Young, Jan Odgaard-Jensen, Simon D French, Mary Ann O'Brien, Marit Johansen, Jeremy Grimshaw, and Andrew D Oxman. 2012. "Audit and feedback: effects on professional practice and healthcare outcomes." Cochrane database of systematic reviews, , (6).
- Jackson, C Kirabo, Jonah E Rockoff, and Douglas O Staiger. 2014. "Teacher effects and teacher-related policies." Annu. Rev. Econ., 6(1): 801–825.
- Jacob, Brian A, and Lars Lefgren. 2008. "Can principals identify effective teachers? Evidence on subjective performance evaluation in education." *Journal of labor Economics*, 26(1): 101–136.
- Janakiraman, Ramkumar, Shantanu Dutta, Catarina Sismeiro, and Philip Stern. 2008. "Physicians' persistence and its implications for their response to promotion of prescription drugs." *Management Science*, 54(6): 1080–1093.
- Kane, Thomas J, Jonah E Rockoff, and Douglas O Staiger. 2008. "What does certification tell us about teacher effectiveness? Evidence from New York City." *Economics of Education review*, 27(6): 615–631.
- Kelso, John M. 2014. "Potential food allergens in medications." Journal of Allergy and Clinical Immunology, 133(6): 1509–1518.
- Kesselheim, Aaron S, Alexander S Misono, Joy L Lee, Margaret R Stedman, M Alan Brookhart, Niteesh K Choudhry, and William H Shrank. 2008. "Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis." Jama, 300(21): 2514–2526.
- Kesselheim, Aaron S, Jerry Avorn, and Ameet Sarpatwari. 2016. "The high cost of prescription drugs in the United States: origins and prospects for reform." Jama, 316(8): 858–871.
- Kesselheim, Aaron S, Katsiaryna Bykov, Jerry Avorn, Angela Tong, Michael Doherty, and Niteesh K Choudhry. 2014. "Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case–control studies." Annals of internal medicine, 161(2): 96–103.
- Kleibergen, Frank, and Richard Paap. 2006. "Generalized reduced rank tests using the singular value decomposition." *Journal of econometrics*, 133(1): 97–126.
- **Klemperer, Paul.** 1995. "Competition when consumers have switching costs: An overview with applications to industrial organization, macroeconomics, and international trade." *The review of economic studies*, 62(4): 515–539.

- Kremer, Michael, and Eric Maskin. 1996. "Wage inequality and segregation by skill." National bureau of economic research.
- Lam, Wai Yin, and Paula Fresco. 2015. "Medication adherence measures: an overview." *BioMed research international*, 2015.
- Morgan, Steven G, and Augustine Lee. 2017. "Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries." *BMJ open*, 7(1): e014287.
- Jolene. 2016.Morris, "University of Phoenix, Online Cam-Course 208r3." pus Syllabus ____ Math retrieved at http://www.jolenemorris.com/mathematics/Math208/CM/Week0/math_208_syllabus.htm on October 26, 2016.
- Mueller, Holger M, Paige P Ouimet, and Elena Simintzi. 2017. "Wage inequality and firm growth." *American Economic Review*, 107(5): 379–83.
- **Ost, Ben.** 2014. "How do teachers improve? The relative importance of specific and general human capital." *American Economic Journal: Applied Economics*, 6(2): 127–51.
- O'Hare, Ann M, Rudolph A Rodriguez, Susan M Hailpern, Eric B Larson, and Manjula Kurella Tamura. 2010. "Regional variation in health care intensity and treatment practices for end-stage renal disease in older adults." *Jama*, 304(2): 180–186.
- **Page, Amy, and Christopher Etherton-Beer.** 2017. "Choosing a medication brand: Excipients, food intolerance and prescribing in older people." *Maturitas.*
- Page, Amy, and Christopher Etherton-Beer. 2018. "Choosing a medication brand: Excipients, food intolerance and prescribing in older people." *Maturitas*, 107: 103–109.
- Papay, John P, and Matthew A Kraft. 2015. "Productivity returns to experience in the teacher labor market: Methodological challenges and new evidence on long-term career improvement." *Journal of Public Economics*, 130: 105–119.
- **Phelps, Charles E.** 2000. "Information diffusion and best practice adoption." In *Handbook* of health economics. Vol. 1, 223–264. Elsevier.
- **Polyakova, Maria.** 2016. "Regulation of insurance with adverse selection and switching costs: Evidence from Medicare Part D." *American Economic Journal: Applied Economics*, 8(3): 165–95.
- Radcliffe, Nicholas J, and Patrick D Surry. 2011. "Real-world uplift modelling with significance-based uplift trees." White Paper TR-2011-1, Stochastic Solutions.
- Rees, Albert. 1993. "The role of fairness in wage determination." Journal of Labor Economics, 243–252.
- **Reid, T.R.** 2010. The Healing of America: A Global Quest for Better, Cheaper, and Fairer Health Care. New York times bestseller, Penguin Books.

- **Rekenhof.** 2013. "Terugbetaling van Geneesmiddelen: Performantie van het Overheidsbeheer."
- Reker, Daniel, Steven M. Blum, Christoph Steiger, Kevin E. Anger, Jamie M. Sommer, John Fanikos, and Giovanni Traverso. 2019a. ""Inactive" ingredients in oral medications." Science Translational Medicine, 11(483).
- Reker, Daniel, Steven M Blum, Christoph Steiger, Kevin E Anger, Jamie M Sommer, John Fanikos, and Giovanni Traverso. 2019b. ""Inactive" ingredients in oral medications." *Science translational medicine*, 11(483): eaau6753.
- Rischatsch, Maurus, Maria Trottmann, and Peter Zweifel. 2013. "Generic substitution, financial interests, and imperfect agency." International Journal of Health Care Finance and Economics, 13(2): 115–138.
- Rivkin, Steven G, Eric A Hanushek, and John F Kain. 2005. "Teachers, schools, and academic achievement." *Econometrica*, 73(2): 417–458.
- **RIZIV/INAMI.** 2009. "Globaal analyseverslag over de inhoud van Farmanet uniek spoor."
- Roberfroid, Dominique, Sabine Stordeur, Cécile Camberlin, Carine Van de Voorde, France Vrijens, and Christian Leonard. 2008. "Physician workforce supply in Belgium: current situation and challenges." Federaal Kenniscentrum voor de Gezondheidszorg.
- **Rockoff, Jonah E.** 2004. "The impact of individual teachers on student achievement: Evidence from panel data." *American economic review*, 94(2): 247–252.
- Rothstein, Jesse. 2009. "Student sorting and bias in value-added estimation: Selection on observables and unobservables." *Education finance and policy*, 4(4): 537–571.
- Rothstein, Jesse. 2010. "Teacher quality in educational production: Tracking, decay, and student achievement." *The Quarterly Journal of Economics*, 125(1): 175–214.
- Rothstein, Jesse. 2015. "Teacher quality policy when supply matters." American Economic Review, 105(1): 100–130.
- Sarpatwari, Ameet, Joshua J Gagne, Zhigang Lu, Eric G Campbell, Wendy J Carman, Cheryl L Enger, Sarah K Dutcher, Wenlei Jiang, and Aaron S Kesselheim. 2019. "A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications." Journal of general internal medicine, 34(3): 420–428.
- Schokkaert, Eric, Joeri Guillaume, and Carine Van de Voorde. 2017. "Risk adjustment in Belgium: why and how to introduce socioeconomic variables in health plan payment."

- Shapiro, Bradley. 2018a. "Promoting wellness or waste? evidence from antidepressant advertising." Evidence from Antidepressant Advertising (December 29, 2018). Becker Friedman Institute for Research in Economics Working Paper, , (2018-14).
- Shapiro, Bradley T. 2018b. "Positive spillovers and free riding in advertising of prescription pharmaceuticals: The case of antidepressants." *Journal of political economy*, 126(1): 381– 437.
- Shrank, William H, Joshua N Liberman, Michael A Fischer, Charmaine Girdish, Troyen A Brennan, and Niteesh K Choudhry. 2011. "Physician perceptions about generic drugs." Annals of Pharmacotherapy, 45(1): 31–38.
- Simoens, Steven. 2012. "A review of generic medicine pricing in Europe." *GaBI Journal*, 1(1): 8–12.
- Sinkinson, Michael, and Amanda Starc. 2018. "Ask your doctor? Direct-to-consumer advertising of pharmaceuticals." *The Review of Economic Studies*.
- Sokol, Michael C, Kimberly A McGuigan, Robert R Verbrugge, and Robert S Epstein. 2005. "Impact of medication adherence on hospitalization risk and healthcare cost." *Medical care*, 521–530.
- Song, Jae, David J Price, Fatih Guvenen, Nicholas Bloom, and Till Von Wachter. 2019. "Firming up inequality." The Quarterly journal of economics, 134(1): 1–50.
- Staiger, Douglas. 2018. "What Healthcare Teaches Us About Measuring Productivity in Higher Education." In Productivity in Higher Education. University of Chicago Press.
- Staiger, Douglas, and James H Stock. 1997. "Instrumental Variables Regression with Weak Instruments." *Econometrica*, 65(3): 557–586.
- Su, Xiaogang, Chih-Ling Tsai, Hansheng Wang, David M Nickerson, and Bogong Li. 2009. "Subgroup analysis via recursive partitioning." Journal of Machine Learning Research, 10(Feb): 141–158.
- **Torgovitsky, Alexander.** 2019. "Nonparametric Inference on State Dependence in Unemployment." University of Chicago, Becker Friedman Institute for Economics Working Paper, , (2019-11).
- Vrijens, France, Carine Van de Voorde, Maria-Isabel Farfan-Portet, Maïte Le Pain, and Oliver Lohest. 2010. "The reference price system and socioeconomic differences in the use of low cost drugs." Federaal Kenniscentrum voor de Gezondheidszorg.
- Wilensky, Gail. 2016. "Changing physician behavior is harder than we thought." Jama, 316(1): 21–22.
- Wouters, Olivier J, Panos G Kanavos, and Martin McKee. 2017. "Comparing generic drug markets in Europe and the United States: prices, volumes, and spending." *The Milbank Quarterly*, 95(3): 554–601.

Yuskavage, Robert E, Erich H Strassner, and Gabriel W Medeiros. 2008. "Outsourcing and Imported Inputs in the US Economy: Insights from Integrated Economic Accounts."